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The search terms for the literature review included cancer, depressive disorder,
prevalence, treatment, psychological therapy, antidepressant medication, multi-
component intervention, nurse-delivered. A number ofelectronic databases were
usedfor searching the literature. These were accessed through e-library NHS and
Athens. The databases included a range ofsources including medical, nursing, Allied
Health Professional and generic journals. A thorough review was undertaken of the
literature concerning the prevalence and treatment ofdepression in both cancer and
non-cancerpopulations.
Cancer and depression are two of the most common causes of death and disability
worldwide (Murray and Lopez 1996, WHO 2004).
As more effective anti-cancer treatments emerge the prognosis for patients with
cancer is constantly improving resulting in a large number of patients living with the
disease for significant periods of time. Cancer for some patients has therefore
become a chronic disease. The treatment of chronic disease focuses primarily on
symptom management and requires a co-ordinated approach to care such as that
described in the chronic illness care model developed by Wagner (1998). For cancer
patients, symptom management is the primary therapy after surgery, chemotherapy,
radiation, hormonal or biological therapies, either as a transition back to follow-up
by primary care services or as a bridge to end-of-life care. Symptom management is
the diagnosis, treatment and monitoring of a symptom and is common to all types of




Depression is becoming one of the most pressing public health problems in the
developed world and is ranked as the fourth leading cause of disease burden globally
(Ustun et al 2004). The more severe form of depression is called Major Depressive
Disorder (MDD). A US epidemiological study showed that the diagnosis ofMDD
was associated with significant functional impairment and almost halfofpeople with
MDD had suicidal ideation, making MDD a serious personal and public health
problem (Hasin et al 2005). Projections suggest that by 2020, in the US, MDD will
be responsible for a larger burden of disease than any other illness (Greenberg et al
2003).
Definition and diagnosis
MDD is characterised by persistent low mood and/or anhedonia with additional
functional impairment and somatic symptoms. It is diagnosed when at least 2 weeks
of persistent depressed mood or anhedonia are present, accompanied by changes
from normal functioning in a total of at least four or more (or at least three if they
have both depressed mood and anhedonia) of the remaining DSMIV (Diagnostic and
Statistical Manual for Mental Disorders Fourth Edition, American Psychiatric
Association 1994) symptoms ofmajor depression (sleep disorder, appetite change,
fatigue, psychomotor retardation and/or agitation, low self-esteem and/or guilt, poor
concentration and/or indecisiveness and thoughts of suicide and/or suicidal ideation
during the current episode).
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Prevalence
The point prevalence ofMDD has been reported to be 5.3% in the USA (Hasin et al
2005) and 7% in the UK (Ayuso-Mateos et al 2001).
MAJOR DEPRESSIVE DISORDER IN CANCER
MDD comorbid with chronic illness such as cancer demands attention as it is a major
determinant of quality of life, is associated with non-adherence to treatment
(DiMatteo et al 2000; Ciechanowski et al 2000; Lin et al 2004), with greater
functional impairment or disability (Sullivan et al 1997; Unutzer et al 2000; Von
Korff et al 2005), with increased physical symptom reporting, with increased medical
costs (Chochinov 2001; Musselman et al 2001; Katon and Ciechanowski 2002) and
is associated with suicide (Cavanagh et al 2003; Chochinov et al 1997 & 1998).
There is also recent published data of a large study ofmore than 10,000 patients over
8 years providing evidence that the coexistence of cancer and depression (although
not specifically MDD) is associated with an increased risk of death from all causes
(Onitilo et al 2006).
Definition and diagnosis in patients with cancer
In cancer patients, although depressive symptoms are often considered an
understandable reaction to cancer, the diagnosis ofMDD follows the same DSMIV
criteria as described above.
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However there is some controversy concerning the use ofDSM criteria in the
diagnosis of depression comorbid with physical illness. Firstly, although DSM
criteria are considered the gold standard, they were developed and validated on
populations without physical illness therefore casting doubt as to whether they
actually are the gold standard for all patients, particularly those with significant
medical illness. Secondly, many depressive symptoms are similar to those of the
medical illness itself, presenting a diagnostic challenge.
In cancer, and specifically in advanced disease, many of the vegetative depressive
symptoms such as appetite loss, weight loss, insomnia, loss of energy and loss of
interest are common to both illnesses. The controversy is centred around determining
the source of the physical symptoms. So, in an attempt to identify an accurate
method of assessing depression in medically ill patients, in particular cancer patients,
researchers have proposed four different approaches: inclusive, aetiologic,
substitutive and exclusive (Cohen-Cole et al 1993; McDaniel et al 2000). The
inclusive approach uses all the symptoms of depression, regardless ofwhether they
may or may not be secondary to a physical illness (Rifkin et al 1985), potentially
resulting in over-diagnosis. In contrast the aetiologic approach counts a symptom
only if it is clearly not caused by the physical illness (Rodin et al 1991), resulting in
variability as it relies on the clinician diagnosing the depression being familiar with
the accompanying medical illness. An approach designed to avoid confusion over the
cause of symptoms, is the substitutive approach which allows physical symptoms
related to the medical illness in question to be replaced with cognitive symptoms
such as indecisiveness, hopelessness and pessimism. For cancer, Endicott provided
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specific modified criteria (Endicott 1984) substituting change in weight or appetite,
sleep disturbance, loss of energy or fatigue and difficulty in thinking or concentration
with depressed appearance, social withdrawal or decreased talkativeness, brooding,
selfpity or pessimism and lack of reactivity in situations that would normally be
pleasant. However a study comparing the Endicott modification against the inclusive
approach (Ciaramella and Poli 2001) found that the prevalence rate dropped from
49% to 29%. The final approach, the exclusive approach proposed by researchers at
the Sloan-Kettering Cancer Institute (Bukberg et al 1984; Plumb and Holland 1981)
eliminates two common symptoms of depression (fatigue and appetite/weight
changes) using only the other symptoms. This approach has been shown to lose
sensitivity, in other words it risks missing cases (Kathol et al 1990).
However, the method used may not be as important as previously thought. A recent
study of the validity ofDSMIV depression criteria in medical co-morbidity (Simon
and Von Korff 2006) found only limited evidence that fatigue, change in weight or
appetite, psychomotor agitation/retardation and sleep disturbance are less valid
indicators of depression in patients with chronic medical conditions.
Prevalence
There is evidence that the relative risk of psychiatric disorder is higher in people with
medical disorders and chronic illness than in the normal population (Rapp et al 1988;
Lustman et al 1998). To put into context the prevalence ofMDD in cancer patients it
is important to review the reported prevalence in other medical illnesses. The
percentage of patients meeting the DSMIV criteria for MDD has been reported to be
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15-20% in heart disease (Krishnan et al 2005), 12-18% in diabetes (Anderson et al
2001; Katon et al 2004a) and 50% in chronic asthma or chronic lung disease
(Goldney et al 2003; Mikkelsen et al 2004). Prevalence rates for MDD in cancer
patients range from 1% to 40% (see table 1.1). Even though these studies have used
standardised DSM criteria for diagnosis, there is a wide range of reported rates.
There could be a number of explanations for this variability. Firstly, the majority of
studies had a high rate of excluded patients which assumes that those not interviewed
would have similar rates of depression and secondly, most studies assessed MDD in
hospitalised patients where its prevalence is known to be higher. Overall the majority
have used small samples of insufficient size to obtain accurate prevalence estimates
in a range of settings (inpatients and outpatients) and in a range of cancer types and
disease stages (curative and palliative).
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Table 1.1: Prevalence of Major Depressive Disorder using a DSM criteria-based
structured clinical interview
Author (year) Population/setting Sample size MDD prevalence
Akechi et al 2001 Lung/ns 129 4.7%
Akechi et al 2004 Mixed advanced
cancers/IP
209 6.7-11.8%
Alexander et all 993 Mixed/IP 60 13%
Aragona et al 1996 Breast/ns 85 2%
Berard et al 1998 Breast &
lymphoma/OP
100 19%
Breitbart et al 2000 Mixed advanced
cancers/IP
92 16%
Bukberg et al 1984 Mixed/IP 62 24%







to pain and palliative
care clinic)
100 28%




Derogatis et al 1983 Mixed/IP&OP 215 6%
Ell et al 2005 Breast &
gynaecological/OP
472 24%
Evans et al 1986 Gynaecological/IP 83 23%
Ginsberg et al 1995 Newly diagnosed
lung/ns
52 2%
Golden et al 1991 Gynaecological/IP 65 23%
Grandi et al 1987 Breast/IP 18 22.2%




Ibbotson et al 1994 Mixed/OP 513 17%**






Kathol et al 1990 Mixed/ns 152 38%
Katz et al 2004 Head and neck/OP 60 5%
Kawase et al 2006 Mixed/
Radiotherapy OP
282 8.5%
Kissane et al 2004 Breast/OP 503 8.3%
Kugaya et al 2000 Newly diagnosed head
and neck/ns
107 3.7%
Love et al 2002 Breast/OP 303 9.6%
Love et al 2004 Metastatic Breast/ns 227 7%
Massie and Holland
1987
Mixed cancers/IP 546 9%
Morton et al 1984 Head and neck
male/OP
48 39.6%
Okamura et al 2000 Breast/ns 55 7%
Payne et al 1999 Breast/OP 31 0%
Razavi et al 1990 Mixed cancers/IP 128 26%
Razavi et al 1992 Lymphoma/OP 117 6.8%**
Sharpe et al 2004a Mixed cancers/OP 3938 7.8%
Sneeuw et al 1993 Breast/ns 1112 5.4%
Walker et al (2007 in
press)
Mixed cancers/OP 361 8.3%
OP=outpatients; IP=inpatients; ns=not specified
**MDD and generalised anxiety disorder combined
In this thesis I intend to focus on the management ofMDD comorbid with cancer.
However, because the literature on depression related to cancer is limited, I have
chosen to review and relate to some of the key literature on the management ofMDD
in primary care and ofMDD comorbid with chronic illnesses other than cancer.
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MANAGEMENT OF DEPRESSION IN PRIMARY CARE
Ninety percent of cases of 'detected' depression are treated in primary care, where
depression is the third most common reason for consultation. The two most
important barriers to effective depression management are under-recognition (30%
remain undetected) and under-treatment (>50% are untreated), (Hays et al 1995).
Recognition
Screening
Lack of recognition of depression in both primary care and medically ill patients is
well documented (Schulberg et al 1985; Neilsen and Williams 1980; Wells et al
1989). Depression screening has therefore been recommended for all medical
populations (Wright 1994, Pignone et al 2002). However, a systematic review found
that increased recognition of depression did not necessarily equate with any benefit
in outcome for disorders managed in non-psychiatric settings (Gilbody et al 2001).
This suggests that unless there is a coherent management plan for patients identified
with depression, screening is of little benefit.
Treatment
However, once detected, the three most commonly used treatment modalities for




There is good evidence for the efficacy of antidepressant drugs in non-cancer
populations (Joffe et al 1996; Butler et al 2005; Krishnan 2005) and of remission of
depressive symptoms (Trivedi et al 2006). However, in practice only a small
proportion of patients achieve a therapeutic dose either because the GP did not
increase the dose (George et al 2000) or because of poor therapy adherence by the
patient (Lin et al 1995).
Psychological treatments
There is also evidence for the efficacy of psychological therapies (Butler et al 2005):
for cognitive therapy (Casacalenda et al 2002); interpersonal therapy (de Mello
2005); non-directive counselling (although only short-term efficacy over usual care)
(Bower et al 2003); and problem solving therapy (PST) (Mynors-Wallis et al 1995)
in treating MDD in non-medically ill populations.
Combined treatments
Interventions that combine pharmacotherapy and psychotherapy have been found to
substantially improve patient outcomes for MDD in a number of non-cancer
populations (Friedman et al 2004; Katon et al 2004b; Pampallona et al 2004;
Callahan et al 2005). In primary care, a patient educational drug compliance
enhancing programme provided by GPs for patients with MDD was superior to usual
care in achieving a treatment response (Akerblad et al 2003) but the treatment effect
was much smaller than that achieved by more complex interventions. Another
similar trial of a drug compliance enhancing programme consisting of a brief
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psychosocial intervention delivered by nurse found a significantly superior effect on
drug adherence compared to usual management with tricyclic antidepressant
medication, but clinical effect in terms of treatment response was only seen in the
subset who were also taking 75mg or more of the tricyclic drug (Peveler et al 1999).
The better outcome in both depression and medication adherence achieved by
combined treatments was supported by Gilbody et al (2003) in a systematic review
which found that almost all trials of depression management using at least two or
combined depression management strategies had positive results in their primary
outcomes and that the most successful interventions combined multiple strategies
such as those specified in the definition of collaborative care models of depression
management.
Collaborative models of depression management
Collaborative models in primary care, also called depression management
programmes (DMP) or collaborative care programmes, contain the following
elements: evidence-based protocols for treatment; structured collaboration between
primary care providers and mental health specialists; active monitoring of adherence
to treatment and of outcomes; and in some cases structured programmes of
psychotherapy (Simon 2006). This type ofmodel is based on the concept of
collaborative management in chronic illness, that is care that strengthens and
supports self-care while assuring that effective medical, preventive and health
maintenance interventions take place (Von Korff et al 1997).
13
At the time of planning my research there had been a small number of large well-
designed randomised controlled trials (RCT) of such interventions for depression in
primary care. Early leading studies using patient education strategies and treatment
interventions delivered by a range ofprimary care health workers (GPs,
psychologists, psychiatrists and nurses) were conducted by a research group in
Seattle led by Professor Wayne Katon.
In 1995 Katon and colleagues published results of a large randomised controlled trial
of a multifaceted intervention for patients with major and minor depression (Katon et
al 1995) consisting ofcollaborative management by the primary care physician and a
consulting psychiatrist, intensive patient education, and monitoring of antidepressant
medication. The intervention achieved a statistically significant improvement in
depressive outcomes for patients with major, but not minor, depression over usual
care. In 1996 the Group published results of a second RCT of a similar intervention
but with the addition of a psychological intervention delivered by a psychologist
integrated into the primary care practice (Katon et al 1996). This also showed a
significantly improved depression outcome for patients with MDD, with a treatment
effect of a similar order ofmagnitude to the previous trial. A further development of
the collaborative care model proposed by Katon's research group was a stepped
approach whereby patients not responding to initial conventional treatment would
receive enhanced care, comprising patient education, two sessions with a primary
care based psychiatrist, nurse case management and collaborative management by
the psychiatrist and GP. This model was tested against usual care in patients with
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persistent MDD and was found to be efficacious in terms of depressive outcomes
over usual care (Katon et al 1999).
The collaborative care model was extended to specific patient populations by
Katzelnick and colleagues in Harvard University, Boston, and its efficacy in the
management ofMDD in high utilisers ofmedical care tested in an RCT across a
large number of primary care practices. The model, a depression management
programme, consisted of GP education, the provision of antidepressant medication
prescribing guidelines, patient education and case management by a primary care
mental health worker. Results published in 2000 showed superior outcomes in
depressive outcomes for patients receiving the new intervention compared to usual
care (Katzelnick et al 2000).
In the same year a research group in the University of California (Hunkeler et al
2000) published results of a trial of the collaborative care model for the management
ofMDD and dysthymia. This model, 'nurse telehealthcare' extended the nurse's role
in case management to include both drug adherence monitoring and support in the
form of problem-solving and activity scheduling by phone, together with GP
prescribed antidepressant medication. Although the intervention was superior in
efficacy over usual care for depressive symptom outcomes, it did not alter adherence
to medication. This was the first trial to provide evidence for the efficacy of phone-
delivered depression treatment, thus broadening its accessibility.
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Although not in phone-delivered format, the same research group also investigated
the dissemination of a depression management programme in a large RCT in forty-
six primary care practices with 1356 patients with MDD comparing a DPM using
nurse case managers to provide treatment monitoring, patient education and
activation and psychotherapist-delivered cognitive behavioural therapy (CBT) with
usual care. This trial demonstrated improvement in depression outcomes in patients
who received the DPM both at six and twelve months but more-over that
dissemination of guidelines for such a DPM to routine practice is effective (Wells et
al 2000).
At about the same time, a group from the University of Colorado were developing
and testing a model for MDD in primary care designed to follow the principles of
chronic disease management, so delivering 'on-going' care up to twenty-four months
with the objective of sustaining or increasing improvement, given that the emerging
evidence at that time was that the initial benefits from collaborative care models for
depression were not sustained beyond a year (Lin et al 1999). The model included
GP prescribed antidepressant medication plus nurse-delivered patient education, and
algorithm-guided support and treatment monitoring from baseline to seven months,
then nurse case management of structured follow-up phone calls between seven and
twenty-four months. The intervention increased response rates significantly
compared with usual care at six months (Rost et al 2001) and long-term remission
rates by a third at twenty-four months (Rost et al 2002). The results of this trial
suggested that a model with structured monitoring beyond the initial phase of
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intensive treatment was an important factor in the maintenance of patient
improvement.
In 2002, the Seattle group published results of the largest trial to date of collaborative
care, the Impact Trial, applying the model to older patients with MDD and multiple
medical conditions (Unutzer et al 2002) and comparing it with usual care in an RCT
of 1801 patients in eighteen primary care clinics. The model involved a depression
care manager (nurse or psychologist) who delivered patient education in the form of
a short educational video-tape and booklet, prepared a treatment plan, monitored
treatment response using a structured assessment tool, managed the patient's
antidepressant regimen alongside their GP and/or gave 6-8 sessions of problem
solving therapy (PST). The benefit over usual care was significant and clinically
substantial at twelve months with persistent long term benefits at two years reported
recently by Hunkeler et al (2006).
In 2003, a collaborative group from the UK, Seattle and Santiago published results of
a stepped care model using nurse or social worker-delivered group psycho-education
and case management with a structured programme of pharmacotherapy for those
with severe or persistent depression for the management ofMDD in a population of
low-income women in Chile (Araya et al 2003). The trial found a large treatment
effect compared to usual care.
However, not all trials have produced positive results. A primary care study ofMDD,
dysthymia and partially remitting MDD comparing collaborative care management
with nurse case management of patient monitoring, treatment planning, and care co¬
ordination with notification to GPs regarding diagnosis (Swindle et al 2003) showed
no significant differences at three and twelve months compared with usual care.
In conclusion, results from the research available at the start ofmy trial and a
systematic evaluation of collaborative models of depression management conducted
by Gilbody and colleagues in 2003 just before the start of the trial, suggested that a
combination of antidepressants, brief psychological treatments, and case
management with 'maintenance care' beyond the initial intensive treatment phase
were important elements of an efficacious model of depression management and that
nurse involvement in combined treatments and collaborative models of depression
management in primary care varying from low intensity, such as providing brief
patient education and medication counselling (Peveler et al 1999), to telephone
support (Hunkeler et al 2000), to nurse case management (Katon et al 1999, Wells et
al 2000, Rost et al 2002, Araya et al 2003) could be an effective method of delivery
of such models.
Since starting the trial, one further large primary care trial of collaborative depression
care for patients with moderate to severe depression starting antidepressant treatment
has been published by the Seattle group (Simon et al 2004). In this trial three
interventions were compared: a telephone-based programme ofmedication
monitoring and care co-ordination; the telephone-based programme with additional
structured 8-session depression-specific CBT delivered by psychotherapists over the
phone; and usual pharmacotherapy. No significant benefits in depression outcomes
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were found by adding the telephone-based medication monitoring programme to
usual pharmacotherapy, nor by adding a brief psychotherapy to usual
pharmacotherapy. However, a combination of all three interventions (the brief
psychotherapy, the telephone-based monitoring programme and usual
pharmacotherapy) produced significant differences in depressive outcomes when
compared to usual pharmacotherapy alone. This trial suggested that a multi-
component intervention may be a contributing factor to overall efficacy of a
collaborative care model.
In addition to the trial described above, three systematic evaluations of collaborative
models of depression management have been published since the start of the trial, a
meta-analysis of twenty-four RCTs published up to 2001 (Badamgarav et al 2003), a
meta-analysis of ten American RCTs published up to 2002 (Neumeyer-Gromen et al
2004) and more recently a meta-analysis of thirty-seven RCTs published up to the
start of 2006 by Gilbody et al (2006). All three evaluations have confirmed the
efficacy of collaborative care models for depression management in primary care
with Gilbody's group providing evidence of longer-term benefit for up to five years.
It seems therefore that the evidence for the efficacy and effectiveness of collaborative
care models for the management ofMDD in primary care is well established.
However, evidence-based strategies for managing MDD in chronic illness or cancer
are less clear.
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MANAGEMENT OF DEPRESSION COMORB1D WITH CHRONIC ILLNESS
INCLUDING CANCER
Recognition
Depression in cancer patients is under-recognised (Passik et al 1998; McDonald et al
1999; Fallowfield et al 2001). The reason for this is complex. Oncologists, and
patients too, may be focussed on the medical management of the cancer. Also health
care professionals working in non-psychiatric settings may be unfamiliar with the
symptoms of depression, particularly as the somatic symptoms can be common to
both illnesses. Another reason frequently put forward is that clinicians may dismiss
depressive symptoms on the assumption that all cancer patients are 'understandably
depressed'. Clinicians may also be hesitant to elicit patients' concerns for fear of
upsetting the patient further or may avoid discussing distressing issues because of
their own discomfort (Goldman et al 1999). In addition to this is the lack of
familiarity with, and availability of, treatment options. Fallowfield and colleagues
(2001) in a large study of the recognition of psychiatric morbidity by doctors in
patients with cancer showed that doctors misclassify over a third of patients. Patients
may also avoid disclosing depressive symptoms because of the associated stigma of
the illness (Maguire 1985; Valente et al 1994) and of the treatment (Von Korff et al
2001) or simply that not all patients want their depression treated (Sharpe et al
2004b). Our own research in a sample of 150 cancer patients with MDD (Sharpe et al
2004a) showed that only half had discussed their low mood with their GP.
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Screening
Self-report screening measures commonly used in the cancer population include the
Hospital Anxiety and Depression Scale (HADS) (Zigmond and Snaith 1983)
originally designed to detect symptoms of depression and anxiety in patients
attending medical outpatient clinics and found to be valid and reliable as a screening
instrument (Bjelland et al 2002). In a cancer population, a total score of 15 or above
on the HADS scale was reported by Ibbotson et al (1994) to be the best cut-off for
identifying patients likely to have a diagnosis of interview-defined depressive or
anxiety disorder. Our own research at a HADS total score cut off of 14/15 gave a
sensitivity of 0.87 (95% C.I. 0.70-0.95), a specificity of 0.85 (95% C.I .0.81 - 0.89)
and a positive predictive value of 0.35 and was considered optimal (Walker et al in
press), thus offering 85% accuracy when compared against the MDD section of the
Structured Clinical Interview (SCID) for DSMIV (First et al 1999).
Given that doctors' recognition of patient distress is poor and that no screening
approach can replace a thorough diagnostic assessment, screening can serve as a
resource efficient method of identifying patients requiring further assessment and
treatment (Cull et al 2001). However it is not clear from the evidence to date what
treatment is effective for MDD in patients with co-morbid chronic illness or cancer.
Treatment
The current treatment for depression in cancer patients is largely derived from
evidence-based treatments in the medically ill population as there are no published
RCTs to date of effective interventions for MDD in cancer patients. In practice the
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management ofMDD in cancer patients is often suboptimal. Very few cancer
patients with MDD receive effective treatment. A UK survey of 150 cancer patients
with MDD showed that 85% were not receiving any appropriate evidence-based
treatment for their depression (Sharpe et al 2004a). This is because of a failure to
detect it (Fallowfield et al 2001), to deliver appropriate treatment, to monitor
progress and to adjust treatment according to response (Von Korff et al 2001;
Greenberg 2004; Sharpe et al 2004a) or simply because their physicians tend to
attribute their depression to their cancer and/or advancing disease.
Antidepressants
Approximately two thirds of patients who have both cancer and MDD do not receive
specific antidepressant treatment (Sharpe et al 2004a).
However, there is emerging evidence for the efficacy of antidepressant drugs in
cancer populations (Razavi et al 1996; Musselman et al 2001; Fisch et al 2003;
Morrow et al 2003; Roscoe et al 2005) as detailed in a recent systematic review by
Williams and Dale (2006).
Psychological treatments
Although there have been no recent meta-analyses of psychological treatment trials
specifically for depression in cancer patients, a meta-analysis of RCTs in 1995
(Meyer and Mark 1995) found very little evidence from well-designed RCTs to
support the efficacy of psychological therapies in treating depression in cancer
populations. However, of the individual trials published after this, cognitive therapy
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(Evans and Connis 1995; Edelman et al 1999; Antoni et al 2001; Kuijer et al 2004),
PST (Nezu et al 2003), and supportive-expressive group therapy (Classen et al 2001)
have been shown to be efficacious.
Combined treatments
There have been no published RCTs of combined treatments for the management of
MDD in cancer patients.
Collaborative models of depression management
There have also been no published RCTs ofmulti-component interventions or
collaborative care models for managing MDD in cancer patients and only one major
trial of a collaborative care model for the management of depression in patients with
chronic illness published after the start of the trial described in this thesis. This was a
trial of a collaborative care model in a primary care setting using nurse-delivered
brief PST for the treatment of patients with MDD and diabetes, the results of which
found it to be superior in terms of depressive outcomes over usual care but in its
effect on glycaemic control (Katon et al 2004b).
Although providing only preliminary evidence of efficacy, Dwight-Johnson and
colleagues (2005) in Los Angeles have conducted a small pilot RCT of a
collaborative model for the management ofMDD using social workers to deliver
PST in low-income female Latina cancer patients. Although this was a small study,
its treatment effect was significant and substantial and provides further evidence of
the potential efficacy of such models in cancer populations.
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In summary, no trials of depression management in chronic illness or in cancer had
been published at the time of starting my trial. Given that a small but robust body of
research had been conducted prior to the start of the trial that had proven the efficacy
and effectiveness ofmulti-component interventions for the management ofMDD in
primary care, and that my preliminary pilot work had found some promising results
in a cancer patient population (discussed briefly in the next chapter), it seemed
logical to further develop a model informed by the pilot work and test this model
formally for its efficacy compared to usual depression management in an RCT.
24
CHAPTER 2:
A NURSE-DELIVERED MULTIPLE MODALITY
APPROACH TO THE MANAGEMENT OF MAJOR
DEPRESSIVE DISORDER IN CANCER PATIENTS
In 1999,1 designed a multi-component, cancer nurse-delivered intervention
collaboratively with Professor Michael Sharpe and tested it in a small non-
randomised matched group design pilot study to perform a preliminary evaluation of
its feasibility and efficacy in the treatment ofMDD in cancer patients, the results of
which were published in 2004 (Sharpe et al 2004b). Thirty patients were allocated to
usual care and thirty to usual care plus an additional intervention which comprised
nurse-delivered patient education and seven sessions of PST, optional GP-prescribed
antidepressant medication and nurse case management including medication
adherence monitoring and co-ordination of care. The nurse received weekly
supervision from the trial psychiatrist. The results of the trial found a statistically
significant reduction in both self-rated and interview-based outcomes at three months
which were largely maintained at six months. For the primary outcome at six months,
38.5% (95% Confidence Intervals 5.4 to 57%) fewer patients in the additional
intervention group still met the diagnosis-based criteria for MDD.
The challenges this role present to nurses were described in a paper published in
2004 (Strong et al 2004). The conclusion was that working with distressed cancer
patients could be burdensome without adequate clinical supervision and that
integrating a mental health intervention into a secondary care service while relating
to primary care was a difficult part of the role.
In summary, results of the pilot study suggested that not only was the intervention
promising in terms of its efficacy but that it was feasible to use nurses to deliver it
and that it was acceptable to patients and their health care team.
However, while the pilot study found encouraging results, non-randomised
comparisons can over-estimate the differences between treatments. Therefore, a
randomised comparison was needed, with a bigger sample size to obtain a more
precise estimate of its efficacy.
A randomised design in a clinical study ensures that each patient has the same
probability of being allocated to each treatment using the play of chance and that the
allocation is not predictable by the patient or treating physician thereby allowing a
valid basis for comparison of treatments, by minimising biases from known and
unknown confounders (Friedman et al 1998). A randomised controlled clinical trial
is therefore a rigorous planned experiment which involves patients and is designed to
elucidate the most appropriate treatment of future patients with a given medical
condition allowing inferences about the efficacy of an intervention to be made in the
population of patients to whom it refers (Pocock 1983).
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The overall aim was to improve the management of depression in cancer patients.
The specific objective was to:
1. Test the efficacy of this intervention model for the treatment ofMDD in
cancer patients ofmixed diagnoses in a randomised controlled trial by
comparing usual care with usual care plus the nurse-delivered, psychiatrist-
supervised multi-component intervention by:
a. Measuring the primary outcome of trial participants at 3 and 6 months
b. Measuring other outcomes at 3 and 6 months, specifically:
i. clinically relevant response to treatment and remission of
depressive symptoms
ii. anxiety, physical functioning, coping, problem-solving ability
and satisfaction with treatment
iii. the association between improvement in depression scores and
aspects of confidence, coping and support
iv. the extent to which baseline factors predict a good outcome at




The design of this study was intended to address the stated hypothesis: Usual care
plus a nurse-delivered, psychiatrist-supervised multi-component treatment
intervention reduces symptoms ofmajor depressive disorder in patients with cancer
to a greater extent than usual care alone.
Subsidiary hypotheses:
1. The additional nurse intervention will improve outcome by a) increasing the
patient's confidence to cope with concerns and b) increasing the patient's
coping ability by teaching them problem solving skills to tackle their
concerns and c) increasing their access to and use of social support
2. At 6 month follow-up, patients treated with the additional nurse-delivered
intervention will maintain the benefit and have benefit superior to those
patients who were allocated to usual care only
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METHODS
Chapter 4: The Design of the Study
Chapter 5: Analysis of Data and Statistical Power
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Justification for randomisation by minimisation
The randomisation procedure
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Table 4.1: Variables measured in the trial
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DESIGN
The design was a single-centre randomised two-arm trial with a six-month follow-up
and was based in the Edinburgh Cancer Centre. One arm was the experimental
intervention arm and the other the 'control' arm which was essentially usual care.
'Usual care' was examined with respect to its ethical considerations and its content.
A review of the evidence for the efficacy of current treatment was undertaken as
discussed in the introduction to this thesis and the conclusion drawn that the current
'standard' treatment was evidence-based. In terms of content, during the pilot phase
of this research I collected and analysed data to assess the 'standard' treatment
received by 150 patients attending the Edinburgh Cancer Centre (Sharpe et al 2004a).
Standard treatment consisted predominantly of GP care and antidepressant
medication.
THE PATIENT SAMPLE
Population, number and source of subjects
Patients with both cancer and MDD were identified from an existing clinical
screening programme in selected outpatient oncology clinics. Patients with lung
cancer were excluded from large-scale screening as, in the majority of cases, their
prognosis was poor and therefore completion of a six month trial was unrealistic and
in terms of data completeness, the risk of loss of outcome data due to death would be
high. However, referrals for diagnostic assessment and subsequent trial eligibility
assessment were accepted and a small lung cancer clinic was screened later in the
trial. From a clinical perspective, there were some patient groups, such as 'head and
neck' cancers and 'upper gastro-intestinal' cancers whose cancer may be related to
alcohol use. Of this group, those patients identified with depression were likely to
have considerable social problems and therefore a brief intervention administered by
a non-mental health clinician was not considered to be appropriate and unlikely to be
effective. Furthermore, from a practical perspective, patients with head and neck
cancers may have residual communication problems making the talking therapy
component of the intervention difficult for both the patient and the therapist. Those
patients diagnosed with MDD and interested in taking part in the trial were assessed
in a three-stage interview for trial eligibility.
Inclusion criteria
The principal inclusion criteria were that the patients had a diagnosis of cancer and
were found on screening to have definite or probable MDD of at least a month's
duration and have a SCL-20 score of at least 1.72. This score has been shown to
have the highest positive predictive value amongst self-report measures for MDD
(Mulrow et al 1995).
Exclusion criteria
Patients excluded from the trial were those with a survival of less than six months as
predicted by their cancer specialist; with another complicating and uncontrolled
medical problem (such as poorly controlled epilepsy or cerebral metastases) or where
antidepressants were contraindicated for medical reasons; who were too ill to
participate in treatment because of ongoing cancer therapy; who had a complicating
major psychiatric diagnosis (such as bipolar affective disorder, psychosis, severe
known personality disorder) or an alcohol or substance misuse problem; who had
chronic depression with a history of continuous depression for more than two years
prior to the screening diagnostic interview; who were receiving active treatment for
their depression from a psychologist or psychiatrist; who were judged to be in need
of urgent psychiatric treatment; who were unable to communicate adequately
because of language problems or cognitive impairment and who lived outside
reasonable travelling distance.
Previous research in the Edinburgh Cancer Centre identified MDD in approximately
8% of patients attending selected oncology outpatient clinics (Sharpe et al 2004a).
This research also showed that recruitment of eligible patients for the trial was
sustainable from the clinics screened at a rate of four patients per week of which
approximately 50% would refuse to take part in the trial. Based on these calculations
over forty-five weeks of screening per year, to recruit two hundred patients (sample
size discussed in next chapter) to the trial would take approximately two years.





Patients with MDD were identified from consecutive cancer centre attenders
(excluding those attending for initial cancer assessment) using a two-stage screening
system. In stage one all patients completed the HADS questionnaire (Zigmond &
Snaith 1983) on a touch screen computer or paper prior to their consultation with the
oncologist at the following outpatient cancer clinics: colorectal, breast,
gynaecological, genitor-urinary, sarcoma, melanoma, haematological, lung and
mixed cancers. A threshold score (total HADS score > 15) identified those patients
likely to have MDD. I also used a threshold score on the HADS depression subscale
of> 10 to identify patients warranting further assessment. In stage two those patients
whom the oncologist predicted had a survival ofmore than six months and who had
scored high on the HADS (HADS> 15 or HADS-D> 10) or who on the automated
screening had endorsed the question about suicidal ideation on the nine-item Patient
Health Questionnaire (PHQ-9), (Kroenke et al 2001, Kroenke and Spitzer 2002),
were interviewed after the consultation and at home over the telephone, using the
SCID, in order to identify those with a diagnosis of definite or probable MDD. The
telephone SCID interview has been shown to have high reliability with the in-person
SCID, (Cacciola et al 1999, Simon et al 1993). Patients referred to the trial were
screened using a one-stage procedure of the telephone diagnostic interview only.
All patients identified with MDD were assessed briefly for trial eligibility at the end
of the diagnostic interview (stage 1), specifically for chronic depression and whether
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they were already receiving treatment for their depression from a mental health
specialist. Those patients who were not excluded at this stage were asked permission
for their contact details to be passed to the research team and for information about
the trial to be sent to them.
Baseline research assessment
I contacted those potentially trial eligible patients more than twenty-four hours after
receipt of the trial information, thus allowing them time to consider participation as
required by the ethics committee. Trial eligibility was assessed over the phone (stage
2) and for those patients potentially trial eligible, an interview time was arranged for
a face-to-face interview (stage 3). At this interview the trial was explained and the
patient completed the self-report Symptom Check-list, (SCL-20) (Derogatis et al
1974), to check eligibility on depression severity. Those scoring >1.72, the severity
score set for this trial, were informed of the randomisation process and those who
agreed to participate were consented for trial participation. At all stages, reasons for
non-inclusion and refusals were recorded.
The Trial
At the eligibility interview, before consent was obtained and the patient formally
entered into the trial, I answered all questions that the patient had, checked that the
patient had understood what the treatments were, what randomisation meant, and that
they would be willing to accept whichever allocated treatment they were offered.
Written consent was then obtained, randomisation performed as described below and
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the patient assigned a trial number. For patients excluded at any stage, I informed
their GP and Oncologist of the patient's MDD diagnosis.
Randomisation
Justification for randomisation by minimisation
Allocation to treatment was concealed during randomisation. Randomisation was
required in order to achieve comparable groups of known and unknown confounders.
However, there is a risk in smaller trials that imbalances in baseline characteristics
may occur. As this trial was relatively small and that there were certain 'suspected'
patient characteristics or potential prognostic factors that should have been
comparable at the beginning of the trial, some 'control' needed to exist to ensure that
the allocation of patients to each group achieved a balance in certain baseline
characteristics between the groups at the end of recruitment. For this reason I chose
to restrict the randomisation using a method called minimisation. This method would
not only ensure that the groups at the end of recruitment and allocation were
comparable but also that each treatment allocation was unpredictable.
The randomisation procedure
To avoid individual trial team members knowing how the risk factors were accruing
and therefore having the ability to predict and therefore influence allocation, the
process of randomisation was handled by the Cancer Research UK clinical trials
service independent of the trial team. This Unit supervised the registration of patients
and operated the computerised randomisation by minimisation programme. This
programme determined which group inclusion of a patient would minimise specific
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differences in known or suspected determinants of outcome. In addition to this
strategy, I chose to employ a random element in the allocation procedure of
0.75:0.25 to further decrease the probability of an individual predicting correctly the
allocation. The value of the method ofminimisation was shown by White and
Freedman (1978) and Smith (1984).
The factors chosen for minimisation in this trial were: gender, age (< 39, 40-79, > 80)
disease site (colorectal, breast, gynaecological and 'other') and extent of disease
(disease free, local disease, and metastatic disease).
Justification for minimisation factors
It was suspected that gender may be a determinant of outcome. The pilot study of
this trial included very few men and it was therefore not possible to show any
statistically significant differences between men and women in their response to
treatment. From clinical experience however, men appear to be less likely to declare
symptoms and are generally less willing to talk about their emotional well-being.
Another factor important when considering balanced and comparable groups was age
as age was considered a possible prognostic factor in recovery from depression.
Disease site and extent of disease may have an effect on recovery but may also be of
prognostic importance. From clinical experience, patients' reaction to recurrence of
their cancer is often worse than initial diagnosis and therefore it seemed important to
ensure comparable groups with regard to both disease and extent of disease.
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Trial outcome assessments
Two research assistants conducted the outcome measures at three and six months and
were kept blind to the patient's treatment status as far as possible. Both were trained
in the administration of the SCID and all of the outcome SCID interviews were re-
rated by another member of the research group trained in SCID interviewing,
independent of the trial team and blind to the patient's treatment allocation. To
minimise bias all the re-rated interviews were used in the final analysis.
The treatment evaluated in the trial
The two treatment conditions compared in the trial were optimised usual care and
optimised usual care plus an experimental intervention.
Optimised usual care:
Usual care was what is currently practised. This was optimised by informing the
patient's GP and Oncologist that their patient had MDD and providing management
advice on request. It was anticipated that a minority ofpatients would be referred to
specialist services.
Optimised usual care plus an experimental intervention:
A nurse-delivered intervention supplemented the optimised usual care. The
intervention was based on the management of depression in primary care patients
developed by the Seattle group (Katon et al 1995). It was delivered over a maximum
of 10 sessions according to a detailed manual (see Appendix A), which included a
treatment response algorithm to determine the number of sessions required. It had
two phases:
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1. The Treatment Phase: This was a nurse-delivered, psychiatrist-supervised
treatment, comprising PST, enhancing social support and encouraging the use of
antidepressant drugs. PST is a simple but flexible brief psychotherapy ofproven
effectiveness for MDD in non-cancer patients that can be applied to a wide variety of
patient concerns (Hawton and Kirk 1989). PST was applied to problems chosen by
the patient and nurse together and included addressing the patient's depression as a
problem. The patient was also encouraged to see their GP to discuss taking an
antidepressant drug and, if required, the nurse facilitated the prescription of
antidepressants through direct contact with primary care. The patient was also
encouraged to seek and use social support (both professional and personal), available
to them. In the final sessions, the patient completed a 'relapse prevention plan'
which is a self-monitoring schedule and action plan for the patient should they
become aware of depressive symptoms returning. The patient's response to treatment
was monitored during the intervention by the treating nurse using a depression
severity measure. For this I selected the PHQ-9, which was routinely completed by
the patient at the beginning of each treatment session.
2. The Monitoring Phase: Active monitoring of depressive symptoms using the
PHQ-9 was performed monthly during the post-acute monitoring phase. Additional
booster sessions up to a maximum of three, delivered by phone or face-to-face, were
offered if relapse was identified or if the patient requested it.
Treatment was delivered in the Western General Hospital at the University of
Edinburgh Cancer Research Centre. For those patients who during treatment were
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unable to attend for individual appointments, telephone based or home based
treatment sessions were conducted.
Recorded for individual patients for analysis were: number of sessions; completion
ofhomework; total treatment time; total administration time; total supervision time
from supervising clinician(s); total direct consultation time from supervising
clinician(s) and details of antidepressant therapy including type, date commenced
and dose increases.
Depression severity measure
The PHQ-9 depression severity measure is a brief self-report questionnaire (see
Appendix B), which makes it useful clinically to determine treatment response. Its
brevity allows quick completion and its self-report attribute eliminates observer bias,
making it useful as a research tool. The PHQ-9 is the depression module of the full
self-report PHQ (Spitzer et al 1999) derived from the PRIME-MD diagnostic
instrument for common mental disorders (Spitzer et al 1994). It scores each of the
nine DSM-IV criteria as 0 (not at all) to 3 (nearly every day). In terms of classifying
severity, the PHQ-9 scores of 5, 10, 15 and 20 represent mild, moderate, moderately
severe, and severe depression, respectively. However, the intention of using the
PHQ-9 was as a measure of severity only. In a study of its criterion validity,
measured against a structured mental health professional interview (based on the
SCID and diagnostic questions from the PRIME-MD) by Kroenke et al (2001), it
was shown to have a sensitivity of 88% and a specificity of 88% for MDD at a cut¬
off score of > 10. It has been suggested that the PHQ-9 is sensitive to change over
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time. From personal discussion with Professor Kurt Kroenke, I chose to
operationalise a 'clinical treatment response' as > 50% reduction in the PHQ-9 score
from the pre-treatment score.
Modification of the trial treatment
A treatment guideline algorithm (in the Quality Control Manual Appendix C) was
used to modify individual treatment programmes, which includes a formal
assessment of clinical treatment response at session five. The treatment team
reviewed all patients not achieving a treatment response in clinical supervision
sessions. Review included: re-assessment; changes to the coping skills training or
changes in the patient's antidepressant medication or dose. In addition, at any stage
of the treatment programme, patients assessed as being at immediate high risk of
suicide received an emergency review by the supervising psychiatrist or by a
member of the hospital psychiatric team.
If the patient achieved a 'treatment response' during intervention, an individualised
'relapse prevention plan' was developed with the patient as per treatment manual
(Appendix A).
Administration and quality control of the treatment intervention and
assessments
The supervising consultant psychiatrist and I provided supervision for all the team
members. The focus of the supervision for the treating nurses was adherence to the
treatment model and discussion of problems arising during treatment. The focus of
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supervision for the research assistants was adherence to the diagnostic criteria of the
SCID assessment and discussion of cases difficult to diagnose for which a consensus
decision on diagnosis was made.
Treatment compliance
Compliance of patients to the trial intervention was analysed according to the
following definitions that were developed to incorporate the two components of the
intervention that could be most accurately measured, antidepressant use and
attendance for the face-to-face problem-solving treatment sessions with the nurse.
Non-compliance was defined as not taking any antidepressant drugs and attendance
for less than two sessions of problem-solving treatment; partial compliance was
minimum compliance in either problem-solving (attendance for two sessions) and/or
in antidepressant medication (taking an antidepressant drug); full compliance was
attendance for more than two sessions (with completion of session work and
homework) and taking an antidepressant drug at therapeutic dose of antidepressant as
doses greater than the minimally effective doses according to prescribing guidelines
(Taylor et al 2005), modified to accept 75mg as effective for tricyclic
antidepressants (Furukawa et al 2002).
Treatment integrity
All therapists were registered nurses with experience in oncology trained according
to a manualised protocol (in Appendix C). Training was delivered over six months
on a part-time basis (twenty-five hours per week) and all therapists were certified for
competency prior to starting treatment in the trial. Certification entailed completion
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and assessment of training in communication skills, SCID diagnostic assessment,
suicide risk assessment and management, basic antidepressant medication
knowledge, case-management, self-management, treatment adherence monitoring,
and problem-solving therapy. Assessment of the major components of the training
was conducted using review of role-play sessions plus assessment of the treatment
delivered to at least five patients and adherence to the treatment manual formally
assessed on the last two patients treated.
Therapists received weekly supervision from the supervising psychiatrist. All therapy
sessions were video-taped and treatment integrity assessed at three monthly intervals
on a randomly selected sample of at least five sessions. Treatment integrity was
defined as adherence to the treatment protocol in at least 80% of the sessions
reviewed over the twenty-four months of treatment delivery and assessed according
to the Quality Control Manual (Appendix C). In addition to this, should a therapist
fail an adherence assessment, thereafter a 5% randomly selected sample of all session
recordings would be assessed for treatment integrity by an independent assessor.
Validity of baseline and outcome assessments
In order to make the diagnostic SCID assessment as valid as possible, a second rater,
blind to the patient's allocated treatment and independent of the trial team, reviewed
taped recordings of the SCID assessment, edited to remove any reference to




Before conducting any trial follow-up assessments, the patient's survival status was
checked by contacting the patient's GP practice. For non-responders to phone and/or
questionnaire follow-up, a reminder letter was sent to the patient. If still no
questionnaire data was received, the team attempted to contact the patient again to
obtain the minimal data (SCL-20) by telephone interview. If all data was refused a
reason was obtained and recorded.
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THE MEASURES USED IN THE TRIAL AND THEIR JUSTIFICATION
I chose to use both self-rated scales and interview-based measures to increase the
robustness of the findings. At baseline, three months and six months, all patients in
the trial were asked to complete self-report questionnaires (appendix D) and a
diagnostic assessment and semi-structured interview over the telephone as listed in
Table 4.1.
From pilot data, the time point at which the maximum effect of treatment was
detectable was at three months and I therefore chose this as the principal outcome
time point. Three months after entry to the trial, there is also less likelihood of
missing data due to patients dying or becoming too ill to participate. However,
measures were also planned at six months to look for persistent and stable
improvement.
The principle outcome measure for the trial was the difference in mean scores on the
SCL-20 measure between the treatment groups at three months.
The secondary outcome measures were to compare between treatment groups at three
months: a) the proportions with a treatment response dichotomised on the SCL-20 as
those patients achieving or not achieving a 50% reduction in the total SCL-20 score
from their baseline score (baseline scores had to be > 1.72); b) the proportions of
patients no longer meeting DSMIV criteria for MDD; and c) the proportions
achieving remission of depression as defined by a SCL-20 score of <0.75.
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The measures used are summarised in table 4.1 and described in more detail in the
section that follows.
Table 4.1 Variables measured in the trial
Semi-structured interview
Demographic information
History of depression and treatment
Current depression and service usage
Cancer status (and from medical notes)
Psychiatric diagnostic interview (by telephone)
Psychiatric diagnosis ofMDD




Subjective rating of confidence, problem-solving ability, and social support
In addition, at 6 months only:
Satisfaction with depression care
Demographic information
Data was collected at the eligibility assessment interview on the following: age,
gender, marital status, whether living alone and employment status. The Scottish
Index ofMultiple Deprivation (SIMD) score (Scottish Executive 2004) was
calculated from the patient's postal code. This score defines poverty in terms of
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relative deprivation by combining information from all five deprivation domains:
income, employment, health, education and access to services. A higher score
represents more poverty.
History of depression and treatment
Data about previous episodes of depression, about treatment received and duration of
treatment was collected at the eligibility assessment interview. In addition to this,
any psychiatric notes were reviewed.
Current depression and service usage
At the diagnostic telephone interview, current depressive symptomatology was
assessed and date of onset of the current depressive episode noted. Current usage of
antidepressant medication, psychological services, complementary and alternative
therapies and of health services was also recorded. For the three and six month
assessment interviews, the recording of service usage related to the previous three
months.
Description of the cancer
I reviewed the patient's oncology case notes prior to randomisation to extract data on
the following: disease site and diagnosis; first or second diagnosis; primary or
recurrent; extent of disease (disease free, local disease, metastases); current
management (monitoring, under investigation, pre-treatment); and whether on active
treatment (radiotherapy or chemotherapy), using a data collection form and working
data definitions validated by an oncologist (see appendix E).
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Psychiatric diagnostic interview
The presence ofMDD and depressive symptoms was determined at the diagnostic
assessment interview using the MDD section of the SCID. MDD requires the patient
to have experienced at least five of nine specified symptoms during the same two-
week period in the previous month and must represent a change from previous
functioning. One of the five symptoms must either be persistent depressed mood or
loss of interest or pleasure in all or almost all activities. Other symptoms included in
the diagnostic criteria are: insomnia or hypersomnia; significant increase or decrease
in weight or appetite; psychomotor agitation or retardation; fatigue or loss of energy;
feelings ofworthlessness or inappropriate guilt; diminished ability to think or
concentrate or indecisiveness; recurrent thoughts of death or suicidal ideation.
Complexity arises in assessing depressive symptoms of patients with medical illness
as many of the symptoms ofmedical illness are similar to symptoms of depression.
Of the advocated solutions to this, there are two approaches appropriate for the
cancer population. The first is the 'exclusive' approach which originated from
research done by the Sloan-Kettering Cancer Institute, (Bukberg et al 1984; Plumb
and Holland 1981) that advocates eliminating the symptoms of anorexia and fatigue
from the nine symptoms of the SCID and making the diagnosis ofMDD reliant on
meeting four out of the remaining seven symptoms. This approach makes it harder
for patients to meet the restricted criteria and may result in a loss of sensitivity,
leading to false negatives. The alternative approach for cancer patients is the reverse
of the 'exclusive' approach. The 'inclusive' approach used by Rifkin and colleagues
(1985), whereby diagnostic decisions are made on the evaluation of observable
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phenomena, does not require aetiologic inferences as advocated by Spitzer and
colleagues (1984), the developers ofDSM-III. Its sensitivity may therefore be high
but specificity lower, possibly leading to over-diagnosis ofMDD. I have chosen the
latter approach for the following reasons. From clinical experience, fatigue and
anorexia are not the only two symptoms shared by patients with the illnesses, cancer
and depression. Depending on the nature of the anticancer treatment, and the extent
of disease, other physical and psychological criteria of the MDD diagnosis can also
be present in patients with cancer, such as insomnia and diminished ability to think
or concentrate. This, together with the need for a method of assessment that requires
as little subjective assessment as possible to increase inter-rater reliability, has
influenced my choice of the 'inclusive' approach for this research trial.
Symptoms were therefore counted toward the diagnosis if present and no judgements
about the aetiology of particular symptoms were made. The interview is a semi-
structured interview and requires training of those individuals administering the
interview. All researchers involved in this trial were trained in its use and deemed
competent in formal assessment including review of taped interviews. Its use by
trained clinicians offers a reliable diagnosis (Williams et al 1992) and is considered
the 'gold standard' interview. For this trial the interview was administered by
telephone. Telephone administration of the SCID interview has been previously
shown to be acceptable to patients (Allen et al 2003).
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Depression
I chose the 20 -item Hopkin's Symptom checklist Depression Scale (SCL-20) as the
principle outcome measure with the primary outcome being the difference in mean
scores on the SCL-20 measure between the treatment groups. The SCL-20 has been
used as an outcome measure in primary care clinical trials of depression management
(Katon et al 1995; Katon et al 1996; Williams et al 2000). It has been found to have
high reliability and validity in multiple studies with medical patients and to be
sensitive to change in depressed primary care patients (Derogatis et al 1974). It is a
short self-report measure derived from the SCL-90 (Derogatis et al 1973) asking the
patient to rate the presence of symptoms 'in the past month', on a measure of a
severity scoring system in the following categories: 'not at all'; 'a little bit';
'moderately'; 'quite a bit'; and 'extremely', scoring 0-4. The score is calculated by
dividing the sum of the scores of each question by the number of questions.
Current criteria for determining improvement in depression aim to distinguish
between different degrees of symptomatic improvement, such as remission or
response. Remission is considered to be a marker ofwellness for various chronic
medical illnesses and treatment is often given until remission is achieved. Similarly
remission of symptoms serves as a marker ofwellness in mood disorders and can
serve as a clinically relevant marker for optimal treatment outcome (Keller 2003).
Based on this concept and on treatment outcome definitions used in similar clinical
trials, I chose to distinguish between a treatment response (50% reduction in the
SCL-20 score from baseline) and remission (a SCL-20 score of<0.75). Remission
was defined in trials ofprimary care patients by Katon's research group as <0.5
(Unutzer et al 2002). However, remission of depression maybe harder to achieve in
cancer patients because of the high somatic symptoms associated with the disease.
This is farther complicated by the fact that cancer patients are often older and
consequently more likely to have other medical problems. Therefore after discussion
with Professor Wayne Katon, a remission score for the group of patients chosen for
this trial of <0.75 was thought to be more clinically realistic. This score was arrived
at by taking the minimal plausible score for patients without depressive symptoms
together with the maximum scores for somatic symptom items to reflect high cancer
symptom burden.
Anxiety
Anxiety was measured using the 10 anxiety items of the SCL-90 questionnaire
(Derogatis et al 1973). The questions relate to symptoms or feelings experienced
"over the last week, including today", on a severity scoring system in the following
categories: 'not at all'; 'a little bit'; 'moderately'; 'quite a bit'; and 'extremely',
scoring 0-4 respectively. The final score is the average of the item scores.
Physical functioning
Physical functioning was assessed using the physical functioning scale from the
EORTC-QLQ-C30 (Aaronson et al 1993) self-report measure. The EORTC-QLQ-
C30 is a widely used self-report measure in clinical trials shown to have good
reliability and validity. The physical functioning scale has 5 items and a total score of
0-100, higher scores representing better functioning (Fayers et al 2001).
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Confidence, problem solving ability, social support
Identifying the mechanism of action of problem-solving therapy would logically
direct research to measurement of self-efficacy, such as confidence, and control.
However a recent trial of depressed patients in primary care suggests that self-
control, mastery, and perception of problem severitymay be proxy measures of
depressed mood (Mynors-Wallis 2002). Depression therefore appears to confound
the determination of the mechanisms of action of problem-solving therapy. I have
adapted available measures to focus mainly on measures of problem-solving ability
using the 'problem-solving and coping strategies' items from the IMPACT study
measures and have included one simple question to measure self-efficacy also used
in the IMPACT study (Unutzer et al 2002). Self-efficacy (confidence) was measured
using a simple Likert-type scale ranging from 0-10. Problem-solving ability was
assessed using three items concerning ability to address problems and the ability to
consider the pros and cons of possible solutions, each item being scored individually
on a scale of 1-4. For all scales higher scores indicated better coping.
In terms ofmeasures of social support, there is a lack of consensus on the definition
of social support. The variability occurs around the concept, mainly: type of support;
perceived availability versus actual support received; and amount of support versus
actual, (Shroevers et al 2003). Furthermore, the reliability and validity ofmost social
support scales have not been adequately tested. Having reviewed many measures, I
have adapted measures used in the IMPACT study (Unutzer et al 2002), resulting in
two simple questions concerning perceived availability of support and likeliness to
use the support available which performed as a scale, ranging from 2-8.
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Satisfaction
At six months, in addition to the above measures, satisfaction with depression care
was assessed using a 7-point scale as used in similar trials (Unutzer et al 2002), a
score of 1 representing 'no care received', 2 'can't answer' and 3-7 poor to excellent,
3 being 'poor' and 7 being 'excellent'.
ETHICAL APPROVAL
The patient's consent to participate in the trial was obtained after a full explanation
had been given of the treatment options, including the conventional and generally
accepted methods of treatment. The patient information sheet and patient consent
form are attached (see Appendix F). The right of the patient to refuse to participate in
the trial without giving reasons was respected. Similarly, the patient was free to
withdraw at any time from the protocol treatment or from the trial without giving
reasons and without prejudicing his/her further treatment.
For all patients their GP was informed of their progress following each trial
assessment. Management advice was given or direct referral to the hospital
psychology services was made.
The protocol for this trial was approved by the Local Research Ethics Committee
(LREC), division of Primary Care/Public & Mental Health Research, LREC Number
2002/7/39. LUHT NHS R&D approval was also obtained - approval reference
number 1632.
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Exploration ofbaseline predictors ofoutcome at three months
EORTC-QLQ-C30




Data from stage one of the screening process was imported from the touch screen
computers in the outpatient department using Excel and downloaded into the
individual patient file in the Trial's main Access Database. Data from the second
stage of screening was entered manually from the paper scoring sheets completed
during the telephone diagnostic interview and the relevant telephone recording
(digitally taped using Retell software) attached to the patient's database file in WAV
format. All other data was entered from the paper forms into the Access database. All
hand entered data was checked for errors. In addition to this, data was checked for
errors of entry by looking for extreme values. All possible errors were checked back
against the paper forms.
All data were analysed using the statistical package SAS version 9.1 and STATA
version 9. The analysis was then performed in a systematic fashion to test pre-stated
hypotheses as follows.
Representativeness of study sample and throughput
Patient throughput from initial screening to trial recruitment was reported, detailing
reasons for patient exclusion and trial refusal. Data for the whole group and those
patients refusing trial participation were described with respect to age, gender, cancer
type and social deprivation score.
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The throughput of patients after randomisation to the trial through follow-up at three
and six months was summarised using the system recommended in the CONSORT
statement on the reporting of trials (Moher et al 2001).
Descriptive data
Data for the whole sample and by treatment group were described. Binary and
categorical variables were presented using numbers with percentages, continuous
using means and standard deviations, or in the case of non-normal data, medians and
ranges. No tests of statistical significance were conducted for differences between
the randomised groups for any baseline variable.
Baseline characteristics
The patients' baseline characteristics were described with respect to age, gender,
marital status (married or cohabiting, single, divorced or separated and widowed),
living situation (living alone, living with partner and other living arrangement),
employment (professional, clerical, manual, unemployed, student,
housewife/husband, medically retired and retired), social deprivation, depression
variables (duration of current depressive episode, previous number of depressive
episodes), current depression treatment (GP contact, antidepressant prescribing,
medication adherence), cancer variables (cancer type, number of primary cancers,
time since first diagnosis, time since most recent cancer diagnosis, extent of disease,
treatment stage) and current cancer treatment (radiotherapy, chemotherapy or both).
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Baseline measures
The patients' baseline measure scores were described with respect to initial screening
HADS, depression (the number of SCID items endorsed and SCL-20 score), anxiety,
physical functioning and coping. As the whole EORTC-QLQ-C30 was used for
assessment, the global health and quality of life, and the functioning and symptom
scales were also described at baseline.
The treatments
Nurse therapist efficacy
The relative efficacy of the nurse therapists was determined by comparing patient
outcome between therapists. No statistical analysis was performed as allocation of
patients to therapists could not be random for practical reasons.
Treatment integrity
Treatment integrity was presented as the percentage of face-to-face sessions rated as
adhering to the treatment manual on a randomly selected sample of at least 10% and
on a further 5% randomly selected sample by an independent assessor.
Treatment compliance
Treatment compliance of the patients in the intervention group was presented as the
proportions of patients achieving full, partial or no compliance together with the
number of therapy sessions attended shown for each category of compliance.
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Non-trial treatments received during the trial
The use of services in the three months preceding the trial outcome assessments other
than those delivered in the trial were described by treatment groups with respect to
use of GP services, mental health specialists, clinical nurse specialists, counselling
services and complementary/alternative therapies.
Missing data
Individual scales were examined to assess the level ofmissing responses. In
accordance with the EORTC scoring manual, missing scores on the EORTC
questionnaire were taken as the average of all present items when less than half the
items on a scale were missing, but were considered missing when at least half of the
items were missing. For the SCL-20 and SCL-90 measures, when less than half the
items measure were missing, the scale score was calculated by dividing the total item
scores by the number of questions answered.
The trial
The study was designed to determine whether supplementing optimised usual care
with the nurse-delivered intervention achieved a greater improvement in depressive
symptoms at three months after randomisation than optimised usual care alone.
An "intention to treat" analysis strategy was employed (Pocock 1983). This is used in
analyses of RCTs and compares all patients in the groups to which they were
originally randomly assigned, even if they did not complete treatment or were later
found not to meet eligibility criteria. The use of this method of analysis reduces the
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risk of overestimating the clinical effectiveness of a treatment (Hollis and Campbell
1999).
Primary outcome
The relative efficacy of the two treatment conditions was determined by calculating
the statistical significance of the difference in mean scores on the self-report SCL-20
between the treatment groups at three months after randomisation. A P value of 0.05
was taken to indicate statistical significance. Analysis ofCovariance (ANCOVA)
was performed using the three month SCL-20 score as the dependent variable whilst
adjusting for the baseline SCL-20 score and the minimisation variables of age,
gender, diagnosis and extent of disease. The validity of this method of analysis was
examined by confirming that the residuals from the fitted model were normal in
distribution. The adjusted mean difference between the groups was presented in
tabular format with 95% confidence intervals and corresponding P value and
graphically as a dot plot indicating the change from baseline to three months in mean
SCL-20 score + 2 standard errors by treatment groups. The standardised effect size
was calculated.
Sensitivity analysis
The analysis for the primary outcome was repeated imputing a 'no change score' for
patients with missing data and presented in tabular format.
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Subgroup analysis
An interaction term was fitted into the ANCOVA model for the three month SCL-20
to determine whether the treatment effect was different in the subgroups for age (age
band <40, 40-79 and >80; cancer type (breast, colorectal, gynaecological and other
cancers); disease extent (disease free, local disease and metastases) and gender. The
results were presented with P values to indicate statistically significant interactions.
Secondary outcomes
All secondary analyses were performed for exploratory purposes only. Statistical
significance was defined as a P value of 0.01 to limit chance findings as a result of
multiple testing.
Depression measure
The relative efficacy of the two treatment conditions was further determined by
comparing the proportions of patients achieving a clinically significant outcome
between the treatment groups at 3 months. Clinical significance was specified as a
50% reduction in SCL-20 score from baseline; a SCL-20 score of <0.75 and no
longer meeting the criteria for MDD on the SCID. All analyses were performed
using logistic regression adjusting for baseline measurement and minimisation
factors and the intervention effect was presented as Odds Ratio with 95% confidence
intervals and P values.
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Relative measures of effect
In order to examine further the clinical significance of the results several additional
calculations were made. The relative risk reduction, absolute risk reduction and
number needed to treat were presented for all clinical indicators and standardized
effect size calculated for the interview-based outcome with 95% confidence
intervals.
Anxiety, physical functioning and coping measures
Differences in the other secondary outcome measures, (EORTC-QLQ-C30 physical
functioning scale, SCL-90 10 item anxiety measure and coping measures), between
the treatment groups were also compared to illustrate and elaborate the main finding.
Measures not normally distributed were transformed and ANCOVA was used for all
measures other than problem-solving, adjusting for baseline SCL-20 scores,
minimisation factors and the outcome measure. The mean difference was presented
as the intervention effect with 95% confidence intervals and P values. For the
problem-solving measure, each item was analysed separately as a comparison
between the treatment groups from baseline to three months in the proportions
endorsing values representing good problem-solving skills.
Six month follow up
Secondary outcomes
No statistical analysis was undertaken at six months as three months was the primary
outcome. The six month outcome was described in two ways: first by describing, by
treatment groups, the proportions with no change or improvement on all secondary
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outcomes (50% reduction in SCL-20 score from baseline; a SCL-20 score of <0.75;
no longer meeting the criteria for MDD on the SCID; EORTC-QLQ-C30 physical
functioning scale; SCL-90 10 item anxiety measure; and coping measures) and
second by plotting the raw SCL-20 scores by treatment group over time presented as
a box plot.
Satisfaction with care
For a satisfaction rating of care received during the trial, the proportions endorsing
care in seven categories of'no care received' to 'excellent' was presented in a table.
Exploratory analysis
Process of change
Changes in measures of a) confidence, b) coping, and c) social support, were
examined at three months as a measure of treatment process. To establish whether
improvement in depression scores was mediated by improvement in aspects of
confidence, coping and support, change in SCL-20 depression scores for each
treatment group was plotted against changes in each of the coping items measured
and its association examined using Spearman's Rank Correlations Coefficient with P
values at the 1% level to indicate significance.
Exploration of baseline predictors of outcome at three months
To identify independent predictors of adjusted SCL-20 score (adjusted for treatment
and baseline SCL-20 score) at three months, a model was fitted to include extent of
disease, duration of depressive episode and number of previous episodes (as
categories of duration more or less than 1 year, and no episodes versus any)
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alongside treatment and SCL-20 baseline score and presented in tabular format to
show effect estimates and p-values.
EORTC-QLQ-C30
All analyses were exploratory. Chance findings resulting from multiple testing could
have occurred therefore even when significance was taken at the 1 % level all results
were considered as an area highlighted for future study rather than a statistical
finding. The scales analysed were those examining functioning (role, emotional,
social and cognitive), global health and quality of life, pain and fatigue.
Analysis of covariance was performed, adjusting three month scores for baseline
score and the four minimisation factors (age, sex, diagnosis and extent of disease).
The adjusted mean difference between the groups was presented in tabular format
with 95% confidence intervals and corresponding p value.
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SAMPLE SIZE AND POWER CALCULATION
The purpose of a sample size calculation is to ensure that the proposed study has a
high chance of detecting, as statistically significant, a worthwhile or clinically
significant effect if it exists, and also to enable us to be reasonably sure that no such
benefit exists if it is not found in the trial.
We considered a difference in proportions of 20% as a clinically meaningful
difference. The initial power calculation was therefore based on detecting a 20%
difference in the proportion of responders (from 20% to 40% of patients achieving a
treatment response defined as a 50% reduction in their SCL-20 score from baseline).
This required 200 cases in total to achieve 80% power with a two-sided significance
level of 0.05 and allowing for an attrition rate of 10%. When the analysis plan was
written prior to trial closure, unblinding and analysis, it was decided to change the
primary outcome to be a difference in the mean SCL-20 score on the advice of the
senior statistician. The reason for this was to maximize the ability of this efficacy
trial to detect a difference between the treatments. When other similar trials were
examined to identify a difference in mean SCL-20 score that equated with our
previous definition of a clinically meaningful treatment response of a 20% difference
in the proportions of responders, a difference in means of 0.21 on the SCL-20 was
identified. This was based on both personal communication with Professor Wayne
Katon and from the results of the IMPACT trial (Unutzer et al 2002) of a difference
in mean SCL-20 scores of 0.28 and standard deviation of 0.5 at four months between
the control and intervention group. The sample size was therefore re-calculated using
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the previous statistical assumptions of 80% power with a two-sided significance level
of 0.05 and allowing for an attrition rate of 10%as follows:
Calculation formula from Altman 1991:
n= 2a2 (Ua+ UB)2
02
where:
n = number of patients per group
a = Standard deviation
0 = effect size (i.e. difference in proportions)
Ua and Up are values calculated from the normal distribution, depending on alpha
and beta. For continuous data: at 80% power Ua = 1.96 and with a standard
deviation of 0.5 Up= 0.84.
therefore:
n= 2 x 0.25 x (1,96 + 0.84)2
0.212
n=88.89
Based on pilot work for this trial patient attrition would be less than ten percent.
Adjusting for 10% loss of follow-up data: 88.89 = 98.77 per group
0.9
Therefore with a total sample size of at least 198, 99 in each group, at a significance
of 5% and a power of 80%, I would be able to detect a true difference of 0.21 in the
mean SCL-20 scores between the groups, when it was used as a continuous scale
assuming a standard deviation of 0.5.
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Hypothesis: Usual care plus a nurse-delivered, psychiatrist-supervised multi-
component treatment intervention reduces symptoms ofmajor depressive disorder
patients with cancer to a greater extent than usual care alone.
RECRUITMENT OF THE TRIAL SAMPLE
Depression Screening
Between 20th June 2003 and 13th January 2006, 8,386 patients were screened using
the HADS and the PHQ as part of an automated touch screen symptom screening
system and for a smaller proportion only the HADS as a paper version. The
automated system is a symptom screening service developed by our Research Group.
As routine practice all patients attending the Edinburgh Cancer Centre outpatient
department are invited to complete symptom screening questionnaires prior to their
oncology consultation. Those patients attending cancer clinics held elsewhere in the
Hospital completed a paper HADS only. Patients who had scored a total HADS score
>15 or a score of >10 on the depression subscale or who had endorsed a question
about suicidal ideation on the automated PHQ were identified for further assessment.
Referrals of patients from Consultants were also accepted for further assessment.
Further assessment involved a phone delivered SCID to identify those patients with
probable or definite Major Depressive Disorder.
Because patients were screened at every clinic attendance, each patient had multiple
screening events recorded. In order to report on patients as opposed to their multiple
screening events, the data for this dataset was selected on the patient's last positive
(MDD) SCID. For those who did not receive a SCID their last high scoring screening
event was selected. For those who did not score high on stage 1 screening
(questionnaire), their last screening event within the time frame was selected. The
details of this are illustrated in Figure 6.1.
Figure 6.1 Screening and assessment ofpatients for probable or definite MDD.
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Over 30 months of screening, 8,386 patients were screened in the following
outpatient cancer clinics: colorectal, breast, gynaecological, genitourinary, sarcoma,
melanoma, haematological, lung and mixed cancers. Referrals from Oncologists
were also screened for depression (n=9). Of the 8,386 patients, 560 (7%) refused
screening (stagel and stage 2 combined), with most refusing to stage 1 screening
(514 refused stage 1 questionnaire screening and 46 refused the stage 2 SCID
interview [see table 6.1]). Of the 8,386 patients, 400 (5%) patients were excluded
from screening (140 excluded at stage 1 screening and 260 excluded from stage 2
SCID [see table 6.12]). We missed screening 620 (7%) patients and incomplete or no
data accounted for 74 patients. We therefore screened 6732 (80%) of the patients
attending the outpatient cancer clinics during the stated time period.
Table 6.1 Reasons for refusal at each stage of screening and assessment








Doesn't want to do it/ Doesn't feel it would help 403 18
Questionnaire/assessment issues 43 3
Doesn't feel depressed/anxious 20 0
Receiving care already/Prefers to see other health care 17 3
professional
Feels emotionally too unwell 12 3
Last clinic visit/Nothing has changed since last visit 11 n/a
Too busy/too many problems/Wants to work on it themselves 3 5
Other* 2 1
No data 3 13
*Recentiy bereaved (1); worried about confidentiality (2)
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Table 6.12 Reasons for exclusion at each stage of screening and assessment
(reasons are exclusive) (n=400)






Unable to contact n/a 98
Advised by Oncology staff not to screen/assess 4 77
Too unwell 56 21
Communication problems 29 14
Interrupted screening/protocol change/screened recently 32 10
(< 6 weeks ago)
Cognitive problems 15 4
Deceased n/a 10
Other* 4 15
No data 0 11
*Borderline HADS (7); assessment not done as prior to start of trial (5); patient already being
used as 'training patient' (2); handcuffed (2); receiving care already (1); questionnaire
completed by escort nurse (1); attending cancer centre for 2nd opinion only (1).
Of the 7,045 patients who completed stage 1 screening in clinic, 2015 (29%) patients
scored high on the HADS (HADS > 15 or HADS-D > 10) or had endorsed the
question about suicidal ideation on the PHQ-9 questionnaire. 2036 patients
proceeded to stage 2 of the screening, which included 9 referrals from clinicians and
12 patients who had appeared low in mood in clinic, had declined stage 1 screening
but had agreed to the telephone interview. Of the 1723 completed SCID interviews,
660/1723 (38%) patients were diagnosed with MDD on the SCID. The MDD
prevalence rate (unadjusted for the 20% not screened) in patients attending (selected)
outpatient cancer clinics at the Western General Hospital is 7.9% (660/8386).
From the patients screened (as described above), 660 patients were diagnosed with
MDD from the telephone SCID interview. The flow of patients through the screening
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and assessment stages of trial recruitment is shown in Figure 6.2. All patients
diagnosed with MDD with an expected survival status ofmore than 6 months as
indicated by their hospital consultant, were approached about the trial.
Figure 6.2 Screening and assessment for trial recruitment.
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Exclusions
Trial eligibility was assessed in 3 stages: A brief assessment obtained during the
SCID interview, designed to exclude the majority of people with chronic depression
or high suicide risk; a semi-structured telephone assessment designed to identify
those patients for whom travel would be burdensome thus avoiding patients having
to travel unnecessarily to the hospital for assessment; and a semi-structured face-to-
face assessment interview, designed primarily to exclude those patients with lower
severity depressive symptoms.
The results of the 3-stage trial eligibility assessment are discussed below and detailed
in Table 6.13. Reasons for ineligibility are not exclusive. Clustering ofmultiple
reasons for trial exclusion occurred most frequently in reasons for psychiatric
exclusion.
Exclusion criteria
Patients excluded from the trial are those:
a. with an expected survival of less than 6 months as predicted by their cancer specialist
b. with another complicating and uncontrolled medical problem (such as poorly controlled
epilepsy or cerebral metastases) or where antidepressants are contraindicated for medical
reasons
c. who are too ill to participate in treatment because of the cancer or its treatment
d. who have a complicating major psychiatric diagnosis (i.e. bipolar affective disorder,
psychosis, severe personality disorder) or an alcohol or substance misuse problem
e. who have chronic depression with a history of continuous depression for more than two years
prior to the screening diagnostic interview
f. who are receiving active treatment for their depression from a psychologist or psychiatrist
g. who are judged to be in need ofurgent psychiatric treatment
h. who are unable to communicate adequately because of language problems or cognitive
impairment
i. who live outside reasonable travelling distance
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Table 6.13 Reasons for ineligibility at each stage of eligibility assessment
(reasons are not exclusive) (n=282)











Expected survival of less than 6 19 5 2
months
Uncontrolled medical condition 0 2 0
Feels physically too unwell 0 7 5
Comorbid psychiatric diagnosis 10 4 2
Current alcohol or substance 12 4 3
misuse
Chronic Depression 62 6 4
Receiving current 33 12 1
psychological/psychiatric
treatment
High suicide risk 31 2 0
Communication problems 0 2 2
Too far to travel 7 26 2
SCL-20 <1.72 0 6 64
Other* 13 17 3
No data 1 0 0
*MDD of borderline 1 month (14); starting Ribavirin treatment (1); antidepressants contra-
indicated (1); previous non-adherence to treatment programmes (1); not able to take time off
work to attend for trial treatment (1); recently bereaved (2); discharged from Oncology
services (6); about to start intensive anti- cancer treatment (2); out of country for next 6
months (1); can't attend as full-time carer (1); recruitment stopped (3).
Medical exclusion (a, b, c)
Survival: Of the 660 patients identified with MDD, 26 patients were deemed by their
cancer specialist to have an expected survival of less than 6 months.
Comorbid uncontrolled/complicating medical problem: Medical problems assessed
as uncontrolled or complicating (uncontrolled heart condition and unstable diabetes)
were found in 2 cases.
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Too ill to participate because of the cancer or its treatment: 12 patients considered
themselves too frail or unwell.
Clustering of reasons did not occur within the medical exclusion criteria but occurred
with 'feeling too ill' and 'feeling the travel would be too burdensome'.
Psychiatric exclusion (d, e, f, g)
Of the 660 patients with MDD, the most common exclusion reason at this stage was
a reported history ofmore than 2 years of continuous depressive symptoms, defined
as chronic depression. Clustering of ineligibility reasons occurred in all the criteria of
psychiatric exclusion.
Co-morbid psychiatric condition or substance/alcohol misuse: 16 patients were
excluded due to previously diagnosed co-morbid psychiatric conditions (eating
disorder 3; chronic anxiety disorder 2; dementia 2; obsessive compulsive disorder 2;
cognitive impairment due to Parkinson's 1; depressive psychosis 1; agoraphobia 1;
bipolar affective disorder with obsessive compulsive disorder 1; chronic and severe
somatisation disorder 1; schizoid personality 1; personality disorder 1), 19 patients
had a current problem with alcohol abuse ofwhich 3 patients also had a current
problem with drug or substance misuse.
Continuous depression for more than 2 years prior to the SCID diagnosis ofMDD:
72 patients were assessed with chronic depression.
Active treatment from a psychiatrist/psychologist: 46 patients were being treated for
their depression and/or other psychiatric diagnoses by mental health specialists.
Requiring urgent psychiatric referral: Of the patients assessed for trial eligibility, 33
patients were assessed as having a suicide risk high enough to warrant immediate
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attention. For these patients, their GP was informed and their care was managed from
primary care services.
Exclusion other reasons (h, i, and 'other')
Four patients were excluded due to communication problems and 35 patients felt
unable to travel to the Research Centre for the trial. Other exclusion reasons are
tabled above, which included one patient who was receiving a chemotherapy trial
agent. Following discussion with the relevant pharmaceutical company the patient
was excluded due to possible drug interaction with antidepressant medication.
Failure to meet study criteria for MDD on the SCL-20 depression measure
Of the patients assessed with the SLC-20 questionnaire, 70 patients were found not
to meet the study criteria SCL-20 score for MDD of > 1.72.
Two patients were never assessed for trial eligibility due to a system error.
Refusals
Numbers of and reasons for refusals at all stages of screening and assessment are
shown in Figure 6.2 and Table 6.14. All reasons are exclusive.
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Table 6.14 Reason for trial refusal at each stage of assessment (reasons are
exclusive) (n=134)











Doesn't want to do it/not 16 27 0
interested/doesn't feel it would help
Wants to work on it themselves/too 10 26 1
many problems/too busy
No reason given 3 12 1
Doesn't feel depressed 0 13 1
Wants to see other HCP/would rather 3 7 2
see GP/receiving GP care already
Other* 2 10 0
*Worried about confidentiality (4); feels too unwell (3); doesn't like hospitals (3); too deaf (1);
GP advised patient not to take part (1).
Of those approached about the trial following a positive diagnosis on the SCID
interview, 34 patients refused trial information. Of the 463 patients proceeding to the
2nd stage of eligibility assessment, the telephone assessment stage, 87 patients
refused the eligibility assessment. The most common refusal reason given was either
'not interested' or 'doesn't want to take part in the trial'. Of the 284 patients who
completed the final stage of eligibility assessment five patients refused. The
percentage ofpatients who refused trial participation was 20% (134/660).
The characteristics of those who refused were compared with the 200 trial
participants showing only a marginal difference between them in cancer type. More
patients with testicular, prostate or urological cancers participated in the trial,
whereas more haematology patients refused trial participation, see Table 6.15. On the
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characteristics examined, the sample of patients who took part in the trial was
representative of the total sample of trial eligible patients diagnosed with MDD.
Table 6.15 Demographic characteristics comparing trial participants and refusers.




































Scottish Index ofMultiple Deprivation score1 12.87






Two hundred patients agreed to trial participation, were consented and randomised.
Randomisation was in almost all cases performed on the same day of consenting. On
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three occasions, the trials unit were unable to provide a randomisation service that
day and in these cases all patients were randomised within 3 days of completing the
trial consent and baseline questionnaires.
Final sample size
Patients were recruited into the study between 16th October 2003 and 19th December
2006. Recruitment was stopped when 200 eligible patients who had given consent to
participate in the study, had been randomised. Full descriptive data was collected on
these patients, who represented 59% (200/337) of the potentially eligible patients.
DEMOGRAPHIC CHARACTERISTICS OF THE SAMPLE AT BASELINE
Gender
It can be seen in Table 6.16 that the sample was predominantly (70.5%) female with
a mean age of 56.6 years.
Living arrangements
The majority (75%) of patients were living with someone, either partner, children or
friend. Only 50 patients (25%) were living alone.
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Currently divorced/separated 33 (16.5)
Widowed 13 (6.5)
Living situation
Living alone 50 (25)
Living with partner 131 (65.5)
Other living arrangement 19 (9.5)
Deprivation
The Scottish Index ofMultiple Deprivation (SIMD) Score (Scottish Executive 2004)
was used to determine the overall deprivation based on the five domains of income,
employment, health, education and access. The SIMD score for the sample was
13.98, indicating that almost 14% of the sample were deprived, see Table 6.17.
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Employment
The pre-illness occupations of the patients covered a range ofjobs; 16% were in
professional positions and 14% were unemployed, see Table 6.17.









Medically retired 8 (4)
Retired 72 (36)




ILLNESS CHARACTERISTICS OF THE SAMPLE AT BASELINE
Depression
The median duration of depressive symptoms prior to assessment was 7 months
although the range extended from 2 to 24 months and for 34.5% (69/200), this was
their first episode of depression, with 45.5% (91/200) reporting having had one
previous episode and 20% (40/200) reporting having had more than one previous
episode of depression. 37% (72/200) of the sample had spoken to their GP about
their current episode of depression. Of these, 75% (54/72) had been offered an
antidepressant, ofwhich 69% (37/54) had accepted a prescription and were taking
them, although only 69% (35/54) of patients had been prescribed an antidepressant
deemed to be prescribed at a therapeutic level i.e. the minimum effective dose
(adequacy of dose defined by the dose specified in the British National formulary
(www.bnf.org) taking into account evidence by Furukawa et al (2002) suggesting
that tricyclic antidepressant drugs may be effective at a lower dose of 75mg, (see
Table 6.18).
89




Duration of current depressive episode in months
Median (range)
7 (2, 24)






Spoken to GP about current episode 72 (37)
(no data = 3)
54 (27)
Offered antidepressant medication
(no data = 2)
Prescribed antidepressant medication
43 (22)
Prescribed therapeutic dose 35(18)
(no data = 1)
Taking full therapeutic dose prescribed
31 (16)
Depression Scores
The median for HADS scores for the sample was 21 ranging from 9 to 39. Scores of
less than 15 were for patients who had endorsed the question on the PHQ concerning
presence of suicidal ideation and were therefore included in the sample eligible for
further assessment. The number of symptoms endorsed from the SCID interview
ranged from 3 to 9 with the median being 6. One patient with only 3 SCID items was
included in the sample diagnosed with MDD as she had endorsed the two core items
of depressed mood and anhedonia, had previously repeatedly scored highly on
screening questionnaires and was therefore felt to have probable MDD. Scores on the
SCL-20 (completed within 1 month of the initial SCID interview) ranged from 1.75
to 3.55 with amedian score of 2.35, (see Table 6.19).
Table 6.19 Baseline depression scores of sample (n=200)
Variable Median (range)
Total HADS score (0 - 21) 21 (9, 39)
Number of SCID symptoms (min 5, max 9) 6 (3, 9)
SCL-20 (0 - 4.0) 2.35 (1.75, 3.55)
Cancer
Cancer type
Of the sample, the majority of patients had breast cancer 43.5% (87), with the
remainder having the following cancers: gynaecological (ovary, uterus and cervix)
15.5% (31); haematological 9.5% (19); prostate 9.5% (19); testicular 8% (16); bowel
6.5% (13); renal 3.5% (7); lung 2% (4); melanoma 1% (2); and sarcoma 1% (2), (see
Figure 6.3).
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Figure 6.3 Cancer type of sample (n=200)
4% 1%
□ Breast ■ Testicular □ Colorectal
□ Gynaecological ■ Haematological □ Lung
■ Melanoma □ Prostate ■ Renal
□ Sarcoma
Cancer characteristics
The median interval since the most recent cancer diagnosis, taken from the time of
trial entry, was 18.4 months with a mode of 7 months and of the sample, a small
number 8.5% (17) had been diagnosed with another primary cancer in the past. A
large number of patients 66% (132) were classed as disease free, a small number
21% (42) had local disease and a smaller number had metastatic disease 13% (26). A
large proportion of the patients were not receiving active treatment and were
currently being monitored for recurrence or disease progression 83% (166) with a
small proportion on active anti-cancer treatment 17% (34), of which 29% (10) were
receiving radiotherapy, 56% (19) were receiving chemotherapy and the remaining
15% (5) were receiving a combination of radiotherapy and chemotherapy (see Table
6.2). Active anti-cancer treatment did not include hormone treatment.





One primary cancer diagnosis 183 (91.5)
Two primary cancer diagnoses 17(8.5)
Median (range)
Length of diagnosis (months)
Time since first primary cancer diagnosis 23.7(0.8, 219.5)












Receiving active treatment 34(17)







* 'most recent cancer diagnosis' refers to diagnosis of a new cancer, a recurrence
or metastases.
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FLOW OF PATIENTS THROUGH THE TRIAL
The progress ofpatients through the trial is shown in Figure 6.4, which is based on
that recommended in the CONSORT statement on the reporting of trials (Moher et al
2001).
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Figure 6.4 Flow of patients though the trial and follow up (CONSORT diagram)
660 Assessed for Eligibility
459 Excluded
325 Did not meet inclusion criteria
134 Refused to participate
200 Randomised
91 Included in 6 month analysis
8 Excluded from analysis
(7 excluded due to missing data
and 1 excluded as data obtained
too late)
0 Lost to follow-up at 3 months
101 Assigned to Usual Care
plus Intervention
98 Received Intervention
3 Never attended treatment session
99 Included in 3 month analysis
0 Excluded from analysis
4 Lost to follow-up at 3 months
(2 died; 1 emigrated; 1 refused)
97 Included in 3 month analysis
4 Excluded from analysis
(all excluded due to missing data)
7 Lost to follow-up by 6 months
(4 died; 2 refused; 1 couldn't be
contacted)
10 Lost to follow-up by 6 months
(5 died; 1 emigrated; 2 refused; 3
couldn't be contacted)
91 Included in 6 month analysis
10 Excluded from analysis
(all excluded due to missing data)
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DEMOGRAPHIC CHARACTERISTICS OF THE TREATMENT GROUPS AT
BASELINE
Randomisation was performed using a random element in the allocation procedure of
0.75:0.25 to yield two treatment groups, 99 patients in the usual care group and 101
in the usual care plus intervention group. The randomisation was also restricted
using a method called minimisation. The characteristics of the randomised groups are
described in the Tables 6.21 to 6.27. There are no substantial differences between the
groups other than in employment characteristics and current treatment for their
depression. More patients in the usual care group were working in clerical jobs and
more patients were unemployed. More patients in the usual care group had consulted
their GP and were receiving antidepressant medication for their current depressive
episode.
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Table 6.21 Demographic characteristics of the treatment groups at baseline.
Number (percent) is shown except when specified.
Variable






Female 71 (72) 70 (69)
Marital status
Married or cohabiting 67 (68) 65 (64)
Single 10(10) 12(12)
Divorced/separated 17(17) 16(16)
Widowed 5 (5) 8 (8)
Living situation
Living alone 24 (24) 26 (26)
Living with partner 69(70) 62(61)
Other living arrangement 6 (6) 13 (13)
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Table 6.22 Deprivation and employment characteristics of the treatment groups at






































1 Scottish Executive (2004)
ILLNESS CHARACTERISTICS OF THE TREATMENT GROUPS AT
BASELINE
Depression
There were no substantial differences in the depression characteristics between the
groups: duration of the current depressive illness prior to assessment, number of
previous episodes of depression, but there were some small differences in treatment
received, the number of patients who had spoken to their GP, been offered and
prescribed an antidepressant, prescribed an antidepressant deemed to be prescribed at
a therapeutic level, and taking the prescribed antidepressant, was slightly higher in
the usual care group, (see Table 6.23).
Table 6.23 Depression characteristics of the treatment groups at baseline. Number
(percent) is shown except when specified.





Duration of current depressive episode in months
Median (range) 6 (2, 24) 8 (2, 24)
Previous episodes of depression
Mean (sd)
0.94 (0.81) 0.85 (0.83)
Median (range) 1 (0-3) 1 (0-4)
Current treatment
Spoken to GP about current episode
40(42)




(no data = 2)
31 (31)
Prescribed antidepressant medication 25 (25) 18 (18)
Prescribed therapeutic dose 20(20)
(no data = 1)
15(15)
Taking full therapeutic dose prescribed 18 (18) 13(13)
Duration of current depressive episode in months
Median (range) 6 (2, 24) 8 (2, 24)
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Depression scores
There was no substantial difference at baseline between the treatment groups in the
mean HADS scores, the mean number of SCID symptoms endorsed or mean SCL-20
scores, as shown in Table 6.24.
Table 6.24 Depression scores of the treatment groups at baseline. Numbers
shown are median scores (range).





Total HADS score (0-21) 21 (9,39) 21 (13,37)
Missing 3 4
Number of SCID symptoms
(min 5, max 9)
6 (3, 9) 7 (4, 9)
SCL-20 (0-4.0) 2.25 (1.75, 3.25) 2.35 (1.75, 3.55)
Cancer
Cancer type
There was no substantial difference in cancer types between the groups, (see Table
6.25).
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Table 6.25 Cancer type of the treatment groups at baseline. Number (percent) is
shown except when specified.




Breast 44 (44) 43 (43)
Gynaecological (ovary, uterus, cervix) 15 (15) 16 (16)
Haematologicaly
10(10) 9(9)








Melanoma 1 (1) 1 (1)
Sarcoma 2 (2) 0 (0)
Cancer characteristics
There was no substantial difference in number of primary cancers, duration of
diagnosis, extent of disease and treatment stage between the groups, (see Table 6.26).
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Table 6.26 Cancer characteristics of the treatment groups at baseline. Number
(percent) is shown except when specified.






One primary cancer diagnosis 89 (90) 94 (93)
Two or more primary cancer diagnoses 10 (10) 7(7)
Length of diagnosis (months)
Time since first primary cancer diagnosis
Median (range)
26.7 (2, 219.5) 22.4 (0.8, 172.6)
Time since most recent cancer diagnosis*
Median (range)
21.5 (0.7, 219.5) 15.8 (0.8, 161.8)
Extent of disease
Disease free 67 (68) 65 (64)
Local disease present 22(22) 20 (20)
Metastases 10 (10) 16(16)
Treatment stage
Pre-treatment/under investigation 17(17) 4(4)
Receiving active treatment 15 (15) 19(19)
Being monitored/ post-treatment assessment 67(68) 78(77)
Anti-cancer treatment
Receiving radiotherapy 3(3) 7(7)
Receiving chemotherapy 10 (10) 9(9)
Receiving both 2(2) 3(3)
* 'most recent cancer diagnosis' refers to diagnosis of a new cancer, a recurrence
or metastases.
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Subsidiary outcome measures in the treatment groups at baseline
Similarly an examination of the subsidiary outcome variables of the EORTC-QLQ-
C30 scales, the 10 anxiety items of the SCL-90, the social support scale and single
item measures of confidence and problem solving ability, (see Table 6.27) shows that
there were no substantial differences between the groups on these variables at
baseline.
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Table 6.27 Subsidiary variables in each treatment group at baseline. Numbers shown








EORTC-QLQ-C30 global health & quality of life
scale
(raw score 2 - 14; %age score 0-100)
42 (0, 92) 42 (0, 67)
EORTC-QLQ-C30 symptom scales
Physical
(raw score 5 - 20; %age score 0-100) 73 (7, 100) 67 (13, 100)
Role
(raw score 2 - 8; %age score 0-100)
50 (0, 100) 50(0, 100)
Cognitive
(raw score 2 - 8; %age score 0-100)
50 (0, 100) 50 (0, 100)
Emotional
(raw score 4-16; %age score 0-100)
33 (0, 83) 33 (0, 92)
Social
(raw score 2 - 8; %age score 0-100)
33 (0, 100) 50 (0, 100)
EORTC-QLQ-C30 functioning scales
Fatigue
(raw score 3 - 12; %age score 0-100)
56(11, 100) 56 (11, 100)
Pain
(raw score 2 - 8; %age score 0-100)
33 (0, 100) 33 (0, 100)
SCL-90 anxiety items (0 - 4.0) 1.3(0.0, 3.7) 1.5 (0.0, 3.9)
Coping measures
Confidence (0-10) 5(0, 10) 5 (0, 10)
Support (2-8) 7 (2, 8) 6 (2, 8)
Problem solving Q3 (1-4) 3(1,4) 3(1,4)
Problem solving Q4 (1-4) 3(1,4) 3(1,4)
Problem solving Q5 (1-4) 2(1,4) 2(1,4)
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THE TREATMENTS
Administration and quality assurance of the treatment
Treatment compliance
All the patients who had agreed to be randomised in the trial and who were offered
the additional trial intervention initially accepted it. Three patients later declined
attending the problem-solving session component of the intervention. All patients
allocated to usual care alone also accepted this.
All patients completed an adequate number of sessions in that all completed at least
two sessions (the minimum number of sessions deemed to be therapeutic). The
minimum number of sessions attended was two and the median number was 7. For
one patient the therapist went to very considerable lengths to avoid the patient
dropping out of therapy. This is discussed further below.
By the end of their treatment programme, 60% of patients were fully compliant (had
participated in and attended a full programme of sessions and were taking a
therapeutic dose of an antidepressant). A further 32% were partially compliant (had
either participated in and attended an adequate number of sessions or were taking a
therapeutic dose of an antidepressant) and the remaining 8% were non-compliant




The two nurse therapists (Yvonne Mcintosh and Jackie Whigham) treated a total of
81 patients (29 and 52 respectively) and I treated 20 patients. The relative efficacy
of the three nurse therapists was determined by comparing the percentage of patients
who met the three predetermined definitions of treatment response (50% reduction in
the SCL-20 MDD score from baseline, no longer meeting DSM criteria for MDD
and remission of depression as defined by SCL-20 score of <0.75) between therapists
at 3 months, see table 6.28. However no statistical analysis was performed as the
allocation of patients to therapists was not random.
Table 6.28 Depression scores of the intervention group at the 3 month follow up by
therapist. Number (percent) is shown except when specified.
Proportions achieving a
clinical treatment response















No data = 1
Not longer meeting criteria
for MDD diagnosis on SCID
21/27
(77.78)
No data = 2
28/50
(56)
No data = 2
15/19 (78.95)
No data = 1
Remission of depression
(SCL-20 score of <0.75)
11/27
(40.74)





No data = 1
*For one patient treated by Y Mcl, the SCL-20 data was obtained too late to be eligible for
inclusion in the main trial analysis but has been included here.
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Untoward events during treatment
No major untoward events occurred during the treatment. There were however a
number ofminor events across both trial groups over the 6 month trial period:
Intervention group
In the additional intervention group, one patient died from a sub-arrachnoid
haemorrhage 16 days after trial entry having completed 3 treatment sessions and
another patient died of cancer-related disease burden just before the three-month
outcome assessment.
By 6 months, a further 4 events occurred, three cancer-related deaths and one
hospital admission for suicide risk management. These events were reported as
'serious adverse events' to the Data Monitoring and Ethics Group and the patients'
deaths were confirmed as unrelated to the trial treatment.
During therapy, two patients developed suicidal ideation, defined as thoughts of
suicide with a plan. This was managed as part of their treatment with supervision
from Professor Sharpe, consultant psychiatrist and principal investigator for the trial.
One of these patients was referred by us after treatment in the trial to general
psychiatry and was managed in the community by a community psychiatric nurse
and the other patient was referred by her GP to the Liaison Psychiatry service at the
local hospital and admitted to a psychiatric ward for treatment.
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Sixteen patients reported suicidal thoughts at the 3 month follow-up assessment of
which one had a plan. At 6 months 11 patients reported suicidal thoughts ofwhich
none reported any suicide plan.
Usual care group
In the usual care only group no events occurred in the first 3 months but by 6 months
4 patients had died of cancer-related causes and one patient had attempted suicide,
for which she had been admitted to general emergency services at the local hospital
and discharged to the care ofher GP.
Eighteen patients reported suicidal ideation at the three-month follow-up, with 4
reporting a plan and at the six-month follow-up 18 patients reported suicidal thoughts
with 3 reporting a plan.
For all patients in the trial reporting suicidal thoughts with a plan, their GP was
informed immediately by phone and letters were sent to both their GP and
Oncologist detailing the suicide risk assessment.
Experiences during treatment
Various issues emerged during the treatment. These were discussed at the weekly
supervision meetings. The obstacles to effective use of the treatment differed
between the patients and are mentioned in more detail below.
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Engagement
Patients were not always entirely convinced that the problem-solving component
could work for their problems. It sometimes took a number of sessions until they
'bought in' to the therapy. One patient had been sceptical throughout his entire
treatment programme but admitted at his 3 month outcome assessment that with
hindsight he had actually found the problem-solving technique and behavioural
activation components very helpful.
Behavioural activation
Cultural differences sometimes required careful planning of activation. Body image
following breast surgery had a profound impact on the activities these patients were
willing to engage in. One patient wouldn't go out with her husband as she felt that he
would be embarrassed by the deterioration in her physical beauty. Anti-cancer
treatments also had an impact. One particular patient following chemotherapy
wouldn't go outside because she was anxious that her wig would get blown away in
the wind. Disease extent also had a major impact on the patient's ability to take part
in physical activity due to fatigue, pain or physical disability. For these patients, less
physical forms ofbehavioural activation were effective, such as resuming a previous
non-physical hobby.
Antidepressant medication
A small number of GPs disagreed with the diagnosis, weren't willing to prescribe
antidepressants or following recommendations were unwilling to change the
medication or increase the dose. An expressed view by GPs was that 'it is normal for
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cancer patients to feel depressed' and for this reason they felt that antidepressant
prescribing was inappropriate or futile. Overall about half of the GPs did not fully
collaborate with the model.
Patients themselves were initially reluctant to try antidepressant medication. Some
patients wanted to try using the other components of the treatment first with the
intention of adding in antidepressant drugs if their progress was slow. Some patients
had misconceptions about the nature of antidepressant therapy. A commonly
expressed view was that the medication was addictive or that they would become
'zombies'. One particular patient who was herself a trained health care professional
declined antidepressants because she felt that her colleagues would know that she
was taking them because of their side effects. However through problem-solving her
mood and the effect it was having on her relationships she realised that her behaviour
while depressed was more obvious to others than any side effects that may occur as a
result of taking antidepressant medication.
One patient took a 'herbal' antidepressant prescribed by a herbalist which he very
rigorously monitored and adjusted according to response. The patient made a very
good recovery and even completed and passed her post graduate degree.
A few patients declined the antidepressant component of the treatment altogether and
recovered in spite of this although recovery tended to be slower.
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Cognitive change
The aims of cognitive change were to alter the patient's view of their depression as a
'natural and expected' consequence ofhaving cancer to understanding their
depression as a separate illness amenable to treatment, to broaden their
understanding of depression and of their own depressive illness specifically in terms
of their personal warning signs and trigger factors for relapse. Ultimately the change
in cognition was aimed at making them more confident in their ability to manage
their depression by equipping them with new skills to cope with concerns and
problems that contribute to the development and/or maintenance of their depression.
The skill taught is a technique based on a problem-solving approach that involves the
patient identifying a list of concerns and working on single concerns in a systematic
way by setting goals related to the concern, then creating solutions to achieve the
goal, considering the pros and cons of each solution, then choosing a solution to
implement before the next therapy session. This constituted the patient's
'homework'.
The difficulty I encountered was that some patients failed to complete their
homework and so progress was slow. When patients failed to complete homework,
this was selected as the problem on which to focus, often resulting in either a plan for
better time management or in redefining the goal set for the original problem.
Patients with very chaotic thinking who reported always being busy found
difficulties with generating solutions and with implementing their solution as
homework. For some patients completing homework appeared overwhelming and in
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these cases implementing the homework was broken down into steps that could be
completed over a number of sessions.
For a few patients, the problem-solving technique seemed too difficult to learn even
when simplified. For one particular woman problem-solving for the entire treatment
programme was simplified to focusing on how to increase her physical activity using
dusting as an example.
An interesting observation by all therapists was that white collar workers, and this
seemed to apply to men in particular, had a tendency to make the problem-solving
process too complicated and as a result had to be taught the skill of breaking
problems into manageable chunks. One man who had been a company director even
felt the need to 'reinvent' the problem-solving technique. This may have given him
some control in the face of impending death.
Support
A commonly encountered reason for patients not willing to access support was the
belief that they shouldn't burden family with more worries as they had already been
burdened with their cancer illness.
Women tended to worry that admitting to family that they were depressed may mean
losing their position within the family of caring for others or as the 'pillar' of the
family. These assumptions were challenged within the problem-solving model by
specifically addressing the issue of lack of support fairly early on in the treatment
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programme thereby allowing the change to occur relatively slowly over the duration
of the programme culminating in a specific plan for accessing support.
For a few patients asking for support felt to them like admitting they weren't coping
when until then they had 'put on a brave face' and covered up any signs of distress.
One man who had lived a very private life was unable to use support as he felt that
this would disrupt his very valued privacy. Instead he chose to combine behavioural
activation with social interaction but did not talk about himself or his concerns
during these interactions.
Pre-illness personality and psychiatric morbidity
In some of the cases, it was clear that the patients would not generally be regarded as
good candidates for a relatively briefpsychological treatment although this had not
been apparent or measurable in any sense at their eligibility assessment.
For a small proportion of the patients, deeply ingrained problems that clearly
antedated the onset of their depression only emerged during therapy, such as
childhood experiences of abuse. For these patients, it was evident that further
treatment from a mental health specialist was recommended.
In another example, it became clear during the treatment of a man that he had a
psychotic component to his depressive illness. He had persistent thoughts of suicide
and when his care was transferred to community psychiatric services became very
verbally abusive to his nurse therapist.
There were a few other patients who had problems with relationships indicative of
personality disorder. For these patients, improvement was slow and minimal.
A/on attendance for therapy sessions
In two cases persistent failure to attend for treatment sessions made delivering the
number of sessions required within the defined time impossible.
For one patient, his reason was that he was a single parent of three children and his
life was chaotic. For the other patient, her work came before her health and therefore
work related meetings would always override therapy appointments.
Other treatments received during the six months of the trial
There were some differences between the groups in use of services. The use of GP
services was higher in the intervention group, the difference being substantial in the
3 to 6 month period. This is reflected in the difference in use of antidepressant
medication. At 3 months, the proportion of patients in the treatment group taking an
antidepressant drug and taking it at a therapeutic level was double that of the usual
care group. At 6 months the proportion of patients taking an antidepressant drug had
reduced in the treatment group but had remained stable in the usual care group.
Almost all patients were taking their antidepressant drug at a therapeutic dose at 6
months. More patients in the usual care group had received counselling and although
the numbers referred to mental health specialists are small in both groups, the trend
during the 6 months is for the usual care group to have consulted specialist mental
health services more than the treatment group. The 'consumption' of complementary
and alternative medicine appeared slightly higher in the usual care group although
the numbers were small. The range of therapies included in this category of service
was diverse, comprising sacro-cranial therapy, spiritual and faith healing, reiki,
reflexology, aromatherapy, crystal healing, colon hydrotherapy and acupuncture. The
numbers are shown in Table 6.29.
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Table 6.29 Use ofgeneral practitioner, other services and complementary and
alternative medicine during the trial. Number (percent) is shown except when
specified.










0-3 months 77/96 (80) 85/96 (89) 162/192 (84)
3-6 months 40/88 (45) 54/88 (61) 94/176 (53)
Mental Health Specialist
0-3 months 7/95 (7) 3/96 (3) 10/191 (5)
3-6 months 10/87(11) 7/89 (8) 17/176(10)
Clinical Nurse Specialist
0-3 months 13/95 (14) 83/96 (86)* 96/191 (50)
3-6 months 11/87(13) 48/88 (55) 59/175 (34)
Counselling**
0-3 months 21/96 (22) 14/96 (15) 35/192 (18)
3-6 months 16/85 (19) 8/89 (9) 24/174 (14)
Comp./Alternative Medicine***
0-3 months 9/95 (9) 7/96 (7) 16/191 (8)
3-6 months 6/86 (7) 3/89 (3) 9/175 (5)
Taking antidepressant drugs
At 3 months 37/99 (37) 72/97 (74) 109/196 (56)
At 6 months 34/91 (37) 58/91 (64) 92/182 (51)
Taking therapeutic level
antidepressant drugs
At 3 months 33/99 (33) 65/97 (67) 98/196 (50)
At 6 months 32/91 (35) 58/91 (64) 90/182 (49)
■"Included some patients reporting seeing the trial depression nurse
** Counselling included attendance at Maggie's (a local drop-in cancer charity), counselling
and breast care nurse
*** Alternative medicine included: sacro-cranial therapy; spiritual and faith healing; reiki,
reflexology; aromatherapy; colon hydrotherapy; crystal healing; acupuncture.
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MISSING DATA
Missing data for the primary outcome variable was minimal. Both the research
assistants and I went to great efforts to maintain the patients' compliance with the
assessments. Strategies to achieve this involved stressing the importance of
delivering full and reliable outcome data to the funding charity at the baseline
assessment together with sending out the self-report outcome assessment forms prior
to the phone-based outcome interview, thereby enabling the research assistants to
obtain any missing self-report data over the phone. This tended to be missing items
of a questionnaire rather than whole missing questionnaire data. In 11 cases, patients
were visited at home, hospital or hospice to recover outcome data.
The outcome data shown below are therefore complete unless otherwise stated. At
three months, the only substantial missing primary outcome data was for four
patients in the additional treatment group. Two patients had died, one patient had
emigrated and one patient did not return the questionnaire. At six months the primary
outcome data was unobtainable for a total of 17 patients. In the usual care group, four
patients had died, two patients did not return their questionnaire and one patient
could not be contacted. One of the patients who hadn't returned the questionnaire
was however willing to describe the two core items of depressed mood and
anhedonia to me when I visited him at home but declined to give any further
information saying that he had been advised by his GP to withdraw from the trial.
This assessment gave us sufficient detail about him to indicate that that there had
been no substantial change in his condition since the previous assessment and this
was used as secondary outcome data. In the treatment group 5 patients had died,
three patients could not be contacted, two patients did not return their questionnaire
and one patient had emigrated. One further patient in the usual care group submitted
her questionnaire data too late and this was therefore excluded from the analysis.
For the primary outcome of the self-report SCL-20, all 99 patients in the usual care
group and 97 of the 101 patients in the treatment group were included in the analysis
at 3 months and at 6 months 91 of the 99 patients in the usual care group and 91 of
the 101 patients in the treatment group were included in the analysis. As described in
the Methods Chapter, a sensitivity analysis was conducted for the 3 month primary
outcome data imputing 'no change' by using baseline data for missing 3 month data.
At 3 months, data for the secondary outcome measure of the SCID assessment for
MDD was missing for 2 patients in the usual care group and for 7 patients in the
treatment group.
All analyses were conducted on a 'modified' intention-to-treat basis (as some
outcome data was missing) and included all randomised patients for whom outcome
data were available (196/200 at 3 months and 181/200 at 6 months).
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OUTCOME AT THREE MONTHS
Hypothesis: Usual care plus a nurse-delivered, psychiatrist-supervised multi-
component treatment intervention reduces symptoms ofmajor depressive disorder in
patients with cancer to a greater extent than usual care alone.
The outcome assessments were performed at the times shown in Table 6.3.
Table 6.3 Time of trial outcome assessments









82.95 (5.81) 82.49 (4.91) 82.72 (5.38)
Assessment two
(6 months/168 days)
165.74 (11.04) 167.73 (7.32) 166.73 (9.39)
As can be seen, the assessments were carried out within 1 week either side of the
calculated follow-up dates for the 3 month assessments and within 2 weeks of the
calculated follow-up dates for the 6 month assessments as per protocol. There was no
substantial difference between the groups in the mean number of days between trial
entry and outcome assessments.
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Outcome response
A fall in SCL-20 score is likely to be greater for those patients with high initial SCL-
20 scores. All outcome analyses therefore included adjusting for baseline scores of
the measure being analysed.
Primary trial outcome
The pre-determined primary outcome variable was the difference in mean scores on
the self-report SCL-20 depression scale (range 0-4) and the pre-specified time point
was 3 months after randomisation.
The chosen method for analysing the primary outcome was Analysis ofCovariance
(ANCOVA), using the 3 month SCL-20 score as the dependent variable whilst
adjusting for the baseline SCL-20 score and the minimisation strata of age, gender,
diagnosis and extent of disease.
For this method to be valid required the residuals from the fitted model to be
approximately normal in distribution. A histogram of studentised residuals (Fig 6.5)
when the ANCOVA model was fitted showed that they were reasonably normal in
distribution.
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Studentised residuals
For the analyses of the primary outcome, a P value of 0.05 (5% level) was taken to
indicate statistical significance and in order to indicate the true range of the outcome
value 95 percent confidence intervals were calculated.
The adjusted mean difference between the two treatment groups is presented in Table
6.31, together with 95% confidence intervals and corresponding P value. These show
that the intervention had a statistically significant effect in reducing the SCL-20
score at three months, with an adjusted mean score 0.34 less than that for patients
receiving usual care, with the true range of the value lying between 0.13 and 0.55.
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Table 6.31 Pre-specified primary outcome: Comparison of the SCL-20 score in the
randomised groups at 3 months using ANCOVA, adjusting for minimisation variables



















*The treatment means and standard deviations in the table above are raw values, but the
intervention effect is adjusted for covariates.
Change in individual patient scores are shown in a dot plot (Figure 6.6). The mean
for each group is shown by a line of plus symbols, and distances 1 standard deviation
either side of the mean are marked by a dotted line. The graph shows a larger
reduction in scores for the intervention group, as is reflected in the analysis of the
primary outcome.
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Usual care Usual care + intervention
The mean for each group is shown by the line of plus symbols.
Robustness ofprimary outcome to missing data
For the four patients with missing data at three months (who were all in the
intervention group), it was assumed that their SCL-20 score had not changed since
baseline. This assumption was fairly conservative, since for the intervention group
only 6 patients of the 97 observed at three months had a score that was as bad as or
worse than their baseline score (see Figure 6.6).
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The previous analysis was repeated to see how this conservative estimate changed
the results. The treatment effect was only made slightly smaller and was still
statistically significant (see table 6.32). This suggests that the result of the primary
outcome analysis was fairly robust to the missing data.
Table 6.32 Pre-specified primary outcome repeated imputing 'no change': Comparison
of the SCL-20 score in the randomised group at 3 months using ANCOVA, adjusting





















*The treatment means and standard deviations in the table above are raw values, but the intervention effect is
adjusted for covariates.
Standardised effect size
The adjusted difference in means (0.34) divided by the pooled standard deviation of
the SCL-20 scores (0.8) gives an effect size (Cohen's d) of 0.43 with confidence
intervals 0.15 to 0.72. This is a moderate treatment effect which will be discussed
later when comparing the outcome of this trial with trials of similar interventions.
Subgroup analysis
To see whether the treatment effect was different in the subgroups of the study
sample, an interaction term was fitted into the ANCOVA model. For the primary
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outcome we looked at the 3 month SCL-20 modelled by baseline SCL-20, age,
gender, cancer site, disease extent and treatment group, see table 6.33.






Age group 40-79 vs. <40 -0.15 (0.35)
0.650
> 80 vs. <40 0.42 (0.74)
Gender Female vs. male -0.00 (0.24)
0.985
Diagnosis Colorectal vs. Breast -0.03 (0.46)
Gynaecological vs. Breast -0.50 (0.32)
0.396
Other vs. Breast 0.04 (0.25)
Disease extent Local disease vs. disease -0.29 (0.27)
free
0.057
Metastatic disease vs. 0.63 (0.34)
disease free
The only interaction that was even marginally significant was that between disease
extent and treatment group. Whilst this may be a chance relationship, the result
suggested that for patients with metastatic disease the effect of intervention on the
SCL-20 at 3 months was smaller by 0.63 than in the disease-free patients, and the
intervention reduced the SCL-20 at 3 months by 0.29 more in patients with local
disease than in disease-free patients. The order of severity of these three categories
of disease extent (disease free, local disease, metastases) was not reflected by the
order of effect sizes; this, along with the p value slightly larger than 0.05 and the fact
that for each of the minimisation factors there were very small numbers in some of
the strata, suggests that the result may not be particularly reliable.
Secondary trial outcome
The pre-determined secondary depression outcome variables were failure to meet the
DSM1V criteria for Major Depressive Disorder; remission of depressive symptoms
defined as a score of <0.75 on the SCL-20 depression measure; and a 50% reduction
from baseline in the SCL-20 score. The pre-specified time point was 3 months after
randomisation.
To account for multiple testing, secondary outcomes were considered only to be
statistically significant if p<0.01. Treatment effects are all for the intervention group
in comparison to the usual care group. Analyses of the secondary outcome measures
were performed using logistic regression adjusting for the baseline measurement and
minimisation factors. The exception to this was remission ofMDD as defined by
SCID interview: this included baseline SCL-20 score rather than SCID items
endorsed since there is not a straightforward relationship between number of items
endorsed and diagnosis ofMDD. The SCL-20 baseline score was included so that
some measure of baseline depression was taken into consideration.
In addition to having a significant effect on the mean SCL-20 score at three months,
there was a statistically significant difference in proportions of patients achieving the
pre-specified secondary outcomes between the groups as shown in Table 6.34. The
intervention had a significant effect on the likelihood of a patient achieving a 50%
reduction in SCL-20 between trial entry and three months, roughly doubling (95% CI
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1.23 to 3.97) the odds, and trebling (1.38 to 6.27) the odds of achieving remission as
defined by a score less than 0.75 on the SCL-20. This suggested that the statistically
significant effect of treatment on the primary outcome was supported by an effect on
clinically important criteria. The odds of not having MDD after three months, as
assessed independently by the clinical diagnostic SCID interview, are increased by
2.76 (1.49 to 5.09) times on the intervention group, which corroborates the remission
results from the self-report SCL-20 score.
Table 6.34 Pre-specified secondary depression outcomes: comparison of treatment
groups at 3 months using Logistic Regression providing Odds Ratio as effect size,
adjusting for baseline SCL-20 scores and minimisation variables; number (percent)


























44/97 (45%) 63/94 (67%) 2.76
(1.49 to 5.09)
0.001
Achieved a reduction of 50% or more from their baseline SCL-20 score of > 1.72
As the SCID remission ofMDD is determined by an algorithm, some of the patients
who were deemed in remission could nonetheless still display one or both of the core
MDD symptoms of anhedonia and depressed mood. Therefore to illustrate remission
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further, Table 6.35 below shows the proportions of patients defined as in remission
but with persisting core depressive symptoms.
Table 6.35 Patients defined as 'in remission' according to SCID interview, yet still
experiencing at least one core symptom of depression; number (percent) is shown





SCID remission patients with depressed mood 6(14) 4(6)
SCID remission patients with anhedonia 3(7) 3 (5)
SCID remission patients experiencing at least
one of the core depressive symptoms 8 (18) 7(11)
Absolute numbers were very similar between the two groups, though this translated
to a lower proportion in the treatment group since there were more patients in SCID
remission in this group.
A simple group comparison of outcome
Figure 6.7 shows that the difference between the treatment groups in the percentage
ofpatients attaining a good outcome based on the clinical diagnostic interview at the
3 month follow up was 22%. This difference is clearly substantial and statistically
significant.
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In order to examine further the clinical significance of the result several additional
calculations were made, see Table 6.36. These will be considered further in the
Discussion chapter.
Standardised effect size
A standardised effect size (SES) is a scale-free measure of the relative size of the
effect of an intervention and hence allows for comparison of relative size of effects
from different studies. The difference in proportions attaining a good outcome was
therefore translated to a standardised effect size. For binary outcome data this is
termed the standardised mean difference (SMD) and is obtained using a multiple of
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the log odds ratio (Chinn 2000). The standardised mean difference of the intervention
based on SCID interview was 0.28.
Relative risk reduction
The effect of a treatment (RRR) can also be estimated by determining the relative
risk reduction of a poor outcome (as defined by failure to achieve a clinical response
at 3 months from baseline).
The relative risk reduction is calculated as the proportion with poor outcome in the
usual care group, minus the proportion with poor outcome in the usual care +
additional intervention group, divided by the proportion with poor outcome in the
usual care group.
The RRR for the treatment effect based on clinical interview outcome assessment
was: 55 - 33 / 55 = 40%
In other words, the additional intervention reduces the risk of persistent depressive
symptoms at 3 months by 40%.
Absolute risk reduction
The absolute risk reduction (ARR) is calculated as the proportion with poor outcome
in the usual care group minus the proportion with poor outcome in the usual care plus
additional intervention group.
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The ARR for the treatment effect based on clinical interview outcome assessment
was 22%. This means that for every 100 patients enrolled in the additional
intervention group, about twenty-two bad outcomes would be averted.
Number needed to treat
The number needed to treat (NNT) gives an estimate of the number of patients we
would need to treat in order to prevent one bad outcome and is calculated as 1/ARR.
So for the treatment effect based on clinical interview outcome assessment the ARR
was 4.6. This means that we only probably have to treat 5 patients to prevent one
patient having a bad outcome.


























Remission of -0.30 17.1 14.7 6.8
MOD (<0.75 on (-0.51,-0.09) (3.8,28.7) (3.4,26.1) (3.8,29.5)
SCL-20)
Remission of -0.28 39.6 21.7 4.6
MDD (SCID) (-0.45,-0.11) (15.2,57.1) (7.9,35.4) (2.8,12.6)
"Minus signs for SMD indicate a reduction in chance of the negative outcome, i.e. that the
intervention group is better
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Other secondary trial outcomes
The pre-specified secondary outcomes of anxiety, physical functioning and coping
were also compared (Table 6.37 and 6.38).
Table 6.37 Secondary Outcomes: Comparison of treatment groups at 3 months
using ANCOVA, adjusting for baseline SCL-20 scores, baseline measures of the
outcome variable and minimization variables as appropriate
Usual care Usual care + Intervention p value
only Intervention effect
(95% CI)
ANCOVA providing mean difference as effect size
Physical functioning N=92 N=91 1.0 0.64
(0-100) 67.6(23.6) 66.8(24.4) (-3.4 to 5.5)
Mean (sd)
SCL-90 anxiety* N=93 N=91 -0.20 0.001
subscale (0-4) 0.97(0.78) 0.78(0.82) (-0.32 to-0.09)
Mean (sd)
Coping measure - N=93 N=91 1.02 0.001
confidence 5.9(2.5) 6.6(2.1) (0.41 to 1.62)
(0-10)
Mean (sd)
Coping measure - N=92 N=91 0.65 0.006
support (2-8) 6.7(2.0) 7.2(1.6) (0.19 to 1.11)
Mean (sd)
* To achieve a normal distribution for ANCOVA the scores for this measure were square root
transformed and the treatment effect cannot therefore be interpreted as actual scores.
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Table 6.38. Secondary Outcomes: Comparison of treatment groups ofproportions
endorsing values representing good problem-solving skills from baseline to 3
















n (%) scoring 3 or 4
At 3 months
n (%) scoring 3 or 4
Q3 63(64) 52 (51) 58 (62) 58 (64)
Q4 70 (71) 71 (70) 68 (73) 70 (77)
Q5 47 (47) 46(46) 53(57) 63 (69)
There was a greater reduction in anxiety as measured by the SCL-90 anxiety subscale
(p=0.001), (the scores for this measure were square root transformed to achieve a
normal distribution and the treatment effect cannot therefore be interpreted as actual
scores) but not in physical functioning (p=0.643).
For the coping measures of support and problem-solving, the functioning of the items
was analysed prior to the results being made available. The purpose of this was to
investigate whether the individual items of each of the support and problem-solving
measures could be considered as a scale. Calculations of Cronbach's alpha indicated
that the two items of support could be analysed together but not the problem-solving
items. To avoid multiple analysis of the problem-solving measure, questions 3, 4 and
5 were chosen for the final analysis.
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For the coping measures, a greater increase in confidence (p=0.001), use of support
(p=0.006) and problem-solving ability was observed with the intervention which is
consistent with some of the treatment effect being mediated by improving coping and
problem-solving skills.
OUTCOME AT SIX MONTH FOLLOW UP
No testing was performed on the data at 6 months as the pre-specified primary
outcome was at 3 months.
Secondary outcomes
Depression
The proportions achieving a good outcome on binary outcomes for the measures of
depression are presented in Table 6.39. Of thel82 patients included in the 6 month
analysis, 65% (59/91) had a good outcome defined by a 50% reduction in SCL-20
score from baseline in the additional intervention group compared with the usual care
group 38% (35/91). On the measure of remission defined as a score of less than 0.75
on the SCL-20 measure 45% (41/91) achieved remission in the additional treatment
group compared to 15% (14/91) in the usual care group. On the clinical interview for
diagnosis ofMDD, 71% (64/91) no longer met the criteria for MDD in the additional
treatment group compared to 55% (49/91) in the usual care group.
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Table 6.39 Depression outcomes at 6 months; number (percentage) with good





50% reduction on SCL-20 score
35 (38) 59 (65)
Remission
(<0.75 on SCL-20 score) 14 (15) 41 (45)
Failure to meet criteria for MDD on SCID
(data missing for 3 patients) 49/89 (55) 64/90 (71)
The proportion of patients having achieved a 50% reduction in SCL-20 score, from
baseline, was higher at six months than at three months for both treatment groups.
The proportion achieving remission had continued to increase from 3 months for the
intervention group, whilst barely changing for the usual care group. As a result, the
gap between the proportions in the two groups is quite wide. Proportions of patients
no longer meeting the criteria for MDD had risen by similar amounts in both
treatment groups.
Overall the difference between the treatment groups at 6 months was similar to that
at 3 months. Although no statistical analysis was undertaken at 6 months, raw SCL-
20 scores indicated a persisting treatment effect as presented in Figure 6.8.
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Figure 6.8 Box plots of SCL-20 scores at 3 and 6 months by treatment group
Usual care Usual care + intervention
] Baseline I 13 months 16 months
The centre line represents the median and the boxes represent the interquartile range. The
dots represent outliers.
Anxiety, physical functioning and coping
From table 6.4 the biggest differences between the groups in the proportion
achieving either no change or an improvement appears in the measures of anxiety,
physical functioning and confidence.
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Table 6.4 Secondary outcomes at 6 months defined as no change or improvement
on 3 month outcomes; number/total number (percentage)







42/80 (53) 57/84 (68)
SCL-90 anxiety subscale 46/81 (57) 62/84 (74)
Coping measure -
confidence
45/81 (56) 59/83 (71)
Coping measure - support 63/80 (79) 72/84 (86)
Problem solving
(scoring 3 or 4)
Q3 63/81 (77) 64/84 (76)
Q4 62/81 (77) 67/84 (80)
Q5 57/81 (70) 67/84 (80)
Satisfaction
Although the satisfaction rating was scored as a scale from 1-7, categories 1 and 2
represent 'no care received' and 'can't answer', while categories 3-7 rate quality of
care as 'poor' (3), 'fair' (4), 'good' (5), very good (6) and 'excellent' (7). The results
are shown in table 6.41.
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Table 6.41 Satisfaction ratings at 6 months by treatment group; Number (percent) is
shown except when specified
Satisfaction score Usual care only
n (%)
N=85




22 (26%) 1 (1%)
2 6 (7%) 3 (3%)
3 3 (4%) 0 (0%)
4 21 (25%) 7 (8%)
5
14(16%) 7 (8%)
6 12 (14%) 27 (31 %)
7 (8%) 41 (48%)
A quarter of the patients in the usual care group said that they had not received any
care, compared to only one patient in the intervention group. Of those who had
received care and were able to rate their care (categories 3-7) there is a clear
difference of opinion between the two treatments, with usual care group showing a
positively skewed distribution whilst the intervention group was negatively skewed.
The satisfaction of patients receiving the intervention was greater than those
receiving usual care.
TREATMENTS RECEIVED DURING THE TRIAL
After each outcome assessment, the progress of each patient was discussed with the
supervising consultant psychiatrist. In all cases, after each outcome assessment, the
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patient's GP and Oncologist were informed of the patient's progress. For those
patients deemed to require additional intervention to that provided within the trial, a
management plan was formulated in the multidisciplinary team, discussed with the
patient and the appropriate management organised. This was in most cases
notification to the GP of failure of the patient to improve and a request for the GP to
review the patient's depression management. In 10 cases, a referral to psychology
services at the Edinburgh Cancer Centre was made and in 2 cases, our
recommendation to the patient's GP, of referral to psychiatric services was carried
out. All other referrals were made independently by the GPs.
At each outcome assessment, patients were asked to report all the additional non-trial
treatment they had received in the period since the last outcome assessment. The
findings have been detailed previously in Table 6.29.
During the first 3 months of the treatment, three patients saw a mental health
specialist after the end of the treatment sessions with the nurse. For other types of
treatments, 14 patients had used counselling services ofwhich the majority had used
the local support centre, The Maggie Centre and 7 patients had received
complementary or alternative medicine.
Between 3 and 6 months another 7 patients had seen a mental health specialist,
another 8 had used counselling services and another 3 had used complementary or
alternative medicine. These rates of service usage are less than those in the usual care
arm as shown in Table 6.29. As the trial intervention is supplementary to usual care,
this confirmed that the patients in the usual care plus additional intervention group
did not 'consume' more 'usual care' than those patients receiving usual care.
COMMENT
The additional nurse-delivered intervention was found in the efficacy trial to produce
a substantially better outcome for depressive symptoms in patients with cancer and
MDD at three months than that achieved by usual care alone. The large treatment
effect seen in the primary outcome is substantiated by the secondary outcomes,
providing robust evidence of efficacy. The six month data also suggest that the
treatment effect is maintained.
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EXPLORATION OF THE PROCESS OF CLINICAL IMPROVEMENT WITH
THE ADDITIONAL NURSE INTERVENTION
This trial provides robust evidence for the effect of the additional nurse-delivered
intervention to usual care on a range of clinically relevant outcome variables. It
cannot tell us what part of the complex intervention was effective in achieving this
change and indeed the purpose of this trial was not to identify the 'effective
ingredient'.
The question items used in this trial to measure a) the patients' confidence; b) their
ability to cope with concerns and problems, and c) their access to and use of social
support were used to understand the process of recovery within the talking therapy
component of the intervention.
The hypothesis was that the additional nurse intervention improves outcome by a)
increasing the patient's confidence to cope with concerns and b) teaching them a skill
to tackle their concerns and c) increasing their access to and use of social support.
This was explored in the following way: (1) To establish whether improvement in
depression scores were mediated by improvement in aspects of confidence, coping
and support, change in SCL-20 depression scores was plotted against change in
scores for each of the coping items measured by treatment group. (2) To examine the
significance of associations between changes in these variables with change in
depression measure scores (SCL-20) in the additional intervention group and usual
care group, correlations were sought using Spearman's Rank Correlation co-efficient,
see Figures 7 - 7.4 below.
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Figure 7 Association (scatterplot and Spearman's Rank correlation coefficient
rho at 1% significance level) of change in SCL-20 depression score at 3 months and
change in the confidence item score (I am confident in my ability to overcome or
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Spearman's rho -0.368 (significant)
Scatterplot of Change in SCL-20
by change in Confidence at 3
months: Usual Care Group
Spearman's rho -0.394 (significant)
Scatterplot of Change in SCL-20
by change in Confidence at 3
months: Treatment Group
Figure 7.1 Association (scatterplot and Spearman's Rank correlation coefficient
rho at 1% significance level) of change in SCL-20 depression score at 3 months and
change in problem-solving item Q3 score (Q3. When I have a decision to make, I
weigh the consequences of each option and compare them against each other)
3 1.00-
Spearman's rho -0.084 (not significant)
Scatter plot of Change in SCL-20
by change in Problem-solving Q3
at 3 months: Usual Care Group
Spearman's rho -0.054 (not significant)
Scatter plot of Change in SCL-20
by change in Problem-solving Q3
at 3 months: Treatment Group
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Figure 7.2 Association (scatterplot and Spearman's Rank correlation coefficient
rho at 1% significance level) of change in SCL-20 depression score at 3 months and
change in problem-solving item Q4 score (Q4. When I am attempting to solve a
problem, I go with the first good idea that comes to mind)
cnPQ4inverse
Spearman's rho -0.080 (not significant)
Scatter plot of Change in SCL-20
by change in Problem-solving Q4
at 3 months: Usual Care Group
Spearman's rho -0.102 (not significant)
Scatter plot of Change in SCL-20
by change in Problem-solving Q4
at 3 months: Treatment Group
Figure 7.3 Association (scatterplot and Spearman's Rank correlation coefficient
rho at 1% significance level) of change in SCL-20 depression score at 3 months and
change in problem-solving item Q5 score (Q5. When a problem occurs in my life, I put
off trying to solve it for as long as possible)
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Spearman's rho -0.216 (not significant) Spearman's rho 0.2 (not significant)
Scatter plot of Change in SCL-20
by change in Problem-solving Q5
at 3 months: Usual Care Group
Scatter plot of Change in SCL-20
by change in Problem-solving Q5
at 3 months: Treatment Group
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Figure 7.4 Association (scatterplot and Spearman's Rank correlation coefficient
rho at 1% significance level) of change in SCL-20 depression score at 3 months and
change in support scale (Amongst the people I know, there is someone I can go to for
























































Spearman's rho -0.116 (not significant)
Scatter plot of Change in SCL-20
by change in Social Support at 3
months: Usual Care Group
Spearman's rho -0.195 (not significant)
Scatter plot of Change in SCL-20
by change in Social Support at 3
months: Treatment Group
No discernable pattern was noted other than with change in the measure of
confidence. There was a statistically significant association between increasing
confidence and improving depression scores with a stronger association in the
treatment group.
Comment
The above findings suggest that a potential mediator of recovery from depression is
increasing the patient's confidence in one's ability to overcome or control an episode
of depression. The stronger effect seen in the treatment group provides preliminary
evidence for the mechanism of the talking therapy being related to increasing patients'
confidence in managing their depression.
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EXPLORATION OF THE PREDICTORS OF OUTCOME
Four demographic and cancer-related minimisation factors were used for
randomisation. No factors relating to the depressive illness were included. In order to
inform future depression intervention trials, subgroup analysis was performed to
identify predictors of outcome although this was not part of the pre-specified
statistical analysis plan.
The number of previous episodes of depression and the length of current episode of
depression were entered into the ANCOVA model to test whether they were
predictive of good outcome.
Table 7 shows that the depression variables have an effect size in relation to the
treatment of a similar order ofmagnitude to the treatment effect we obtained in the
trial. Thus both depression variables were independent predictors of the SCL-20
score at three months at the 5% level and as such should be included as minimisation
factors in any future trials to ensure reasonable balance between treatment arms so
that any effect assigned to treatment is genuinely caused by the treatment.
The factors that were used in the trial for minimisation did not appear to have
significantly influenced either the primary outcome (SCL-20) or the effect of
treatment on the primary outcome, with the possible exception of extent of disease.
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SCL-20 at baseline 0.53 (0.3 to 0.77) <0.0001
Treatment
Intervention vs. control
-0.34 (-0.55 to-0.13) 0.002
Extent of disease
Local vs. disease free
Metastatic vs. disease free
0.06 (-0.19 to 0.32)
0.18 (-0.14 to 0.49)
0.538
Duration of current depressive
episode
More than a year vs.
1 year or less 0.33 (0.08 to 0.57) 0.009
Previous episodes
> 1 vs. none
0.24 (0.02 to 0.46) 0.0305
Comment
Whilst I did not stratify on or adjust for these depression factors in analysing the
trial, when using these three factors only as covariates (see table 7), the treatment
effect is identical to that found in our planned analysis adjusting for age, gender,
diagnosis and disease extent, which was reported at three months. Also of note is
that the baseline comparability of the two trial treatment groups with respect to
depression factors was satisfactory. Whether a greater imbalance would have
affected the reported treatment effect cannot not be ruled out.
EXPLORATION OF TREATMENT EFFECT ON FUNCTIONING, QUALITY
OF LIFE AND OTHER KEY CANCER-RELATED SYMPTOMS
The whole EORTC questionnaire was administered to participants upon entry to the
trial, and again at three months. Only one scale was selected for analysis as a
secondary outcome. There are, however, numerous symptom scales, many ofwhich
will not be analysed here since the treatment being evaluated is not expected to affect
many cancer-related symptoms. The scales analysed were those examining
functioning (role, emotional, social and cognitive), global health and quality of life,
pain and fatigue.
The treatment effect shown in table 7.1 is the adjusted difference in mean scores at
three months, from the ANCOVA. Treatment effects are all for the intervention
group in comparison to the usual care group.
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Table 7.1 Exploratory analyses of EORTC QLQ-C30 scales: comparison of





































































* Scores range from 0 to 100; a higher score represents a higher level of the quantity being
measured i.e. higher fatigue scores represent worse fatigue but higher functioning scores
represent better functioning.
Table 7.1 shows small p-values for emotional functioning, fatigue and cognitive
functioning, suggesting that there may be an effect of the intervention on each of
these aspects. The direction of each of these differences favours the intervention.
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Further investigation would be required to establish these results conclusively.
Moreover, the effect sizes themselves are not large when compared to an increase of
percentage made by one point increase in the raw score (the raw score varies
according to the number, and range, of items in the scale). For emotional
functioning, each point increase corresponds to an increase of 8.33 in the scale score;
for cognitive functioning, each point corresponds to 16.67 and for fatigue, 11.11.
Thus it is only the emotional functioning that shows, after adjustment, a mean
difference ofmore than one point in raw scores.
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The principal findings of the trial were that:
1. Patients who received optimised usual care plus the additional nurse-delivered
multi-component intervention had a substantially better and statistically significantly
better outcome on the pre-defined primary depression outcome measure than those
who received optimised usual care only;
2. The treatment effect observed was fairly large with a number needed to treat of
five (95% CI 3.1 to 21.8);
3. The benefit was sustained at the six month follow up.
Patients who had received the additional intervention also showed statistically
significant improvements over usual care on the secondary outcome measures. These
results serve to reinforce the effect on the primary outcome. However, no significant
differences were observed on the measure of physical functioning between treatment
groups although this is perhaps not a surprising finding given the nature of the
comorbid illness of cancer.
PROCESS OF IMPROVEMENT
In a multi-component intervention it is not possible to conclude the mechanism by
which patients improve. However, exploratory investigations of the mechanism by
which the talking therapy component of the intervention improved depressive
outcomes found a correlation between change in depression scores and change in




Although exploratory, this analysis revealed some potential predictors. A history of
one or more previous episodes of depression and a duration of current episode of
depression ofmore than one year emerged as additional independent predictors of
the SCL-20 score at three months. This suggests that these two factors in addition to
baseline depression severity were predictive of good outcome.
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Maintenance of treatment effect
Comment
The findings of this trial must be interpreted in the context ofmethodological
limitations which I will discuss individually below.
DEFINITION OF CASES
Were the cases really MDD?
Despite on-going controversy about the use of the DSM criteria for diagnosing MDD
in cancer patients, the inclusive diagnostic approach was used in this trial and it
could be argued therefore that the cases were not MDD cases because of the
significant somatic symptoms of the comorbid cancer. However the validity of these
diagnoses was reinforced by using a measure of depression severity. Furthermore the
prevalence found in this study is similar to those obtained by other studies using a
variety of depression criteria and measures suggesting therefore that the diagnostic
approach used in this trial correctly identified the severe end of the spectrum that is
MDD.
REPRESENTATIVENESS OF THE SAMPLE TO THE TARGET
POPULATION
Is the sample representative of patients with MDD in the target
population?
Sampling bias in this trial was minimal and restricted only to those trial-imposed
exclusion criteria that would 'risk' patient withdrawal or loss of data due to practical
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reasons. The two criteria that require some consideration with regard to whether the
sample relates accurately to the target population are patients who live outside
reasonable travelling distance and those engaged in a course of intensive anti-cancer
treatment.
Firstly, by excluding patients for reasons of travelling distance, in Scotland, this
would exclude patients more likely to be living in rural communities. Therefore, in
terms of efficacy of the intervention model, it is uncertain whether the model would
have been less or more efficacious in these patients as it is unclear whether rurally-
living patients have more or less support than their urban-dwelling counterparts. This
issue could therefore not only have had an impact on the trial results but may have
implications for the generalisability of this model to rural Scotland.
Secondly, by excluding patients engaged in intensive anti-cancer treatment which
really only excluded those patients in the middle of a course of chemotherapy, the
results of this trial cannot claim that this model is efficacious at all stages of cancer
treatment. However, in practice it is unlikely that any clinician would recommend
another treatment, whatever type of treatment, for a patient already engaged in
intensive medical treatment for a life-threatening disease and would be more likely to
wait until the course of intensive treatment had finished. Hence I consider this issue
to be less important in terms of the generalisability of the sample to the target
population.
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For all other exclusion criteria, these criteria were imposed in order to define the
target population, that is, those patients likely to benefit from the intervention. Hence
psychiatric criteria excluded patients with chronic mental health problems or
psychiatric comorbidity and medical criteria excluded patients with uncontrolled
medical comorbidity.
In terms of patients with poor prognoses, the treatment was not designed as a
treatment for cancer patients who were near death as this has the added complexity
of significant physical deterioration and warrants separate research with an adapted
model. The treatment in this trial was designed for relatively well outpatients with a
relatively good cancer prognosis ofmore than a year, reflected in the fact that the
majority ofpatients in the sample had inactive disease. The predominance of females
is explained by the fact that the large lung cancer clinics were not screened as the
majority of these patients would have had a poor prognosis so that the screened
sample was over-representative of females and consequently of breast cancer.
A strength of the trial was that patient recruitment relied on a system of routine
screening and identification of patients with MDD regardless of trial eligibility at
that stage and thereby didn't rely on non-research staff to determine eligibility which
can introduce selection bias with clinicians perhaps wanting to 'save' their patients
from being subjected to experimental interventions thereby deeming them to be
ineligible. There was some suspicion of this happening to a small degree at the start
of the trial as initially we relied on the clinicians to indicate whether they thought
that the patient 'would be well enough to complete a six month trial' and this
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question offered an option for excluding their patient from being offered trial
participation. Hence the system was changed so that there was no involvement at all
by NHS staff in determining trial eligibility.
Conversely, engagement of patients by highly trained research staffmay have
contributed to the 'above average' acceptance rate for trials of psychological-type
treatments. This may present a particular problem when considering the
generalisability of not only the intervention but the whole depression management
system including the initial screening of patients.
Another strength of the trial was that sampling was derived from a cancer population
attending a regional cancer centre, with a catchment population of 1.5 million people
in the south-east of Scotland, and is therefore fairly representative ofpatients
attending a regional cancer outpatient department. In terms of the target population
the characteristics of the sample population were in similar proportions for cancer
type (mostly breast, genito-urinary and gynaecological cancers) and gender (mostly
females) and with similar mean age (approximately mid 50s) to the MDD population
identified in a previous study of consecutive patients attending the cancer centre
(Sharpe et al 2004a).
Were the refusers different from the trial participants?
More patients with testicular, prostate or urological cancers participated in the trial,
whereas more haematology patients refused trial participation, although these
differences were marginal. Hence on the characteristics examined, the sample of
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patients who took part in the trial was representative of the total sample of trial
eligible patients diagnosed with MDD.
Recruitment of patients to this trial was challenging and although 20% of potentially
eligible patients with MDD refused trial participation the strength of this study is that
the commitment of the team, a vital ingredient to successful trial recruitment,
resulted in a sample fairly representative of the target population and with a refuser
sample not that dissimilar to the trial sample.
In summary, the sample is probably representative of adult cancer patients, without
chronic or comorbid psychiatric problems and with a prognosis of good or stable
health for at least 6 months and survival of at least 12 months, attending a cancer
centre as an outpatient, although it does exclude head and neck and lung cancer
populations.
SAMPLE SIZE
Was the sample size and outcome data available for analysis adequate
to answer the research question?
The trial was powered to look for a difference of 0.21 in the mean SCL-20 scores
between the groups, when it is used as a continuous scale and as the trial had
originally been powered to look for a 20% difference in proportions achieving a
treatment response (50% drop on the SCL-20 measure from baseline) the trial was
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adequately powered for both treatment outcomes. The sample size calculations had
factored in a 10% attrition rate at three months. However, very little data was lost at
three months (2%) and at six months (9%) and therefore the sample size was
adequate for the detection of a difference in outcome at both time points. The tight
confidence intervals also suggest that the sample size was sufficient to obtain a fairly
accurate estimate of the 'true' treatment effect.
ELIGIBILITY AND RANDOMISATION
Were any ineligible patients entered into the trial in error?
The two particularly difficult eligibility criteria to assess were current psychiatric
problems other than the diagnosed MDD and cancer prognosis. The assessments
were rigorous and where there was uncertainty about either of these two criteria, the
final decision was made only after consultation with an appropriate clinician or
referral to case notes (although the availability of previous psychiatric notes was
limited to those patients having received care in Lothian). While it was often easier
to clarify survival prognosis and indeed follow up data loss suggests that this was
achieved fairly accurately, it was more difficult to detect personality disorders with
the trial eligibility assessment and as a result, a small number of patients with
personality disorders were entered into the trial. The frequency of this error cannot
be known as this was only detected during the treatment programme for those
patients who had been allocated to the additional intervention group. However, the
frequency of the disorder would probably have been similar in both trial groups due
to the randomisation procedure. Furthermore, the patients with personality disorders
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in the trial improved, suggesting that while patients with personality disorders may
have presented more of a therapeutic challenge to the nurse, their outcome was
nevertheless good.
There were no particular limitations with the randomisation process. The requirement
for allocation concealment was satisfied.
SPECIFICATION OF TREATMENTS GIVEN
Was the experimental intervention true to the protocol-specified model
and did the treatment received as 'optimised usual care' differ between
the groups?
There are potential difficulties with defining exactly the specification of treatment
given. As with a cake recipe, the ingredients are defined but there will inevitably be
variation in the end result because of quality differences of individual ingredients and
the way in which they are mixed. Similarly, in any trial ofmulti-component
interventions there will be a variation in the exact therapies and 'doses' given.
However the components of the interventions both in the 'additional experimental
intervention group' and in the 'optimised usual care group' were carefully
monitored.
Firstly, the experimental intervention was delivered according to a manual, the
therapists were trained, and the therapy supervised in weekly meetings. Adherence to
the treatment protocol was very strictly monitored and formally assessed, the results
of which showed a very high adherence rating. The only difference between patients
was the nature of the concerns worked on during sessions. The number of sessions
patients received also varied although this was based on their treatment response
dictated by a treatment guideline algorithm.
Secondly, analysis found that 'optimised' usual care consisted largely of visits to
general practitioners and antidepressant medication with almost a quarter receiving
some form of counselling. A minority of patients received specialist mental health
care or alternative or complimentary therapy across both groups. Other than
antidepressant use, the usual care component was similar between the treatment
groups. This difference was expected, as a component of the intervention was
encouragement to consult their GP about antidepressant therapy. It can therefore be
assumed that the differential outcome was not the result of a significant difference in
care received other than the experimental intervention.
LIMITATIONS OF THE OUTCOME MEASUREMENT
Was there any evidence of the measure not operating as intended?
For the primary outcome, symptoms were measured by self-report and although it is
assumed that validity studies account for potential patient reporting bias, there is still
a chance that patients may have chosen to minimise or emphasise their symptoms.
This is a difficult problem to address but the assessments of patients reporting
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symptom severity at either extremes of the spectrum, 'outliers', were examined and
of the two outliers, (one in each treatment group), their 'extreme values' were
reported consistently across self-report and interview-based assessments and over
time. I am fairly certain therefore that there is no evidence to support any concern
over patient reporting bias.
Anecdotally, older patients tended to under-report their symptoms or regard them as
being insignificant and related more to "just old age". However, as the patients were
randomly allocated to either treatment, and that the age distribution for each group
was comparable, I have assumed that had this factor been operating, it would have
been operating in approximately equal frequency in each group.
CLINICAL VALIDITY OF THE OUTCOME MEASURES
Does the self-rating measure mean anything clinically?
I decided that to aid the clinical interpretation of the results, a diagnostic outcome
was essential rather than just the change in a numerical rating on a symptom scale
and that every effort would be made to reduce the impact of observer bias (by
independent re-rating of edited assessment interviews as previously discussed) and of
any limitations of the measure itself (by backing it up with a clinical interpretation of
the self-report symptom scale by converting it to a dichotomous outcome of
treatment response or not and remission ofMDD or not).
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The limitations of the use of the SCID for the diagnosis ofMDD in cancer patients
have been previously discussed. However given these limitations and the potential
limitation of poor adherence to the interview schedule and inter-rater reliability,
these would presumably have applied fairly consistently across patients and to all
outcome assessment points thus making the change in proportions of those patients
diagnosed with MDD fairly accurate. This appeared to be the case as the clinical
interpretation of treatment response using both interview and self rated assessments
was very similar, with a difference between groups of 19% on a 50% reduction in
SCL-20 score from baseline and 22% for no longer MDD on the SCID interview.
Although from a purely statistical stance, too many analyses ofmeasures of one
construct are not good practice, observing convergence of the results has provided
robustness and clinical validity to the findings.
BLINDNESS
Was blindness to treatment allocation achieved?
Any interview-based outcome measure has the potential to introduce bias by the
interviewer becoming 'unblinded' to patient allocation. It is very difficult to achieve
blindness in any intervention that involves the delivery of psychological treatments
and in fact is the case in any trial that involves an intervention that looks obviously
different from that offered in the control group and results in the patient knowing
" which intervention they are receiving.
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In this trial, firstly the patients were not 'blind' to their treatment allocation. This
could not be avoided by trial design and needs some consideration of the effect this
could have had on the results. Inevitably some patients would have had some
preference for one of the two treatments over the other. This could have resulted in
patients feeling disappointed by not receiving their preferred choice of treatment and
as a result they may have consciously or unconsciously exaggerated or minimised
their trial outcome assessment responses. There is however no recognised way of
measuring or preventing this bias and furthermore no way of assessing the potential
impact of this on the results as not all patients would have considered (and indeed
didn't) the additional nurse-delivered intervention as the desirable or preferred
treatment option. Therefore it is not clear whether the resulting effect would have
inflated the treatment effect. If one hypothesised that the additional intervention was
the preferred option and that patients receiving this minimised their symptoms at
their outcome assessments and that those allocated to usual care maximised their
responses then the overall effect may have resulted in a treatment effect inflated
beyond the 'true' treatment effect. In conclusion, response bias in this trial could
not be proactively prevented nor accounted for in any way in the analysis and it
remains therefore that response bias could have operated in this trial.
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NON-SPECIFIC TREATMENT EFFECTS
Was the comparison group appropriate?
An important factor in this trial or in any trial of psychological treatment versus no
psychological treatment is whether merely an equivalent amount of 'attention', that
is the presence of the therapist for a similar period, in this case approximately seven
sessions, could have had a similar therapeutic effect on the patient. So in other words
a stricter comparison of usual care plus the additional nurse-delivered intervention
versus usual care plus speaking with a nurse about non-health related or 'neutral'
topics may methodologically have been more correct. However practically this
would have been difficult to do in terms of controlling the topic of conversation.
Furthermore the literature on the treatment ofMDD suggests that it is unlikely that
only 'attention' would be effective. There is therefore no way of knowing from this
trial design to what degree non-specific treatment effects in the intervention group, if
any, were operating.
ACTIVE INGREDIENT
What was the most 'effective' ingredient in the model?
The trial was not designed to identify the active or most effective 'ingredient' nor to
determine whether a simpler intervention would have been as efficacious. Previously
conducted studies have tested various components of this model in isolation, the
results ofwhich have been previously discussed. However, I did conduct exploratory
analyses to establish whether improving coping skills mediated clinical
improvement, the results ofwhich suggested that increasing patients' confidence was
associated with clinical improvement. It does not establish a causal relationship and
cannot establish which component of the model was the most 'effective' ingredient,
merely that an ingredient of the PST component contributed in some way to the
overall efficacy of the intervention.
MAINTENANCE OF TREATMENT EFFECT
Does the treatment effect last beyond the intervention period?
Whether the treatment effect is sustained beyond six months has not been
established. Follow up is on-going and will be reported when data are available but
the trial is not designed or funded to explore longer-term effects. However, a recent
systematic review (Gilbody et al 2006) suggests that the treatment effect of
collaborative care models extends beyond a year with effects still evident at 5 years,
although collecting data to show this in cancer populations would be a challenge
because of loss of data due to death.
COMMENT
In summary, the trial had methodological limitations. The major unavoidable ones
were: the possibility ofmeasurement bias, that is the effect of patients being aware of
which treatment they were receiving; response bias, that is the effect of patients
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exaggerating or minimising their trial outcome assessment responses; and the
possibility that non-specific treatment effects may have been operating, the
implications of which, if any, are impossible to determine. However, a large
treatment effect was observed on the primary outcome measure with statistically
significant benefits seen on all other measures other than physical functioning
suggesting that the interpretation of the findings is fairly accurate.
So although non-specific treatment effects and measurement and response bias could
not be avoided, the trial had the advantages of recruitment via mass screening of
patients rather than referral, rigorous patients selection, a sample population ofmixed
cancers at different stages of disease and treatment, known confounders accounted
for by using minimisation in randomising patients, the use of a strict quality
assurance procedure, the use ofmore than one therapist and very few missing data,
making the findings robust.
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CHAPTER 10: OTHER RELEVANT RESEARCH
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Table 10.1: Key trials of the collaborative depression care model
List of Figures
Figure 10.1: The development of the collaborative depression care model
TRIALS PUBLISHED BEFORE THE START OF THIS TRIAL
Prior to starting this trial, there had been no published trials ofmulti-component
interventions for the management ofMDD in cancer patients or patients with chronic
illness. However there were published results of the three main early efficacy trials
ofmodels of collaborative care models ofMDD management in primary care
settings (Katon et al 1995, 1996 and 1999). The first of these trials used a simplified
model with a patient education component, the second trial added a brief problem
solving treatment to the package and the third trial used a stepped care model
whereby patients not responding to standard conventional treatment would receive
enhanced care of a similar package to that used in the 1996 trial. Following this, two
effectiveness trials of the simplified collaborative care model (Rost et al 2001) and
the additional PST model (Wells et al 2000) were published. A number of other trials
were conducted extending the model to different patient populations of high utilisers
ofmedical care (Katzelnick et al 2000), older people (Unutzer et al 2002) and low-
income women (Araya et al 2003) and extending its mode of delivery to phone-
delivered treatment (Hunkeler et al 2000), detailed in Table 10.1. The development
of the collaborative model, with key trials, are depicted in Figure 10.1.
TRIALS PUBLISHED AFTER THE START OF THIS TRIAL
Since the start of the trial, a second efficacy trial of a phone-delivered collaborative
care model for MDD in primary care has been published (Simon et al 2004).
However publications of collaborative care models for the management ofMDD
applied to chronic illness or cancer have been few. Katon and colleagues (2004)
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published findings from their trial of extending the stepped care model to a
population of patients with diabetes. This was the first reported trial of this model
applied to chronic illness. Of key relevance to my research however has been the
publication of a randomised pilot study of the model applied to cancer patients by the
group in Los Angeles (Dwight-Johnson et al 2005). These two trials will be
discussed in more detail below:
The Pathways study (Katon et al 2004)
This was a randomised efficacy trial comparing the stepped care collaborative model
of depression management in patients with diabetes with usual depression
management in terms of outcomes in depression and diabetes. A total of 329 patients
were recruited from nine primary health care centres in one health care system with
diabetes mellitus and comorbid persistent depression and/or dysthymia as identified
by self-report measures. Unlike the trial described in this thesis there was no
interviewed based verification of the self-report 'diagnosis' and the depression
severity scale score for trial entry was set much lower (at 1.1) than that used in this
trial. The sample in fact comprised 70% dysthymia and less severe depression and
was therefore quite different from the sample in this trial in terms of severity and
chronicity.
The experimental treatment delivered was enhanced education and support of
antidepressant medication prescribed by the GP or PST provided by a supervised
depression clinical nurse specialist in collaboration with the GP over twelve weeks in
approximately half hour sessions spaced at two weekly intervals with continued
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monitoring for up to a year. Treatment was provided in a stepped fashion whereby
patients received different types and intensities of services if they still had persistent
depressive symptoms at twelve weeks. Their treatment programme is therefore more
focussed on non-responders than this trial, targeting those with no treatment response
by a set period more intensively and actively engaging them in further treatment,
although in content very similar to my intervention and delivered by a nurse.
However it is unclear whether they too used nurses without any prior mental health
training.
The pre-specified criteria for good outcome, defined as 'response to treatment', was
the difference between the treatment groups in proportions achieving firstly a forty
percent reduction from baseline and secondly a fifty percent reduction from baseline
in the SLC-90 depression scale score at six and twelve months. An analysis of group
trends over time in mean depression scores was also performed. Outcomes expressed
as treatment response found a statistically significant and clinically important but
small difference between the groups in proportions achieving a 40% reduction in
depression scores at twelve months but not at six months and no statistically
significant differences at either time points between groups when a more stringent
clinical indicator of 50% reduction was applied. Outcomes expressed as change in
mean depression scores over time found a statistically significant difference between
the intervention groups at six and twelve months. These results are not consistent
with mine. The only clinically defined outcome that was statistically significant was
for a 40% reduction in depression scores and only at twelve months. The
standardised effect size of the results was 0.11. Although I do not have twelve month
data from this trial for direct comparison, my six month data on a 50% reduction in
SCL-20 score from baseline as a standardised effect size of 0.22, is a bigger effect
size than that found in the Pathways Trial.
A similar comparison can be made however with the care received in the usual care
group in that usual care was actually 'enhanced usual care', enhanced by
encouraging the patient to discuss their depression with their GP and that a
significant number of the usual care patients received antidepressant medication.
In summary, the patient population was similar in terms of comorbid chronic illness
but not comparable in terms of depression severity. The treatment, although similar
in content, was delivered by a supervised nurse but the treatment programme was
longer and intensified for 'non-responders'. The outcome measure was the same but
treatment response was defined at a lower cut-off. However, overall, the Pathways
trial was the first trial of a collaborative model applied to chronic illness. The finding
of a delayed larger treatment effect is comparable in part with the results ofmy trial
where the treatment effect has increased over time.
The Latina study (Dwight-Johnson et al 2005)
This was a randomised pilot trial comparing the collaborative care model of
depression management in patients with cancer in an Oncology setting with usual
depression management in terms of depression outcomes and cancer treatment
adherence. Fifty-five female low-income Latina patients (with MDD, persistent
depressive symptoms for a month or dysthymia as assessed by self-report measures
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rather than interview-based diagnoses) were recruited from the breast and
gynaecological outpatient clinics of a US public sector Oncology centre. Although
there was no trial entry criterion for depression severity, the mean PHQ-9 score at
baseline was greater than 10 and the exclusion criteria applied were the same as
those used in my trial and patients were screened as opposed to recruited by referral,
hence capturing a sample representative of fairly well cancer patients with no
significant psychiatric comorbidity other than the depression. However, the patient
sample is not directly comparable with my trial sample in terms of depression
severity and chronicity, ethnicity, social deprivation status and is gender-specific.
However, this is first trial, albeit a pilot study, from another research group that has
investigated the efficacy of the collaborative care model for depression in a cancer
population and is therefore the only comparison that can be made to date.
The experimental treatment delivered in the Latina trial was either eight weekly
sessions of PST provided by a psychiatrist-supervised depression clinical specialist
(social worker) or antidepressant medication (prescribed by the Oncologist and
monitored by the depression specialist) as their first-line treatment, plus education
and support to increase antidepressant medication adherence and access to
appropriate services. Patients not responding to treatment at the end of eight sessions
of PST or by week eight, as defined by not achieving a 50% reduction in depressive
symptoms, were reassessed by the psychiatrist and treatment adjusted.
Their treatment programme is very similar to the one used in this trial. The treatment
provider although not a nurse was supervised by a psychiatrist and received regular
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scheduled supervision meetings. The treatment programme was delivered according
to a manual, depressive symptoms monitored and treatment adjusted according to
treatment response using the same clinical indicator of response as in my trial. The
differences appear to be primarily to do with the package of treatment offered. It is
not clear whether patients had the option of PST together with antidepressant
medication. If not, then this is a major difference from the model inmy trial, where
the treatment package consisted ofmultiple components including antidepressant
medication and PST although the combination of these two components was not
compulsory. The usual care component was also similar to that provided in my trial
with the diagnosis being given to the doctor or main health care provider and
documented in the patient's Oncology notes.
The pre-specified criteria for good depression and cancer treatment adherence
outcomes was the difference between the treatment groups in proportions achieving
'response to treatment', defined as a fifty percent reduction from baseline in the
PHQ-9 depression scale score at eight months, and the proportions adherent to cancer
treatment. Statistically significant differences between groups were found in
depression outcome but not for cancer treatment adherence. These results although
only preliminary and imprecise, as indicated by the wide confidence intervals, are
consistent with mine. Furthermore, non significant findings for effect on physical
functioning are also consistent. From their discussion of barriers to implementing
this model in the Oncology setting, problems with securing additional consultation
slots with the Oncologist in order to prescribe an antidepressant were mentioned.
Integration with the Oncology setting has been an on-going and evolving component
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ofmy model and consistent with the Latina study conclusion, it seems necessary to
provide additional resources for the implementation of the model rather than using
existing resources.
In summary, the patient population was similar in terms of comorbid cancer but
again not comparable in terms of depression severity. The treatment although similar
in individual components was different in the package offered to patients. However,
overall, the Latina trial was the first trial of a collaborative model applied to cancer
conducted by another research group.
In addition to these two trials, three systematic reviews of depression management
programmes published after the start ofmy trial (Badmagarav et al 2003; Neumeyer-
Gromen et al 2004; Gilbody et al 2006) have confirmed the efficacy and
effectiveness ofprimary care based multicomponent interventions for the treatment
of depression. Although not time-equivalent, comparing the treatment effect size of
0.43 (95% CI 0.15 to 0.72) from this trial's three month outcome results with the six
month outcome pooled effect size of 0.25 (95% CI 0.18 to 0.32) from the most recent
systematic review (Gilbody et al 2006), illustrates that the results of this trial are
similar in effect.
On a cautionary note however is that although there is sufficient evidence now to
demonstrate a reliable, consistent and statistically significant benefit of the
collaborative model over usual care for depression in primary care, it should not be
assumed that this model can be applied to other disease-specific patient populations
without further research. A Canadian study of case management by nurses in patients
with heart disease found no overall impact on either survival or psychological
outcomes in post-myocardial infarction patients with high levels of distress and even
showed increased cardiac and all-cause mortality in women who received the
intervention (Frasure-Smith et al 1997). However the patient sample was not of
identified cases of depression but rather patients with high levels of distress, the
nurses had not received any training in psychiatric disorder screening or
psychotherapeutic techniques and case management did not involve any direct
intervention other than reassurance, advice and referral. Hence although the model
could not be considered 'true' to the collaborative care model, it does illustrate that
this type of care may not in fact be beneficial to all groups of patients.
An interesting finding in my trial was the lack of effect of the intervention on
physical functioning. This was not an unexpected finding, and is consistent with
those of other trials and the review by Badmagarav et al (2003) that found very little
evidence of effectiveness of disease management programmes for depression on
physical functioning with the pooled estimate showing an effect close to that of usual
care. Furthermore, aiming to achieve any benefit in physical functioning may be
unrealistic in patients with chronic illness, especially illnesses like cancer that have a
natural course ofphysical deterioration.
In summary there is insufficient evidence to draw strong conclusions about the
efficacy and none about the effectiveness of the collaborative care model for the
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management ofMDD in cancer patients. However, this trial provides the first piece
of robust evidence of its efficacy in a relatively well cancer population.
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The trial reported here has several clinical implications:
1. An efficacious and potential effective intervention has been developed for
patients with MDD comorbid with cancer
2. Adding the intervention to usual care achieves a better outcome than usual care
alone
3. The number ofprevious episodes of depression, length of current episode of
depression, depression severity and possibly extent of cancer disease may be
independent predictors of outcome
4. There is suggestive evidence that increasing patients' confidence in their ability
to control an episode of depression is associated with good outcome
Firstly, it would be premature to recommend this intervention for general clinical
practice. The evidence is only preliminary and it is likely that the treatment effect
will be diluted when transferred into routine practice. For instance, in this type of
intervention trial the clinicians' and therapists' abilities are likely to have an impact
on the patient's recovery more so than a clinician's impact in a drug trial. Caution is
therefore needed when introducing such a treatment into practice because it is
effectively generalising the achievement of the most skilled and experienced
clinicians and nurses and hence requires testing in a large pragmatic trial to provide
evidence of its generalisability and effectiveness.
Secondly, providing this intervention in the UK NHS may require additional
resources. It is not clear whether existing clinical cancer nurse specialists would take
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on the role of depression management or whether a new 'breed' of clinical nurse
specialists would deliver this intervention. Whatever clinical configuration evolves
will depend on both the results of the next planned effectiveness trial and the way in
which the NHS is prepared to deliver the model.
Implications for research
Measures
Although primary care trials to date have been fairly consistent in their use of
measures for the initial diagnosis and for assessment or outcome, there has been
considerable debate about the diagnosis ofMDD in cancer patients. However, as
more trials are undertaken, the need for uniformity is essential in order to compare
findings. Further validation studies in cancer populations are required for the main
measures that have been used previously in the primary care trials, that is the SCL-
20, the HAM-D, the CES-D, the DSM1V SCID interview criteria, the PHQ-9 and
maybe more radically the single-item screener, "Are you depressed most of the
time?"
Methods
The efficacy of the collaborative depression care model for minor depression has not
been proven. Early studies failed to show any significant benefit for this group of
patients (Katon et al 1995 and 1996). Future research with this model in cancer
patients should also therefore focus on more severe depression, providing an
opportunity to develop an appropriate intervention for forms of lesser distress.
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The efficacy of the collaborative depression care model has also not been applied to
cancer population subgroups such as poor prognosis patients. As previously
mentioned this may require adaptation of the model necessitating piloting before an
efficacy trial can be undertaken.
More research is also necessary to test the model in other chronic illnesses and its
effect on medical outcome. This has already begun with Katon's trial in patients with
diabetes (Katon et al 2004).
Finally, given that there is evidence to suggest that the coexistence of cancer and
depression is associated with an increased risk of death from all causes (Onitilo et al
2006), another area of research interest would be the effect of depression and its
management on survival. This would be methodologically challenging in a
population with high death rates at varying intervals although perhaps more feasible
in cancer-specific populations with fairly accurate predictions of survival.
LONG-TERM OUTCOME
Indications are that there is long-term benefit from primary care based collaborative
depression care models (Gilbody et al 2006). The research challenge is therefore to
provide long-term outcome data for a cancer population. However the nature of the




It may be clinically more logical to apply a stepped approach to the management of
those patients with a previous history of depression, with severe MDD and those
with more advanced disease as these may be predictive of poor outcome. Thus
additional treatment or appropriate referral could be made if a treatment response
was not achieved within a set period as done in other trials. However, I suspect that
for patients with advanced disease, the model may require adaptation to
accommodate deteriorating physical functioning and reliance on others for help, thus
compromising the essence of the model, that of control over one's illness.
Implications for research
The identification of independent predictors of poor outcome provides information
for future trials, having implications for both the randomisation of patients and the
analysis of the data. It is now clear that depression history, current severity of
depressive symptoms and extent of the cancer are possibly the more important
factors in achieving comparable groups than gender, age and cancer type.
COMMENT
However, in spite of emerging evidence for an effective approach to the management
of depression in cancer patients, there remains a fundamental question: Do the
patients want the treatment and will the health care team give it? From my
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experience of this trial, I think there may be a barrier to be overcome, before
depression management can ever be accepted into routine practice, that is, a
fundamental beliefunderlying the all too often heard comment of "Well, it's
understandable they have depression, after all they have cancer!"
In my view, the key issue is not about whether depression is an understandable
reaction or not but is about whether it is treatable or not? The results presented in this
thesis provide evidence for the fact that severe depression in cancer can be treated so
returning to the question ofwhether it is understandable or not makes the question
rather pointless and the lack of treatment possibly unethical.
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CHAPTER 12:
THE CURRENT STATUS OF THE COLLABORATIVE
CARE MODEL APPROACH TO THE MANAGEMENT
OF MAJOR DEPRESSIVE DISORDER IN CANCER
PATIENTS
192
There have been no reported studies to date of the efficacy of a nurse-delivered
multi-component intervention for the management ofMDD in cancer patients. There
is now sufficient evidence to prove the effectiveness of collaborative depression care
models in primary care and preliminary evidence for its efficacy in patients with
comorbid chronic illness. The trial reported here is, as far as I am aware, the first
randomised controlled trial of collaborative care that has been extended beyond
depression managed in primary care to depression managed in secondary care
integrated with primary care thus providing a fourth element of oncology care to the
three elements of chronic disease management of: case manager; a primary care
physician; and access to specialist mental health care. Furthermore, the trial is the
first trial of a collaborative model outside of the US and the first in cancer.
There is however growing evidence of the efficacy of nurse-delivered interventions
for symptoms other than depression in cancer populations. Of the few reported
evaluations of nurse-delivered interventions in cancer patients, favourable outcomes
were shown in two large randomised controlled trials: the management of distress
associated with breathlessness in lung cancer patients (Bredin et al 1999); and an
intervention designed to reduce symptom limitation for patients undergoing
chemotherapy (Given et al 2004).
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CONCLUSIONS
Chapter 13: Review of Aims and Hypotheses
Chapter 14: Future Research





The overall aim was to improve the management of depression in patients with
cancer. The specific objective was to:
1. Test the efficacy of this intervention model for the treatment ofMDD
in cancer patients ofmixed diagnoses in a randomised controlled trial
by comparing usual care with usual care plus the nurse-delivered,
psychiatrist-supervised multi-component intervention by:
a. Measuring the primary outcome of trial participants at 3 and
6 months
The efficacy of the intervention model was tested at three months using the primary
outcome measure of the SCL-20. A substantially better and statistically significantly
better outcome was obtained for those patients receiving the additional intervention
with the benefit being sustained at the six-month follow-up. The main hypothesis that
usual care plus a nurse-delivered, psychiatrist-supervised multi-component treatment
intervention would reduce symptoms ofmajor depressive disorder in patients with
cancer to a greater extent than usual care alone was supported.
b. Measuring other outcomes at 3 and 6 months, specifically:
L clinically relevant response to treatment and remission ofdepressive symptoms
The efficacy of the intervention model was tested at three months using clinically
important criteria of treatment response and remission. There was a statistically
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significant difference in proportions of patients achieving the pre-specified secondary
outcomes between the groups at three months. Observing convergence of the results
has provided robustness and clinical validity to the findings of the primary outcome.
Furthermore, the findings suggest that the differences in benefit may even be larger
at six months. The hypothesis is shown to be supported that at the 6 month follow-
up, patients treated with the additional nurse-delivered intervention will maintain the
benefit and have benefit superior to those patients who were allocated to usual care
only.
ii. anxiety, physicalfunctioning, coping, problem solving ability and satisfaction
with treatment
The efficacy of the intervention model was tested at three months using measures of
anxiety, physical functioning, coping and problem-solving. A greater reduction in
anxiety and a greater increase in all coping measures were observed in the
intervention group. However, no significant differences were observed on the
measure of physical functioning between treatment groups at three months. This was
not a surprising finding and reinforces findings of similar trials in chronic illness.
Although no formal significance testing was performed at six months, the treatment
effect for physical functioning was larger in favour of the intervention group.
Satisfaction with treatment measured at six months found that the satisfaction of
patients receiving the intervention was greater than those receiving usual care.
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Hi. the association between improvement in depression scores and aspects of
confidence, coping and support
The associations between improvement in depression scores and measures of
confidence, coping and support were explored at three months. A correlation was
found between improvement in depression outcome and change in measures of
confidence but not of support and coping, suggesting that increasing patients'
confidence may have had an influence on outcome. The hypothesis that the
additional nurse intervention improves outcome by a) increasing the patient's
confidence to cope with concerns and b) increasing their coping skills by teaching
them a skill to tackle their concerns and c) increasing their access to and use of social
support therefore receives some support and can only be considered as exploratory
findings.
iv. the extent to which baseline factorspredict a good outcome at 3 months
(although this was exploratory and notpart ofthe pre-specified statistical analysis
plan)
At the 3 month outcome, exploratory analysis suggested that the principal
independent predictors of good outcome were: allocation to the additional
intervention arm; no previous history of depression; a current episode of less than
one year's duration; and a low baseline depression severity score. It was surprising
that neither gender, nor any cancer related variables such as extent of disease nor
whether the patient was receiving active anti-cancer treatment emerged as predictors
of response.
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In conclusion the overall aim which was to improve the management of depression in
cancer has been largely achieved. However, a large effectiveness trial is now
required to determine whether the intervention is effective when implemented out-
with a research environment in the 'real world' of a health care system.
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CHAPTER 14: FUTURE RESEARCH
Sections
The evaluations of interventions
Comment
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There is now sufficient evidence of the efficacy and effectiveness in primary care of
the collaborative depression care model (Gilbody et al 2006).
Further research is now required to evaluate the application of this approach to other
patient populations such as those with comorbid medical disease.
THE EVALUATION OF INTERVENTIONS
This is the first reported efficacy trial of a collaborative care model for MDD in
cancer patients. Hence it requires both replication and evaluation of effectiveness.
Since the completion of this research, further funding has been secured to conduct a
large pragmatic trial across Scotland to investigate the effectiveness of this approach
to depression care for cancer patients. A proof of concept trial of this model applied
to patients with poor prognosis has also received funding and will be conducted in
Edinburgh.
There are three issues that warrant some thought before further research is
undertaken:
Firstly, Gilbody's review (Gilbody et al 2006) indicated that the addition of
psychotherapy to medication was not associated with increased effect size suggesting
that psychotherapy may not be an 'effective' ingredient of treatment. Future research
into the intervention proposed here should therefore assess the benefit of the problem
solving therapy. Perhaps a model that provides support and monitoring to ensure
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patient compliance to antidepressant medication would be as effective and less costly
to provide.
Secondly, trials using case managers with a mental health background found greater
efficacy (Gilbody et al 2006). However it remains unclear whether it is better for the
case managers treating depression in cancer patients to have a mental health
background or a cancer background.
Thirdly, there is a need for trials large enough to be able to identify predictors of
response. Exploratory findings from this research suggest that the severity and length
of the current depressive episode and a previous history of depression predicts
response to treatment. This may therefore provide some substance on which to base a
refined model, for instance a model whereby patients at risk of poor response to
treatment are given more intense treatment or are provided with an additional
component.
COMMENT
In summary, there is a robust body of evidence to support the effectiveness of
collaborative depression care in primary care but only limited evidence of its efficacy
and effectiveness in patients with comorbid medical conditions and next to none in
cancer patients. There is therefore a pressing need for research into the management
of depression in patients with cancer.
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APPENDICES
Appendix A: Treatment Manual
TREATMENT OF MAJOR DEPRESSIVE DISORDER
IN ONCOLOGY PATIENTS
Nurse treatment manual
Vanessa Strong, Michael Sharpe, Ann Cull,
with advice from Peter Maguire, Amanda Ramirez, Allan House,
Wayne Katon, Arthur Nezu, Christine Nezu and lona Davis
(Copyright University of Edinburgh 2000)
REQUIREMENTS
This manual presupposes that the treating nurse has:
1. Good knowledge of oncology nursing
2. Attended formal training in
• Interviewing and eliciting concerns
• Diagnosing and assessing depression and suicide risk
• Use of antidepressant medication
• Advanced Coping Skills Training therapy
It is intended to be administered only after demonstration of competence and under the
supervision of a qualified mental health professional. This manual is a framework for
delivering the treatment and the nurse requires expertise to tailor this treatment to the
individual patient. Text in italics are recommendations for presentation of facts and/or ways
of questioning.
OUTLINE OF TREATMENT
The treatment is based on a detailed assessment of the patient and is carried out in 6
sessions with the possibility of extending the therapy to a maximum of 10 sessions over a
maximum of 13 weeks. Sessions 1 and 2 are to be completed in the first week - subsequent
sessions are spaced at approximately weekly intervals.
GENERAL POINTS
Interpersonal style
• BE POSITIVE - 'well done'
• BE EMPATHIC - 'that must have been hard for you'
• BE CURIOUS - 'what was that like; how do you feel about that?'
• BE SPECIFIC - 'tell me exactly what that is like'' can you give me an example?'
• BE PRACTICAL - 'let's see just how that would work'
• BE FACILITATING - 'would you like to try that out here first?'
• BE REALISTIC- 'is that goal something we can reach - or should we rethink it?'
RECORDING TIME / COST OF TREATMENT
For each patient, record:
• all contact time (face to face and on phone)
• time spent in administrative duties
• time psychiatrist/psychologist gives nurse in supervision
• Any face to face time between psychiatrist /psychologist and patient




















Focus= Review of relapse prevention plan
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Session 1 Treatment Assessment
Focus= General Assessment
AIMS: Explain approach and length of treatment (start planning for end of
therapy)
Engage patient
Elicit exhaustive list of concerns
Elicit patient's understanding of their cancer and depression
Assess depressive symptoms and suicide risk
Find out what treatment they have had and are receiving now
Clarify other problems
Obtain background history and current circumstances/resources
Explain the approach of advanced coping skills training
Mini coping technique example using depression as the problem
Agree approach and plan treatment





1 to 1.5 hours
List of concerns
Patient's perception of cancer and depression
Depressive symptoms on SCID and suicidality
Initial concerns list
Initial plan re: depression
Read patient information booklet
See GP re: antidepressants or appropriate homework task
HOMEWORK
NURSE:
Letter to GP re: patient and antidepressants (faxed/sent/phoned)
Letter to patient's Oncologist (with copies to any other health care





The following explanation might be given:
Who am I?
My name is ...I am a Specialist nurse who is trained in helping patients who are attending
the Oncology Service and who also have a problem with (low mood) depression.
Purpose of interview
I would like to work with you to see if together we can help you feel better.
What we will cover today
Today I suggest that we devote the next hour or so to reviewing how you are at present.
After that, I propose that we meet on up to 7 more occasions to work together on how you
might overcome the depression and the problems that are contributing to it.
How long do we have?
We have about an hour. We have a number of things to cover so I may need to interrupt you.
Is that OK?
Is there anything you would like to ask at this stage?"
Did you have any worries or concerns about coming today?
Give patient a treatment information booklet (appendix a) and consent form for recording
interviews (if using this method for supervision) (appendix b).
Ask patient to complete the PHQ-9 (appendix c) before starting the session.
PATIENT'S BASIC INFORMATION





• Who at home - who provides support?
• GP and how get on with? (remember to check GP contact details)
• Who is the oncologist and how long have they been coming to clinic?
PATIENTS IMMEDIATE CONCERNS
Now I'd like to make a list of all your current concerns. Once we have the list, we can talk
about each of these individually.
• Make list of all (at least 3) concerns with brief description of each (but defer detail)
• Ask and be specific about whether they consider loneliness a problem if social support
appears limited and add to the list
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• Ensure cancer and depression (or equivalent) on list
Say ' anything else' 'can you describe that to me' 'can you give me an example'
Use empathy ' that must be difficult - was that upsetting?'
Once list obtained summarize for patient
ENQUIRY ABOUT CANCER
Now I'd like to ask you about your experience of your cancer
Tell me the story of the cancer. (If necessary prompt with...)
• How did it start?
• When was it diagnosed?
• How has it been treated?
• Ask how do you feel about that?
• Current Symptoms (list) - ask about pain
What is your current treatment?
• What drugs and how often?
• How effective do you think it will be
In what way is the cancer a problem for you NOW... ?
How do you feel about your cancer?
When you think about it do you have any particular words or images?
What do you think the cause is? (optional)







Is there anything you can do?
How effective do you think it will be?
Have you thought about dying?
What is the worst thing for YOU about dying?
How do you see the future (probe their understanding of their prognosis)?
ENQUIRY ABOUT DEPRESSION
Understanding of the nature and cause of depression.
I'd now like to ask you about your depression
Tell me the story of the depression. If necessary prompt with...
• How did it start?
• Why do you think you got 'down in the dumps'/low/miserable? (use the word/term the
patient uses to describe their mood)
• When was it diagnosed?
• How has it been treated?
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What is your current treatment?
• What drugs and how often? (Precise medication dosages; duration; adherence and
helpfulness)
• How effective do you think it will be?
How is the depression a problem FOR YOU NOW... ?
Current Symptoms
• List symptoms (use the SCID as guidance, appendix d) and check for suicidality and
chart on SCID scoring sheet, also appendix d)
• Check for bipolar disease. Do you have any episodes that you feel very happy and full of
energy? Have you ever had any episodes like that in the past?







Is there anything you can do yourself?
How effective do you think it will be?
Do you think you can overcome depression?
Have you ever had depression before? (when, duration and how treated)
CURRENT CIRCUMSTANCES
Now I'd like to ask in a bit more detail about how you are NOW
• Other current illness
• ALL current medication/treatment
• Current alcohol intake (units per week)
• Current social support - including shortcomings in network or use of network (important
issue so be probing)
BACKGROUND
I'd like to ask you a few more things about your background
• family history of cancer and depression and/or previous experience of illness/cancer
• personal upbringing, occupations and relationships
• Usual personality/ how you usually cope with stress.
Apart from this challenge that you are facing now, can you think of any other challenges you
have faced in your life? (be probing - it would be unusual to find a person who hasn't
experienced something difficult in their life)
You've obviously coped with things before in your life - how do you usually cope?
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CONSTRUCTION OF CURRENT CONCERNS LIST
That has been very helpful because you've now told me that are problems for you,
would you say that is a problem for you that you may want to add to the list?
• Add any others that emerged during the therapy.
• If the patient has hinted at another concern or it seems to be present, offer that to the
patient as a potential concern, which they may wish to endorse.
• Ask and be specific about whether they consider loneliness a problem if social support
appears limited and add to the list (i.e. is loneliness a problem for you?)
Let's list together your main concerns NOW?
Make sure to check for any other concerns
Once all concerns explored summarize again
OK to summarize...
One problem is the fact that you've got/had cancer.
You've now got a second problem with depression
The other concerns you've told me about are...
• List and clarify each
*********IVlake sure problems are specific and precisely formulated**********
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EXPLAINING THE APPROACH TO TREATMENT
I would like to work with you to help you feel better.
Depression is an illness and can make the cancer feel worse - it makes physical symptoms
seem worse, and makes you feel more helpless and pessimistic.
The good news is that we know a great deal about how to help people overcome depression
The word 'depression' can be misleading because it is also used to describe people simply
feeling unhappy. In fact depression is a term used to describe a collection of symptoms such
as low mood, loss of interest, lack of concentration, poor sleep or feeling irritable (etc - relate
to the symptoms the patient has presented with). It is thought that people may be more
vulnerable to developing this collection of symptoms because of genetics or previous
experiences in their lives. We know that depression is usually triggered by stress and it is
associated with changes in the chemistry of the brain. Once this happens, you may not feel
very positive and may feel that you aren't coping as well with the problems in your life. Once
the depression has started, it can be kept going by these feelings of hopelessness/loss of
control. So depression is related to the way we think about things that happen in our lives
and to the way we cope with them.
So depression is a real illness and the good news is that it is treatable!
There are very successful treatments for depression. The two main ones are antidepressant
therapy and talking therapies. Our approach is to offer both together - the antidepressants to
reverse the chemical changes in the brain and the talking therapy to help you cope with
problems happening in your life and to address the feelings you have as a result of the
depression. You will not be forced to accept both however. Both work individually but
together are more effective.
The talking therapy component of the treatment is a very practical approach to help you with
the way you are coping with problems. This treatment will help you tackle problems which
will make you will feel more in control and better able to cope. We call this talking therapy
advanced coping skills training. It is also a long-term skill that can help you in the future.
What is involved is that you choose one problem to work on in the session. Once you have
generated solutions to the chosen problem, you then choose an achievable solution to try at
home before the next session. By doing this, you will become very skilled at coping and
therefore more confident that you can influence what happens to you..
As a result, the symptoms of depression that you are experiencing will improve.
Do you have any questions before we move on? (use the FAQ sheet, appendix e), as a
guide to answering any questions)
This part of the session will be a bit different from what we have done so far. It is where you
do the work. It is the beginning ofyour advanced coping skills training program. As part of
this training I will show you a technique to approaching problems.
ADVANCED COPING WORKSHEET - exercise for depression
The aims of this part of the session are: -
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• To review the patients symptoms of depression and their problems,
• To explain the rationale and principles of the advanced coping skills component of the
treatment;
• To illustrate the stages of advanced coping using a specific problem such as low mood
as an example.
In this session the stages of advanced coping are described to the patient and discussed in
detail, so that the patient understands how and why it is likely to help. It is important to
motivate the patient to comply with treatment.
Procedure
First, I will summarize the concerns you have told me about and then I will explain how to
approach the problem in a new way. There are some concerns on your list that you may
consider to be problems for you, which you may want to tackle. But today, I'd like to use the
example ofyour 'low mood'/ depression (use the patient's term for their depression) to
illustrate how to use this new technique.
Explain 'advanced coping skills' using the following framework:
Problems
List the problems in a clear and concrete form (suggesting that the first to tackle may
be low mood/depression).
Goals
Identify a goal for this problem that is concrete and achievable before the next
session. This should be practical e.g. doing one positive thing.
Solutions
Encourage as many solutions to this as he/she can generate. Ensure the following
are on the list and discussed...
Antidepressants including eliciting patient's pros and cons - educate where appropriate.
Getting anti-depressant drug treatment from the patient's doctor (usually GP but Oncologist
if patient rarely sees GP) should be examined as a solution. In this way, the emphasis on the
use of antidepressants should not be detrimental to the empowerment of the patient in the
'advanced coping' context.
Pros and cons
The examination of the pros and cons of this solution will bring to light issues about the
acceptability to the patient of anti-depressant drugs and provide an opportunity for education
using the patient information pack.
Chosen solution and plan
The patient should have a clear set of tasks that need to be completed before the next
session, referred to as homework, and listed on the advanced coping skills work sheet (see
appendix f). If the patient is already taking antidepressant medication, the patient should be
encouraged to chose a solution that will also contribute to 'relieving' the depression (could be
as simple as seeing the grandchildren more often or be a form of behavioural activation, see
below)
Consider using role-play if the patient lacks confidence about the tasks.
Behavioural activation. Getting going and scheduling pleasurable activities.
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In addition to the advanced coping exercise, encourage the patient to consider doing
something active they enjoy before the next session eg walk with a friend, going swimming
etc (behavioural activation)
At the end of the first session, the nurse should emphasize that much ground has already
been covered in that session. The patient doesn't have to remember all this initial material
because further explanations will be given in subsequent sessions.
Using and building network of social support
The importance of building a support network should be emphasized at this point to prepare
for the end of the sessions. Explain that this will be explored in the next session using the
advanced coping technique.
The session concludes with three important 'take home' messages: -
• Depression is an illness that is treatable. It is an illness that causes you to think in a
more negative way and makes you feel less able to cope with problems;
• We can't solve the cancer but if other problems important to you can be tackled, the way
you think about events in your life alters and the symptoms of depression will improve;
• Specific tasks need to be completed before the next session.
ENDING THE SESSION AND MAKING A PLAN
I'd like you to read the patient information booklet and then to meet with me again in a few
days. What do you think? Do you have any questions?
Allow time for the patient to ask questions and clarify issues
BEFORE END OF SESSION
• 'Ensure agree to a further 5-7 sessions;
• Plan time and place of next appointment (3-4 days following session 1);
• Ensure plan for antidepressants (either starting medication or increasing dose).
IF AGREED - patient will see doctor;
• Nurse will contact doctor by post/phone.
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Clinical condition - symptoms, state of cancer, treatment and any change or addition
to current medication. If the patient has already started antidepressant therapy
since session 1, chart type, dose, date started and also any side effects.
Mood state and any suicidality
Homework





Explain the advanced coping skills technique again and work on support and social
networks. If however this is not a problem for the patient, work on a problem of the
patient's choice with some guidance to choosing a problem that has achievable
solutions.
Plan
Homework (Social network -plan for future)
Next appointment for approximately 1 week's time
DURATION: 45 mins max
OUTPUTS: Plan for next problem
Next appointment
HOMEWORK One task - chosen to overcome hopelessness
PATIENT:
HOMEWORK Complete treatment summary sheet
NURSE: Discuss in supervision
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Session 2 Format
The nurse should check the patient's clinical improvement by asking the patient to complete
the PHQ-9 before the start of the session.
REVIEW AND SET THE AGENDA
First, I want to go over the reason for using this therapy again. Then I want to check briefly
with you about how you have been feeling since I saw you last - physically and emotionally.
Then how you managed with your homework from last time.
Remember I explained that depression is related to the way we think about things that
happen in our lives and to the way we cope with them. Symptoms of depression occur when
you don't feel positive and you feel that you aren't coping as well with the problems in your
life. Therefore ifyou are able to tackle the problems, you will feel more in control, better able
to cope and the symptoms of depression that you are experiencing will improve. Today I
want to focus on the way you normally cope with problems, then practise the advanced
coping skills technique using a problem ofyour choosing from your list of concerns.
But first
• Ask about reactions to last session; Any questions about our last session - anything
upsetting?
• Clinical condition - Symptoms; state of cancer and treatment and medication. How are
you getting on? What is happening with your treatment?
• Mood state and any suicidality - How are you feeling in your mood? Have you had any
thoughts of harming yourself?
Homework.
• Advanced Coping Skills - check their homework sheet
Your homework last week was to look at ways of coping with *** (or depression). How
did you get on with this? Did it work? Any problems? (give huge amounts of praise if
they implemented their solution).
If their solution was Antidepressants. Did you see your GP? Are you taking
antidepressants? Any problem taking them? Any problem with side effects? Do you think
that they are helping yet? Chart type, dose, side effects, instructions given by GP and
follow-up arranged by GP.
(If they didn't achieve the homework then take that as the problem to tackle this
session.)
• Behavioural Activation Are you doing things? Is that helping you feel better? Any
problems with this?
Review concerns - Let's go over the things that have been concerning you. Let's review our
original list. Do you still think it is right? Is there anything you want to change or add?
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COPING SKILLS TRAINING
The technique you practised last week, the advanced coping technique, can be more difficult
for some people than others. The reason for this is that there are some things about how you
normally cope that can get in the way. It would be worthwhile before we carry on to check if
any of these apply to you so that we can be mindful of them as we use the technique.
For instance, it's a bit like going on an advanced driving test. Lets just think of what would
stop you getting through the course. You might be the kind ofperson who shuts their eyes in
an emergency - well if we were trying to teach you how to steer out of a scid, the first thing
to do would be to make sure you keep you eyes open.
Similarly, things that might make it difficult for people to learn AND use the advanced coping
skills technique are things like....
• a tendency to rush into things without thinking (impulsiveness)
• a tendency to rely on other people to sort things out or feeling that you aren't
confident enough yourself to tackle problems (dependency)
• a tendency to agonise over decisions (indecisiveness)
How would you describe yourself? Do any of the above apply to you?
Ok that's very helpful. When you go through your training course we need to be mindful of
your tendency to ****, otherwise when you attempt to tackle a problem we might run into
trouble.
We will continue practising the technique called advanced coping skills which you used in
the last session.
This will
• help you improve your skills in tackling problems
• increase your sense of control
• decrease distress, and therefore....
• improve your quality of life
In this session we will explore a problem that some patients experience that of poor social
support, which is in fact an important moderator of stress. In other words, people who have
positive social support feel less stressed by problems they encounter.
Social network - Explore social network in detail. Be probing and inquisitive.
So first I want to just ask you about the support you have at the moment
Who are you able to talk to about your concerns? Does that help? Any problems here?
(Today you have told me that support and having someone to talk to is limited. Because
support is an important part of your recovery and something that needs to be planned in
preparation for the end of these sessions, I want you to apply the advanced coping
technique to this problem in this session.)
OR
(It seems from what you are telling me that you have a good range ofpeople who you can
talk to after these sessions have finished. We will talk about your support again towards the
end of this therapy but in today's session, I would like to help you tackle a problem from your
list in the way that you did last session.)
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Explain the advanced coping technique again with emphasis on the first step of 'defining the
problem', working on current problem (social support)
Complete a worksheet on the current problem (support or other), emphasising the
importance of defining the problem. Describe this step as gathering information/facts about
the problem in the way that a detective would. The clearer the problem, the easier it will be
for the patient to generate solutions.
Pretend you are a detective:
• Gather all the facts
• Describe the facts in clear language
• Separate the facts from what you think about the situation
Ask the questions, Who? What? Where? When? How?
HOMEWORK
For your homework this week, I want you to try your chosen solution to addressing the
problem of support (or appropriate problem if social support not a problem).
This homework is the basis for next week's session and it is therefore important that you try
this. If you find it too difficult, try doing a bit every day.
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Session 3-5 Treatment
Session 5 focus = formal treatment response
assessment
Session 5 = formal review in supervision of treatment response and treatment plan reviewed




Clinical condition - symptoms, state of cancer, and treatment.
Mood state and any suicidality








Work on current problem
Plan
Homework
Next appointment for approximately 1 week's time
DURATION: 30-45 mins
OUTPUTS: Plan/homework for target problem
Plan for medication
Return date and time
HOMEWORK Advanced coping task
PATIENT:
HOMEWORK Review in supervision. Discuss treatment response (formally in
session 5
NURSE: using the treatment modification algorithm (appendix g) and discuss
treatment plan with supervisor.
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Session 3-5 Format
REVIEW AND SET THE AGENDA
The nurse should check the patient's clinical improvement using the PHQ-9 and general
progress at the beginning of each session.The patient's coping skills homework should be
reviewed at the beginning of each session.
First, I want to check briefly with you about how you have been feeling since I saw you last -
physically and emotionally. Then how you managed with your homework from last time.
• Ask about reactions to last session; Any questions about our last session - anything
upsetting?
• Clinical condition - symptoms state of cancer and treatment. How are you getting on?
What is happening with your treatment?
• Mood state and any suicidality - How are you feeling in your mood? Have you had any
thoughts of harming yourself?
Antidepressants Are you taking antidepressants? Any problem taking them? Any
problem with side effects? Do you think that they are helping? Chart dose, side effects,
effectiveness. If the dose is not at therapeutic level, encourage the patient to consult
his/her GP to discuss an increase in dose.
Homework.
• Advanced Coping Skills - check their homework sheet
Your homework last week was to look at ***. How did you get on with this? Did it work?
Any problems? (give huge amounts of praise if they implemented their solution). (If they
didn't achieve the homework then take that as the problem to tackle this session)
Activation Are you doing things? Is that helping you feel better? Any problems with this?
Review concerns
Let's go over the things that have been concerning you. Let's review our original list. Do you
still think it is right? Is there anything you want to change? What shall we work on today?
COPING SKILLS TRAINING
The remainder of the time should be spent in coping skills tasks limited to one per session or
HOMEWORK
one over a number of sessions if the problem is complicated.
Set homework relating to a current problem or trial an alternative solution to last session's
problem if the chosen solution was unsuccessful or had limited effect.
Plan next appointment for approximately 1 week's time.
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Session 6 Treatment
Focus = formulating a relapse prevention plan




Clinical condition - symptoms, state of cancer, and treatment.
Mood state and any suicidality
Acceptability, dose (and appropriate increase) and compliance with antidepressant
medication should be reviewed.
Homework
• Activation
• Explore the success of previous session's implemented solution
Concerns
Work
Work on current problem
Complete the relapse prevention plan
Plan
Homework
Next appointment (for approximately 1 week's time)
DURATION: 30-45 mins
OUTPUTS: Plan for target problem
Relapse prevention plan
Plan for medication
Return date and time
HOMEWORK
PATIENT: Coping skills task
HOMEWORK
NURSE: Review in supervision. Discuss relapse prevention plan with supervisor
Note that supervision for all patients completing session 5 is compulsory. A formal




REVIEW AND SET THE AGENDA
The nurse should check the patient's clinical improvement using the PHQ-9 and general
progress at the beginning of the session. The patient's coping skills homework should be
reviewed at the beginning of the session.
First, I want to check briefly with you about how you have been feeling since I saw you last -
physically and emotionally. Then how you managed with your homework from last time.
• Ask about reactions to last session; Any questions about our last session - anything
upsetting?
• Clinical condition - symptoms state of cancer and treatment. How are you getting on?
What is happening with your treatment?
• Mood state and any suicidality - How are you feeling in your mood? Have you had any
thoughts of harming yourself?
Antidepressants Are you still taking the antidepressants? Any problem taking them? Any
problem with side effects? Do you think that they are helping?
Chart dose, side effects, effectiveness. If the dose is not at therapeutic level, encourage
the patient to consult his/her GP to discuss an increase in dose.
Homework
• Advanced Coping Skills - check their homework
Your homework last week was to look at ****. How did you get on with this? Did it work?
Any problems? (give huge amounts of praise if they implemented their solution)
(If they didn't achieve the homework then take that as the problem to tackle this session)
• Activation Are you doing things? Is that helping you feel better? Any problems with this?
Review concerns
Let's go over the things that have been concerning you. Let's review our original list. Do you
still think it is right? Is there anything you want to change? What shall we work on today?
COPING SKILLS TRAINING
The remainder of the time should be spent in coping skills tasks limited to one per session or
one over a number of sessions if the problem is complicated.
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RELAPSE PREVENTION PLAN
It is important after this treatment finishes, that you not only use your training in advanced
coping skills in the future to prevent problems getting on top of you but also to regularly
assess how you feel. Today I want to start looking at your individual plan to stay well. Your
plan should include self-monitoring, identification of factors that may make the depression
more likely to return (trigger factors) and a plan of action ifyou suspect the depression is
returning. At the back ofyour patient information booklet you will find a form you can fill in
(see appendix h) that covers all these things I have just mentioned. Today we should try and
work through this together.
Work through the relapse prevention plan to help the patient identify their first signs and
symptoms of depression by referring to the onset of this episode. Identify their trigger factors
(such as family problems or deterioration in health). Work through their plan of action should
the depression return emphasizing the importance of using the strategies that worked this
time and using the new coping technique.
HOMEWORK
Set homework relating to a current problem or trial an alternative solution to last session's
problem if the chosen solution was unsuccessful or had limited effect.
Complete the relapse prevention plan if not completed in session.





Clinical condition - symptoms, state of cancer, and treatment
Mood state and any suicidality
Antidepressants Acceptability, dose (and appropriate increase) and compliance with
antidepressant medication should be reviewed.
Homework
• Activation
• Relapse prevention plan
Concerns
Work
Work on current problem or relapse prevention plan or revisit social support if that
was an identified concern
Assessment of understanding of advanced coping skills technique
Plan
Homework
Next appointment (approximately 1 week's time)
DURATION: 30 - 45 mins
OUTPUTS: Plan for target problem
Plan for medication
Return date and time
HOMEWORK
PATIENT: Coping skills task
HOMEWORK
NURSE: Review in supervision
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REVIEW AND SET THE AGENDA
First, I want to check briefly with you about how you have been feeling since I saw you last -
physically and emotionally. Then how you managed with your homework from last time.
• Ask about reactions to last session; Any questions about our last session - anything
upsetting?
• Clinical condition - symptoms state of cancer and treatment. How are you getting on?
What is happening with your treatment?
• Mood state and any suicidality - How are you feeling in your mood? Have you had any
thoughts of harming yourself?
Antidepressants Are you still taking antidepressants? Any problem taking them? Any
problem with side effects? Do you think that they are helping?
Homework
• Advanced Coping Skills - check their homework
Your homework last week was to look at ****. How did you get on with this? Did it work?
Any problems? (give huge amounts of praise if they implemented their solution)
(If they didn't achieve the homework then take that as the problem to tackle this session)
• Activation Are you doing things? Is that helping you feel better? Any problems with this?
Review concerns
Let's go over the things that have been concerning you. Let's review our original list. Do you
still think it is right? Is there anything you want to change? What shall we work on today?
Review the patient's progress.
Review the patient's coping skills homework and/or development of their relapse prevention.
REVIEW OF COPING SKILLS TRAINING
The progress made by the patient and the lessons they have learned from the training in
coping skills should be reviewed.
The relapse prevention plan should be reviewed in session.
Review their support network.
The remainder of the time should be spent in coping skills tasks.
HOMEWORK
Set homework relating to a current problem or trial an alternative solution to last session's
problem.
Plan next appointment for approximately 1 week's time - to complete 8-week treatment
period.
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Session 8 Ending treatment
Focus = Review of relapse prevention plan
AIMS: Review last session
Review homework
Review mental state including suicidality
Review problem list - what's done & what remains







Future plan for coping skills
Future plan for medication
Future plan for support
Completed relapse prevention plan
See GP and discuss progress and plan
HOMEWORK
NURSE: Review in supervision
Write to GP - discuss on telephone if necessary
Plan further contact options
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Session 8 Format
REVIEW AND SET THE AGENDA
First, I want to check briefly with you about how you have been feeling since I saw you last -
physically and emotionally. Then how you managed with your homework from last time.
• Ask about reactions to last session; Any questions about our last session - anything
upsetting?
• Clinical condition - symptoms state of cancer and treatment. How are you getting on?
What is happening with your treatment?
• Mood state and any suicidally - How are you feeling in your mood? Have you had any
thoughts of harming yourself?
Antidepressants Are you still taking antidepressants? Any problem taking them? Any
problem with side effects? Do you think that they are helping?
Homework
• Advanced Coping Skills - check their homework
Your homework last week was to look at ****. How did you get on with this? Did it work?
Any problems? (give huge amounts of praise if they implemented their solution)
(If they didn't achieve the homework then take that as the problem to tackle this session)
• Activation Are you doing things? Is that helping you feel better? Any problems with this?
Review concerns
Let's go over the things that have been concerning you. Let's review our original list. Do you
still think it is right? Is there anything you want to change? What shall we work on today?
Review the patient's progress.
Review the patient's coping skills homework and/or development of their relapse prevention
plan.
Discuss their plans for future self-help - addressed with coping worksheet on 'support' in
session 2 and session 7's discussion.
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REVIEW OF TRAINING IN ADVANCED COPING SKILLS
Review original concerns list and the concerns that have been worked on in the coping skills
sessions to reinforce the patient's progress/recovery.
• Summarise the concerns outstanding from the original list and explore with the patient
their relative importance to their current situation.
• Discuss how their advanced coping skills technique can now be applied to these
problems in the same way that they have done in the therapy sessions. Assess their
confidence to be able to do this out of therapy.
• Reinforce the three important factors in recovery from depression and their role in
preventing another depressive episode.
The (three) things that have helped in your recovery have been: a talking therapy;
(antidepressant medication) and support from other people. If you continue to manage
problems that happen in your life using the advanced coping technique, you will be less
likely to become depressed again. Your medication is important and should be reviewed
regularly by your GP and you should keep him informed of your progress. Also the
support available to you if used in the way that we explored in one of the sessions, will
help you cope with any future concerns.
FURTHER CONTACT
The basis on which further contact with the nurse will occur should be outlined.
The treatment period has now ended. We have planned how you will continue to actively
address your problems and concerns on your own and from whom you will seek support.
It is better for you ifyou now practice managing any problems you encounter in this way. If
you need to contact me for a 'booster' session of what we have done, you can give me a




SITUATIONS WHEN PATIENTS SHOULD BE DISCUSSED WITH A SUPERVISING
PSYCHIA TRIST/PSYCHOLOGIST
• Nurse's concern about suicide risk (see guidance notes on suicidally)
• Patient's failure to show any reduction in depression by session 5 as per
treatment algorithm, appendix g.
• Difficulties with compliance/tolerance of antidepressant medication.
All the above topics should be brought to supervision. In case of urgent concern, a member
of Liaison Psychiatry Service should be contacted the same day. It will be at the
Psychiatrist's discretion to whether the patient is seen. Any time the psychiatrist spends
seeing the patient will be recorded.
GUIDANCE NOTES 2
PATIENTS WHO ARE SUICIDAL OR HOPELESS
All patients should be assessed at session 1 using the SCID and explicitly asked about
suicidal ideation.
In all subsequent sessions, suicidal ideation should be explored.
If any patient whose depression worsens, who expresses hopelessness or a desire to be
dead, further questioning should be conducted regarding their suicidal thoughts.
Once suicidal ideation is elicited it should be explored as follows:
• How often do you have these thoughts?
• How strong are they?
• What would you do?
• Have you ever acted on them?
• Do you think you might?
• What would make that more likely?
• What would make it less likely?
• Do you think you are at risk now?
If after completing the above the nurse has concern that the patient is at risk she should
contact the supervising psychiatrist and the patient's GP.
If she thinks that they are at immediate risk she should not leave the patient and call urgently




In the case of severe concurrent anxiety disorder, the general approach to treatment
should be the same.
Additional specific measures are as follows:
• Ask person what thoughts/fears are associated with the anxiety and
discuss/problem solve them.
• Suggest 'worry time' and relaxation for generalized anxiety
• Advise about hazards of avoidance for phobic anxiety
• Explain that anxiety is likely to respond to same treatment as depression and
encourage them to persevere.
Where the above measures are insufficient or where anxiety is so severe it is interfering
with therapy, seek supervision.
GUIDANCE NOTES 4
CONTACT AFTER THE 8-10 SESSION TREATMENT
It should be made clear to patients that this is a 10-session treatment and that progress will
be assessed after that. After the post 8-session assessment the patient should be discussed
in supervision.
If at the formal treatment response evaluation at session 5 and at the end of treatment it is
clear that they have not improved or are worse, discuss in supervision and prompt them to
plan other help and support.
If there is concern about failure to progress the following options may be considered.
1. Supervising nurse to review
2. Refer to other treatment outside the study
3. Review by study psychiatrist/psychologist
If there is any concern about suicide risk, this should be discussed as outlined on guidance
sheet 2. The finite nature of the regular face-to-face contact should be spelt out at the
beginning of treatment so that future support is placed on the agenda early on.
At the end of the therapy, the basis on which further contact with the nurse will occur should
be outlined:
• The patient is invited to contact the nurse at any time after the end of the therapy and
'booster' sessions can be arranged either as face to face or telephone contact.
If a patient contacts you record this and time spent.
• In addition to this the nurse will contact the patient at regular monthly intervals while the
patient remains on study.
The contact should be discussed with the supervisor.
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APPENDIX a: PATIENT INFORMATION BOOKLET
What is depression?
When we talk about feeling depressed in the
everyday sense, we generally mean we have hit a
bad patch and are feeling down.
However the type of depression that you may be
experiencing is more severe. In fact it is
considered an illness. Depressive illness can
affect both men and women of all ages and from
all walks of life.
Each person who is depressed will experience it in
his or her own particular way. However
depression usually affects your mood, thinking,
behaviour and physical health.
• People with depressive illness usually (but
not always) feel low in mood.
• You may feel bad or negative about yourself,
about everything around you and about the
future.
1
Why do people get depressed?
There are many causes of depression.
Sometimes the trigger will be obvious - a
bereavement, redundancy or divorce for example.
Sometimes the trigger can be an illness such as
cancer. Sometimes there may be a build up of
many things or, there may be no apparent
reason.
Once depression has started it can be self-
perpetuating. For example, loss of energy,
interest and motivation leads to doing less. Doing
less makes life less rewarding and tends to make
the depression worse. People with depression
can become trapped in this sort of vicious circle.
Another effect of depression is to make you think
that nothing can help. You may feel isolated and
feel that you should be able to overcome this
illness on your own. It can be impossible to
imagine things changing in any way. However
this is not in fact true. There are treatments for
depression and they are effective.
3
You may experience some or all of the following:
• Concentration on even simple tasks can
be difficult. Making even the smallest
decisions can become impossible.
• Everything can become a struggle.
Enjoyment of and interest in other people
and events, even enjoyment in life itself
can be reduced. Consequently you may
often find that you are able to do less.
You may
• feel generally less well
• have disrupted sleep, wake early or sleep
more than before.
• eat more than usual and gain weight or
eat less and lose weight
• have more aches and pains.
• lack energy.
2
What can be done?
Even though it may be understandable that people
with cancer become depressed, it doesn't mean that
the depression that comes with cancer cannot be
treated. It can. Treatment will help you cope better.
There are three treatments that usually help people
with a depressive illness:
1. Talking treatments such as Advanced coping
skills training. These involve seeing a trained
therapist who helps you to get back in control
of your life and escape from the vicious circles
of depression.
2. Antidepressant medication helps with
depression in most cases. These drugs help to
reverse the changes in the brain that occur with
depression and can help you cope better.
3. Support from others helps you to get your




ADVANCED COPING SKILLS TRAINING
Each of us has developed our own way of coping with
difficulties we encounter in life. However we can
usually benefit by learning to cope better. Coping better
makes us less depressed. One way of doing this is to
learn advanced coping skills.
A trained therapist helps you to identify and cope more
effectively with the problems you have.
Treatment involves 8-10 weekly sessions. You will be
asked to come to the hospital every week. If for any
reason you cannot attend, the session will be
conducted over the phone. It is important as far as
possible to avoid missing sessions.
The way that you think is a three part process made up
of feelings, thoughts and actions. How you feel affects
how you think and behave. When you are depressed,
you may want to change the way that you feel but
emotions are not readily controlled. It is actually much
easier to change your actions and thoughts. What you
do and what you think will in turn change how you feel.
5
You as the patient play the most important part in
treatment.
Your problems or concerns will be identified and
listed. You and your nurse will then choose one
to work on and decide on a goal. During the
treatment session you are helped to think of your
own possible solutions to a problem and to
consider the advantages and disadvantages of
each solution. The important part of the treatment
is the time between the sessions when you try out
a solution of your choosing.
Once practised, this technique for tackling
problems can be used to tackle any problems
arising in the future even after these sessions
have finished.
At first it may seem a big effort to get started but
when you achieve something yourself it can be
very satisfying.
This sense of success and achievement is the
beginning of getting back in charge of your life
and overcoming the depressive illness.
6
ANTIDEPRESSANT DRUGS
Antidepressants are drugs that treat depressive illness.
They work by helping to restore the right balance of
chemicals (neurotransmitters) in the brain. There are
several different kinds of antidepressants.
Doctors may well recommend a course of
antidepressant drugs for you. Antidepressants are not
tranquillizers and do not cause problems with addiction
in the same way that tranquillisers do.
Taking an antidepressant will increase your chances of
recovering quickly and you will find it easier to help
yourself in other ways. There is good evidence that
antidepressant medication is effective for people who
have both depression and a medical condition such as
cancer.
Antidepressant therapy usually takes 2-4 weeks before
any significant improvement appears (and 2-6 months
before maximal improvement occurs). So it is important
to persevere with it to get the full benefit.
7
Side effects do occur but are not usually a major
problem. Even if you do experience side effects,
the longer-term benefits of the medication are
likely to outweigh this short-term inconvenience.
However, if you find the side effects difficult to live
with, you should continue to take the tablets and
arrange to see your doctor. He/she may be able
to change the tablet to one with fewer side
effects.
If the antidepressants do seem to help you should
continue to take them for at least 6 months after
you start feeling better. If you stop sooner than
this the depression may come back.
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SUPPORT FROM OTHER PEOPLE
Being able to talk to people about what is bothering
you can be helpful in overcoming distress. It is often
helpful to identify a family member, friend or a partner
whom you can call on for extra support.
Whilst you are seeing the nurse you will feel
supported by her. Developing a plan for how you will
get support after the sessions is very important. It will
be discussed early in your treatment.
When people are depressed they often don't want to
socialise, even with friends and family. But when you
avoid people, you deprive yourself of a source of
fulfilment and pleasure, and it's easy to become even
more depressed. This leads to doing less and less
with others until you feel so depressed that you spend
most of your time alone, again another vicious cycle in
depression.
Even though it seems hard at first, it is important to
work to build and strengthen your 'support system'.
This is the circle of people with whom you can talk
freely, feel comfortable and seek comfort.
You may wonder who would want to be with you in
your present state of mind. There are also some
things that can get in the way of being able to
speak freely, like having cancer. You may feel
guilty about making others upset by talking about
your illness.
The question of how to deal with the things that
get in the way of your relationships with others is
something you can talk about during the treatment
sessions.
Also keep in mind that antidepressant medication
can increase your energy and decrease your
irritability, so taking an antidepressant could help
improve the time you spend with other people
10
Most people with depression do get better after several
months, or even sooner with effective treatments.
We are all different but we do all have risk factors that
can put us at risk of depression recurring.
Unfortunately some people may have another episode
of depression in the future. So this means that we
need to pay attention to our moods.
Included in this booklet is a plan to help prevent
depression recurring. It is something that you have to
practice and continue using.
it can be hard initially to think about the way that you
felt before you started making changes in your life .By
being aware of your thoughts and feelings, you can
identify changes in your mood and intervene early,
before your depression becomes severe.
11
Relapse Prevention Plan
Keep doing what works
Eg. Increasing your pleasurable
activities
Antidepressant therapy
Using the support of those around you
Identify things in your life that increase stress
Eg. Paying bills
Identify what coping strategies that have
worked for you in the past
Eg. Going for a walk, having a bath
Prepare yourself for high risk situations
These may be everyday annoyances
Eg. Falling behind with work OR
They could be very stressful events
Eg. Financial problems
Watch for early warning signs
You will have signs that are personal to
you








I will look for other signs of depression if I find myself:1.2.3.4.5.6.
Mv Booster Plan
If I notice depression returning I will:1.2.3.4.5.6.
7.
13
The trigger factors that I need to be aware of
are7.8.9.
10.
Summary of advanced coping skills
technique
Clearly identify the problem
List solutions that may solve the problem
Try a solution out
Assess the results
You may decide to choose another solution and
try it out
Reward yourself for the progress
14
FURTHER INFORMATION
Your specialist nurse will explain the treatment to you in
more detail. She is an experienced cancer nurse who
has trained in helping cancer patients who are also
suffering from a depressive illness. If you have any





The Edinburgh Cancer Centre
Western General Hospital.
EDINBURGH Tel: ******
The doctor in charge of the depression treatment
programme is:





APPENDIX b: RECORDING CONSENT FORM
RECORDING CONSENT FORM
Supervisors: Dr Michael Sharpe & Vanessa Strong
When we interview people we can't always write down everything they say. We use forms,
which help us to score or summarise information that people give us but it is important for us
to check from time to time that the forms accurately represent what patients say. To check
this we are asking for your permission to audiotape and/or videotape your treatment sessions.
If you agree, your nurse will interview you and record your responses on a paper form as
usual. She will also tape the interview. The tapes will used to check that information has been
accurately recorded and tapes may also be reviewed by the supervising clinician. With your
consent, tapes may be used for training purposes.
I do not give permission for treatment sessions to be taped
I give my permission for treatment sessions to be taped
I give permission for the tapes to be used for training other health care
professionals
• I understand that 1 may ask for the tape/camera to be switched off at any
time
• I understand that when the recordings have been used for the above purposes they will
be erased.




Over the last week, how often





Little interest or pleasure in doing things
Feeling down, depressed, or hopeless
Trouble falling or staying asleep, or sleeping
too much
Feeling tired or having little energy
Poor appetite or overeating
Feeling bad about yourself, or that you are a
failure, or have let yourself or your family
down
Trouble concentrating on things, such as
reading the newspaper or watching television
Moving or speaking so slowly that other people
have noticed. Or the opposite - being so
fidgety or restless that you have been moving
around a lot more than usual
Thoughts that you would be better off dead,
or of hurting yourself in some way





APPENDIX d: SCID Interview and Scoring Sheet
SCID INTERVIEW QUESTIONS
OK, firstly I'd like you to think about your general mood, let's just concentrate on how you've
been feeling during the past month (focus on the worst 2 weeks)
1. Depressed mood (most of the day)
Have you been feeling down in the dumps or low at all?
How bad was that?
How low did you feel?
Can you tell me a little more about it? Can you describe how you feel when you are
depressed? Do you get emotional, or upset? Do you ever cry? How often?
How much of the time have you felt like that?
Does this low mood last most of the day, nearly ever day?
How long have you been feeling like this?
2. Loss of interest or pleasure
(Explore lack of interest in relation to practical and physical constraints)
Are you still able to enjoy doing things that you used to?
Do you feel that you have lost interest in things that you used to enjoy?
Is there anything that you CAN do now that you still enjoy?
When did you last have a good time?
Have you been able to laugh at anything lately?
How much of the time have you felt like that?
(Is it for most of the day, nearly every day?)
How long have you been feeling like this?
Lets just focus on the worst 2 weeks you've had during that period
3. Weight loss/gain
How was your appetite - are your eating patterns different to how they used to be?
Do you eat more or less than you used to?
Have you lost or gained any weight in the past month?
How much weight would you have gained or lost do you think? (Do you know how much you
weigh now?)
Has your appetite been like this most days in the past few weeks?
4. Sleeping patterns
How have you been sleeping over the past couple of weeks?
Do you have trouble falling asleep?
Do you have trouble staying asleep?
Do you wake earlier than usual, how much earlier?
[Are taking sleeping tablets? How long have you been taking them? What was you sleep like
before you started taking them?]
How many hours sleep a night are you getting? Is this nearly every night? Is this different to
your normal sleeping pattern?
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5. Psychomotor agitation or retardation
(must be observable by others)
Have you been feeling fidgety or restless lately? (Do you pace?)
Can you sit and relax, for example in front of the television?
Or have you felt the opposite - more slowed down than usual?
Was this so bad that others have noticed it?
(What about your husband/partner/children/friends - have they noticed these symptoms?)
Have you felt like this most of the day, nearly every day?
6. Fatigue/low energy [note if on chemotherapy]
Over this period of time have you been feeling particularly tired?
Does this tiredness last most of the day?
Do you feel that you have less energy than usual?
Have you felt like this most of the day, nearly every day?
7. Worthlessness, guilt (must have guilt component)
I'm interested in how you feel about yourself at the moment. Has the way that you feel about
yourself altered in any way?
Do you feel bad about yourself?
Do you ever feel so bad about yourself that you feel worthless?
Do you feel guilty about anything that you have done or not done?
Have you felt like this most of the day, nearly every day?
8. Lack of concentration/thinking ability
Do you have trouble concentrating? Does your mind ever wander?
What kinds of things do you have trouble concentrating on?
Does this happen nearly every day?
What about watching TV or reading a book?
Do you find it difficult to make decisions or plan ahead?
Have you felt like this most of the day, nearly every day?
9. Suicide risk (KEEP QUESTIONS SIMPLE AND UNCOMPLICATED)
Can you tell me how bad things have got for you?
Have you ever felt that it's not worth carrying on?
Have things been so bad that you thought that maybe you'd be better off dead?
If high risk continue with questions over....
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IF SUICIDAL THOUGHTS ARE PRESENT
How often have you had these thoughts?
How strong are these thoughts?
Have you ever made a plan to end your life?
Have you made any preparations to end your life?
Have you ever actually tried to end your life? If so, how?
How likely do you think it is that you would take your own life?
What would make it more likely?
What would make it less likely?
OR What would stop you from doing anything do you think?
Do you feel at risk now?
Who do you have that you can talk to about these feelings?
Have you told your doctor?
Are you alone? [explore]
It seems to me that you are at some risk of harming yourself and I'm a bit concerned about
that. I'd like to get one of our clinical team in touch with you today to talk more with you.
Will you be OK until then?
Check that patient will be at home (refer to suicide management protocol).
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SCID CRITERIA AND SCORING
To make a diagnosis of MDD, five or more of the following criteria must have been present
during the same 2 week period in the past month and represent a change from previous
functioning.
At least one of the five symptoms must be either question 1 or 2 (core symptoms).
[Scoring: Y = yes (symptom present) N = no (symptom not present)]
CORE SYMPTOMS
1 Depressed mood most of the day, nearly every day
as indicated either by subjective report (feels sad or Y N
empty) or observation (tearful).
2 Markedly diminished interest or pleasure in all, or
almost all activities most of the day, nearly every day, Y N
representing a significant change from previous functioning
3 Significant weight loss when not dieting, or weight
gain (a change of more than 5% in 1 month) OR Y N
decrease or increase in appetite nearly every day
4 Insomnia or hypersomnia nearly every day Y N
5 Psychomotor agitation or retardation nearly every
day (must be observable by others) Y N
6 Fatigue OR loss of energy nearly every day Y N
7 Feelings of worthlessness OR excessive or
inappropriate guilt nearly every day
(not merely self-reproach about being Y N
sick, or low self-esteem)
8 Diminished ability to think or concentrate or Y N
indecisiveness, nearly every day
9 Recurrent thoughts of death (not just fear of dying)
Recurrent suicidal ideation without a specific plan, Y N
OR a suicide attempt or a specific plan for committing suicide
(Does not need to be present every day)
TOTAL SCORE 19 MDD DIAGNOSIS: YES/NO
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Suicide Risk Management Protocol
(Treatment Version)
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APPENDIX e: FAQ SHEET
DEPRESSION AND ITS TREATMENT FAQ
1. What is Depression?
The depression we are talking about is an illness. The word depression can be
misleading because it is also used to describe people simply feeling unhappy.
2. What causes depression?
People may be more vulnerable to developing the illness because of genetics or
pervious experience in their life, it is usually triggered by stress and it is associated with
changes in the chemistry of the brain. It is a real illness and the good news is it is
treatable.
3. But I am not the sort of person to develop depression (I am a coper)?
Anybody can develop depression. In your case you have had some particularly severe
stresses to cope with. Depression is not a sign of weakness it's an illness.
4. But I should be able to cope with depression myself?
Whilst there are things you can do to help yourself get better, it is unrealistic to think that
you can just pull yourself out of depression by will power alone. Many famous people
with extreme will-power (e.g. Winston Churchill) also suffered depression.
5. How do antidepressant drugs work?
Antidepressants drugs work by reversing the chemical changes in the brain associated
with depression. That is they help to make the brain chemistry more normal.
6. How long do you need to take antidepressants for?
The first thing to say is that antidepressants take up to two months before they have their
beneficial effects, therefore it is important to take them for at least this long to give them
a fair trial. If they are helpful there is no set answer to how long you should take them,
but most people would suggest that at least six months.
7. Aren't antidepressant drugs addictive?
That depends what you mean by addictive. In the sense that people need to increase
the dose or go seeking illicit supplies they are certainly not. In a sense that a small
number of people taking some of these drugs develop usually transient unpleasant
symptoms, if they stop them suddenly, they may be or at least some of them may be. In
practice we find this really is not a major problem. The one drug that has been pointed
to as causing these "withdrawal symptoms" is paroxetine, so if you are particularly
concerned about these it is best to choose another drug. There are many to choose
from.
8. Which antidepressant drug should I take?
There are a number of antidepressant drugs. The one that is best for you is worked out
largely by trial and error. This means that if the first drug doesn't suit you after a
reasonable trial it is worth considering changing to another. The drugs are probably all
more or less equally effective although if you or your family have had a good response to
a particular drug it may mean that that one is most likely to help you. Otherwise we
choose the drugs mainly on their other actions. For example some are sedative, and
these are particularly useful taken at night for those who have difficulty getting off to
sleep. On the other hand people who tend to feel sleepy or drowsy are better taking one
that is a little bit more stimulating. Similarly some tend to cause an increase in appetite
and weight, and some a decrease. By considering these things it is possible for you and
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your doctor to make the best guess first choice, and also to think of what be an
alternative should that one not suit you.
9. What is the point of the talking treatment (the problem solving)?
It has been known for a long time that talking treatments can help people get better from
depression. That is because once a depressive illness has started it can be kept going
by feelings of being helpless and hopeless about the problems one faces. Problem
solving works not by solving all your problems (that would be impossible) but by giving
you the skills to tackle problems effectively so that you feel more in control and less
helpless. The other benefit of problem solving is that it is a long-term skill that can help
you in the future.
10. How do I learn problem solving?
You will learn problem solving with the help of the nurse/therapist. Learning problem
solving is as much learning a skill, as it is a treatment. That is, you will be given things to
read and things to do, you will try them out as "homework" and come back to see your
therapist who will act in part like a teacher. And don't worry if learning has not always
been easy for you because almost any one can learn problems solving the main thing is
to have supervised practice.
11. Why take an antidepressant drug and do problem solving?
It is possible that either treatment alone could help you recover from the depressive
illness. However, many years of research has shown that both treatments together are
better than either alone.
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APPENDIX f: COPING WITH CONCERNS WORK SHEET
Date:
Session:
What is the Problem?
What are my Goals?
Solution Pros Cons
Solutions to achieve goals:
Choice of Solution:
Steps I need to take to achieve this solution:
Things that would stop me achieving this:
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Appendix g: Treatment Guideline Algorithm
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Appendix h: Relapse Prevention Plan
Self Monitoring Plan








If I notice depression returning I will:1.2.3.4.5.6.7. The trigger factors that I need to be aware of are1.2.3.4.5.6.7.8.9. _10.Summary of advanced coping skills technigueClearly identify the problemList solutions that may solve the problemTry a solution outAssess the resultsYou may decide to choose another solution and try itoutReward yourself for the progress
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Appendix B: Severity Measure - PHQ-9
Over the last 2 weeks, how often have you been bothered by any of the following
problems?
Not Several More than Nearly
at all days half the every
days day
Little interest or pleasure in doing things
Feeling down, depressed, or hopeless
Trouble falling or staying asleep, or sleeping
too much
Feeling tired or having little energy
Poor appetite or overeating
Feeling bad about yourself, or that you are
a failure, or have let yourself or your family
down
Trouble concentrating on things, such as
reading the newspaper or watching television
Moving or speaking so slowly that other
people have noticed. Or the opposite - being
so fidgety or restless that you have been
moving around a lot more than usual
Thoughts that you would be better off dead,
or of hurting yourself in some way
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INTRODUCTION
Quality control for the trial intervention will consist of quality control of both the training and of
the delivery of the treatment.
Training will be delivered according to the training protocol outlined in this document and
competency assessed in a consistent way using a predefined protocol.
On-going quality control will be provided in the form of weekly supervision by the consultant
psychiatrist and senior clinical nurse specialist. The focus of the supervision for the treating
nurses will be adherence to the research protocol, adherence to the treatment model and
discussion of problems arising during treatment.
In addition to this, quality control of the treatment delivery will be assessed formally every 3
months using a structured assessment of each of the components of the treatment, outlined
in Figure 2. Adherence to the treatment manual and appropriate use of communication
techniques will be assessed by the supervising clinicians on a randomly selected sample of
5 treatment sessions. Adherence will be measured on session specific items using a Likert-
type scale rating of 1 to 3 (low to high) as used by Katon et al 1996. The criterion for
adherence to the treatment manual is attainment of a score at or above the predefined
session threshold scores in > 25 sessions out of 30 (to achieve a total of 30 sessions




The training programme is outlined below in the order in which it should be delivered. In turn,
each component of the programme is outlined in flow diagram format with details of the
structure and methods of competence assessment.
Training in each of the components is delivered by a trained therapist.
Communication and Interview Skills training
Communication Skills training session on interview management, interview techniques and
eliciting concerns
Face-to-face role-play (video-taped) of eliciting concerns of a cancer patient
Critical review of tape by supervisor
Face-to-face role-play (video-taped) of unstructured interview of a cancer patient
Critical review of tape by supervisor
Role-play (video-taped) + critical review is repeated until competency is achieved
Suicide Assessment & Management training
Training session on risk assessment of suicidal patients
Face-to-face role-play (video-taped) of suicide risk assessment interview
Critical review of tape by supervisor
Training session on suicide risk management
Role-play + (video-taped) critical review is repeated until competency and adherence to the
suicide risk management protocol is achieved
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(see Appendix d of Treatment Manual for Suicide Risk Assessment interview questions and
Suicide Risk Management Protocol)
SCID assessment training
Training session on DSM1V diagnostic interview for depression (SCID)
Face-to-face role-play (video-taped) of SCID interview
Critical review of tape by supervisor
Role-play of telephone SCID interview (audio-recorded)
Critical review of tape by supervisor
(see Appendix C for SCID interview questions and scoring sheet)
THEN (after deemed competent in the above)
5 consecutive SCID interviews with real patients conducted and scored over the phone
(audio-taped)
Interviews scored by second rater for inter-rater reliability
Competency is defined as 100% inter-rater SCID scoring concurrence
Overall competency in conducting a SCID interview is:
competency in conducting and scoring a telephone SCID interview with a 'live' patient
+
achievement of 100% inter-rater reliability (assessed on 5 interviews)
+
competency in suicide risk assessment and management
Antidepressant medication
Tutorial on depression and the use of antidepressants + reading material
Face-to-face role-play (video-taped) of interview with patient where an explanation of
depression and answers to questions posed by patients is required
Critical review of tape by supervisor
Role-play + critical review is repeated until competency is achieved
Competency is achieved when an adequate explanation of depressive illness can be given
and questions answered adequately + an adequate knowledge of antidepressants, their
main side effects and main contra-indications as assessed by written or taped aural
examination
Case management
Training session on active case management.
Information recording-. Training in recording of relevant information
Accurate record-taking of information is assessed against a video-taped patient treatment
session.
Written communication: Competency assessment of letter-writing is conducted
Verbal communication: Face-to-face role-play (video-taped) of case discussion with 'real'
Oncologist. Competency assessed on ability to answer questions from the Oncologist
Self management
Tutorial and discussion on techniques for effective time management, on the function of
supervision and on therapeutic relationship monitoring.
Competency assessment not applicable
Adherence to treatment manual
Tutorial on importance of adherence and on the methods employed to conduct adherence
checks
Adherence check performed on a minimum of 12 sessions on the last 2 patients treated
using the treatment manual adherence assessment detailed in section 2.3
The adherence check will therefore be performed on 2 full treatment programmes of which
there will be 2 session 1s, and 2 relapse-prevention treatment sessions
Adherence is:
Acceptable adherence score in 2 session 1s and 2 relapse prevention sessions
+ acceptable adherence score in at least 7 of the other 8 sessions
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1.2 Duration
The training programme is based on 6 months at 25 hours per week.
1.3 Competency Assessment
Competency must be achieved in each of the components of the training programme shown
in Figure 1 in the order outlined in section 1.1 in addition to demonstration of adherence to
the treatment manual (as detailed in section 2.1). Competency must be achieved in
communications skills before proceeding to training in suicide assessment and SCID
diagnostic interviews. The time required to complete this training is approximately 2 months.
Following this, training in all other components and in the treatment intervention can proceed
which allows 4 months of training to include the treatment of 5 patients.
At the end of the training period, adherence to the treatment manual is formally assessed on
the last 2 patients treated.






















2.1 INTERVENTION ADHERENCE PROTOCOL
Intervention Programme
Treatment duration: (max 10 sessions over max 13 weeks; session duration S1 = max 90
mins, S2-8 = max 45 mins)
Adherence to treatment guideline (see appendix g of Treatment Manual): Score on the PHQ-
9 should be calculated weekly monitoring for a 50% drop in score from baseline.
Treatment follow-up: Monthly telephone contact
Treatment manual & Communication skills
Treatment manual adherence scoring sheet used which includes communication skills
techniques, (see Appendix 1 for Treatment Manual adherence scoring sheet). Criterion for
adherence is adherence in ^ 25 sessions out of 30.
Case management





Patient's progress presented weekly + adherence to treatment guideline with formal review
presentation at session 5.
2.2 TIMING
Formal documented adherence checks will be conducted every 3 months. Adherence to
the treatment manual will be assessed on a randomly selected sample of 5 sessions
every 3 months (to achieve a total of 30 sessions reviewed over the time of the study
intervention [24 months] using the criteria for adherence which is adherence in ^ 25
sessions out of 30).
2.3 TREATMENT INTEGRITY ASSESSMENT
Treatment integrity is confirmed if adherence is achieved in all the components listed in
Figure 2 and detailed in section 2.1 and documented using the treatment integrity
assessment form (appendix 2).
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3.1 TREATMENT INTEGRITY MONITORING
Following each treatment integrity assessment, formal feedback will be given to the therapist
by the clinical supervisor(s) using the treatment integrity assessment result form (appendix
3). Any points requiring attention will be discussed and a training plan agreed.
Should the therapist fail to meet the required criteria for adequate adherence to the trial
intervention protocol as detailed in section 2.3, this will be discussed with the supervisor(s)
and a remedial plan agreed and documented.
If the failure in adherence is due to therapy content (i.e. drift from the treatment model
prescribed in the treatment manual), re-training will be organised and a formal competency
check carried out as detailed in section 1.3 and Figure 1. During this period it will be at the
discretion of the supervisor whether treatment of patients within the trial should continue.
Should the therapist be deemed suitable to continue treating patients, the therapist will be
given a reduced patient caseload and a plan of close monitoring shall be agreed and
documented. This may involve assessment of a block of treatment sessions or of each
treatment session and formal assessment and feedback before continuation of the next
treatment session is permitted.
Should the therapist be deemed unsuitable to continue treating patients, the remedial plan
will include re-training and formal assessment of competency and the therapist will not be
permitted to treat patients during the re-training period.
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In any event, should the therapist fail to meet the competency assessment after every
reasonable effort has been made to re-train the therapist, the therapist will cease to treat
patients and be replaced.
SECTION 4
APPENDICES
Appendix 1: Treatment Manual adherence measure scoring sheet
SESSION 1
Adherence rating
(low 1 to high 3)
1 2 3
Introduction (setting the agenda)
Who I am, my training, who I help
Purpose of the intervention -To work with you
Time -We have around an hour









Listing of immediate concerns
Probing of loneliness and support
Summarising of list
Cancer History
Identifies difficulties about the cancer diagnosis or treatment
Elicits problems NOW caused by the cancer
Identifies impact of the cancer using checklist
Checks with patient whether any of the above problems




Current treatment, dosage, duration, adherence and effect
285
Previous depression history
Check for sense of control...Is there anything
you can do yourself to overcome depression
Elicits problems NOW caused by the depression
Identifies impact of the depression using checklist
Checks with patient whether any of the above problems
should be added to the concerns checklist
Diagnosis and identification of the nature of the patient's depression






Checks for any other medication
Checks for any other current illness, medication, treatment
Current social support, nursing etc
Background
Elicits method of coping with life events
Construction of Current Concerns
Summarises and asks patient for any additions to list
Proposes additions noted from assessment
Adds the depression to the list
Adequate explanation of treatment covering the following points
Collaborative approach - patient and nurse
Depression is a real illness and is treatable
Explanation of the main treatment options available
Explanation of role of support
Checks for questions and uses FAQ sheet for guidance
Adequate explanation of the treatment intervention covering the following points
Tackling problems by reducing them to smaller parts
Explanation of the coping skills technique
Advanced Coping Skills Example
Explains the worksheet
Uses example of depression
Technique
Defines problem adequately
Elicits exhaustive list of solutions
Examines pros and cons of each solution
Sets homework agreeing date/time
Checks for barriers to achieving homework
Gives patient encouragement and praise
following completion of worksheet
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Encourages behavioural activation
Discusses support network briefly
Ending the session and making a plan
Checks with patient for any questions
Agrees to further 5-7 sessions
Sets date and time for next session
Agrees set homework
Summarises what depression is
Summarises why doing advanced coping skills training will help
After session:
Completes GP and Oncologist letters
Writes up assessment
Presents case for discussion in supervision
























(low 1 to high 3)
1 2 3
Administration of process measure (PHQ-9)
Enquires about changes in clinical condition from previous week
Enquires about mood state this week with specific interrogation of following items:
Mood
Suicidal ideation




Reviews homework from previous week
Checks on progress in behavioural activation
Gives praise on successful completion of homework
Checks for new concerns
Explores specifically social support issue




Elicits exhaustive list of solutions
Examines pros and cons of each solution
Sets homework with date/time if appropriate
Checks for barriers to achieving homework
Encourages behavioural activation
Ending the session and making a plan
Checks with patient for any questions
Sets date and time for next session
Agrees set homework
After session:
Writes up session notes
Presents progress for discussion in supervision
General non-session specific adherence items
























(low 1 to high 3)
1 2 3
Administration of process measure (PHQ-9)
Enquires about changes in clinical condition from previous week
Enquires about mood state this week with specific interrogation of following items:
Mood
Suicidal ideation




Reviews homework from previous week
Checks on progress in behavioural activation
Gives praise on successful completion of homework
Checks for new concerns
Explores specifically social support issue





Elicits exhaustive list of solutions
Examines pros and cons of each solution
Sets homework with date/time if appropriate
Checks for barriers to achieving homework
Encourages behavioural activation
Ending the session and making a plan
Checks with patient for any questions
Sets date and time for next session
Agrees set homework
After session:
Formal assessment of progress
Presentation of case to supervising psychiatrist
Reduction in PHQ-9 score discussed
Management plan agreed with supervisor






















SESSION 6 (or penultimate session)
Adherence rating
(low 1 to high 3)
1 2 3
Administration of process measure (PHQ-9)
Enquires about changes in clinical condition from previous week
Enquires about mood state this week with specific interrogation of following items:
Mood
Suicidal ideation




Reviews homework from previous week
Checks on progress in behavioural activation
Gives praise on success completion of homework
Checks for new concerns
Formal assessment of progress discussed with patient, specifically:
Reduction in PHQ-9 score discussed
Management plan agreed with supervisor discussed
Explains the relapse prevention plan
Completes relapse prevention worksheet
Technique
Identifies & charts the patient's presenting symptoms
Identifies & charts the patient's depression trigger factors
Identifies & charts strategies that have improved the depression
Develops action plan for detection of return of depression
Develops action plan for treatment of future depression
Sets homework:
Further development of the relapse prevention worksheet
Encourages behavioural activation
Ending the session and making a plan
Checks with patient for any questions
Sets date and time for next session
Agrees set homework
After session:
Writes up session notes
Presents progress for discussion in supervision
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General non-session specific adherence items





















SESSION 7 (or final session)
Adherence rating
(low 1 to high 3)
1 2 3
Administration of process measure (PHQ-9)
Enquires about changes in clinical condition from previous week
Enquires about mood state this week with specific interrogation of following items:
Mood
Suicidal ideation




Reviews homework from previous week
Checks on progress in behavioural activation
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Gives praise on success completion of homework
Checks for new concerns
Reviews the relapse prevention plan
Reviews the worksheet for social support
Plans strategy for future social support beyond the treatment
Ending the treatment and making a plan
Checks with patient for any questions
Reinforces importance of regular monitoring of mood
Reinforces importance of relapse prevention plan
Agrees monthly monitoring phone calls
After session:
Writes up session notes
Completes GP and Oncologist letters
Presents progress for discussion in supervision






















Appendix 2: Treatment Integrity Assessment Form
To be conducted every 4 months
Name of therapist:
Adherence check No: Time period:
Assessed by: Date of assessment:
Treatment Programme
(Assessed on a randomly selected sample of 2 patients treated during the previous 4
months)
Yes No
Treatment duration Max 10 sessions
Max 13 weeks
Session duration S1 max 90 mins
S2-10 max 45 mins
Any additional suicide risk assessment time required?
Treatment follow-up Monthly telephone sessions
Max 45 mins
Treatment Manual & Communication Skills
(Assessed on a randomly selected sample of 6 treatment sessions of which at least 1 should
be an assessment session + 1 a relapse-prevention session)
Yes No
Adherence achieved in 5 of 6 sessions reviewed
Case Management




(Assessment on all cases of patients with high risk)
Yes No
Adherence to suicide risk assessment protocol
Adherence to suicide risk management protocol
Supervision
(Assessment from on-going monitoring)
Yes No
Appropriate use of supervision
Weekly case presentation (formal case review at S5)
Adherence to the treatment guideline
Notes:
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Appendix 3: Treatment Integrity Assessment Result Form
To be conducted every 4 months
Name of therapist:
Adherence check No:
























We are interested in some things about you and your health. Please answer all of
the questions yourself by circling the number that best applies to you. There are no
"right" or "wrong" answers.
Not A Quite Very
at all little a bit much
Do you have any trouble doing strenuous activities,
like carrying a heavy shopping bag or suitcase?
Do you have any trouble taking a long walk?
Do you have any trouble taking a short walk outside
of the house?
Do you need to stay in bed or a chair during the
day?
Do you need help with eating, dressing, washing,
yourself or using the toilet?
Not A Quite Very
At All Little a Bit Much
During the past week:
Were you limited in doing either your work or other
daily activities?
Were you limited in pursing your hobbies or other
leisure time activities?
Were you short of breath?
Have you had pain?
Did you need to rest?
Have you had trouble sleeping?
Have you felt weak?
Have you lacked appetite?
Have you felt nauseated?
Have you vomited?
Have you been constipated?




During the past week:
Not A Quite Very
at all little a bit much
Did pain interfere with your daily activities?
Have you had difficulty in concentrating on things,
like reading a newspaper or watching television?
Did you feel tense?
Did you worry?
Did you feel irritable?
Did you feel depressed?
Have you had difficulty remembering things?
Has your physical condition or medical treatment
interfered with your family life?
Has your physical condition or medical treatment
interfered with you social activities?
Has your health or medical treatment caused you
financial difficulties?
For the following questions please circle the number between 1 and 7
that best applies to you
How would you rate your overall health during the past week?
1 2 3 4 5 6 7
Very poor Excellent
How would you rate your overall quality of life during the past week?




The next questions ask about how much you were distressed by various symptoms
in the past month. The categories are: Not at all, a little bit. Moderately,
Quite a Bit and Extremely.
Overall, in the past month how much were you distressed by...
Not at A little Moderately Quite a Extremely
all bit bit
Feeling lonely or blue
Feeling hopeless about the future
Feeling no interest in things




Awakening in the early morning
Sleep that is restless or disturbed
Thinking, speaking and moving at a
slower pace
Feeling so restless you couldn't sit still
Thoughts of death or dying
Thoughts of ending your life
Feeling low in energy or slowed down
Feeling everything is an effort







Over the last week, including today,
HOW MUCH WERE YOU DISTRESSED BY:
Not at A little Moderately Quite a Extremely
all bit bit
Nervousness or shakiness inside
Trembling
Suddenly scared for no reason
Feeling fearful
Heart pounding or racing
Feeling tense or keyed up
Spells of terror or panic
Feeling so restless you couldn't
sit still
The feeling that something bad
is going to happen to you




The next question asks how confident you feel NOW.
On a scale of 0 to 10, where 0 means "not at all confident" and 10
means "extremely confident", circle the number that best
represents your answer to the following questions.
How confident are you in your ability to overcome or control an episode of
depression?
0123456789 10
NOT AT ALL EXTREMELY
CONFIDENT CONFIDENT
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The next few questions have to do with strategies you normally use to
solve problems. Tick the box that best describes your answer to the
following statements:
THINKING OF NOW Not at all Slightly true Moderately true Very true
When my first efforts to solve a
problem fail, I know if I persist and
do not give up easily, I will be able
to eventually find a good solution.
When I am trying to solve a
problem, I get so upset that I
cannot think clearly.
When I have a decision to make, I
weigh the consequences of each
option and compare them against
each other.
When I am attempting to solve a
problem, I go with the first good
idea that comes to mind.
When a problem occurs in my life, I
put off trying to solve it for as long
as possible.
Amongst the people I know, there
is someone I can go to for support.
If I needed to, I would go to this
person for support.
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Satisfaction with care questionnaire
Over the last 6 months how would you rate the quality of care you have
received for your depression?








Appendix E: Data collection form and data definitions
NB Take all clinical data as at date of positive MDD diagnosis on SCID
Date of 1st primary cancer
diagnosis Date:
1st Primary cancer diagnosis &
site Dx: Site:
Date of second primary cancer
diagnosis Date:





Recurrence of local disease
Metastases & site Site:











Data Definitions for Clinical data collection
Date of 1st primary cancer
diagnosis
Chart date cancer diagnosis was made from date on (in order of
preference): pathology confirmation (for Lothian patients, use apex
system), radiology reports eg CT scan report or from medical note
annotations/letters. (For test reports, take date of test not date of report).
304
1st primary cancer diagnosis &
site
Chart cancer diagnosis and site of primary lesion (obtain from medical
notes as above)
Date of second primary cancer
diagnosis
Chart date 2"" primary cancer diagnosis was made from date on (in
order of preference): pathology confirmation (for Lothian patients, use
apex system), radiology reports e.g. CT scan report or from medical note
annotations/letters. (For test reports, take date of test not date of report).
2na primary cancer diagnosis &
site
Chart cancer diagnosis and site of 2"a primary lesion (obtain from




Recurrence of local disease
Metastases & site
No disease evident (patient likely to be attending for routine follow-up for
observation)
Presence of disease - can be pre-treatment, or residual disease, i.e.
disease still there after treatment
Where patient has had previous confirmation of no evidence of disease
after treatment/surgery but disease has re-appeared in the same site
Presence of distant spread of disease (e.g. primary diagnosis is breast
with metastases in spine). Chart also site(s) of metastases, (note that
axillary node involvement with a breast cancer diagnosis is classed as
local disease not metastatic whereas for most other cancers lymph node
disease is metastatic - if in doubt ask a clinician for clarification i.e.
Lucy/Dawn)
Date of local recurrence Chart date local recurrence diagnosis was made from date on (in order
of preference): pathology confirmation (for Lothian patients, use apex
system), radiology reports e.g. CT scan report or from medical note
annotations/letters. (For test reports, take date of test not date of report).
Date of metastases Chart date metastatic diagnosis was made from date on (in order of
preference): pathology confirmation (for Lothian patients, use apex
system), radiology reports e.g. CT scan report or from medical note








Diagnosis made but waiting for treatment (e.g. surgery, chemo,
radiotherapy)
Currently undergoing active anti-cancer treatment - radical or palliative
(e.g. Surgery, radiotherapy or chemotherapy but also includes adjuvant
Rx or chemo)
Patient being seen for check-ups for basic monitoring/observation but
not receiving any active treatment or under any investigation (may be on
long-term hormone treatment e.g. Zoladex or Arimidex but not HRT)
Where last medical entry suspects relapse, spread or new Cancer
diagnosis and patient is waiting for investigations and/or results, (look for
evidence in notes of raised tumour markers e.g. prostate- PSA, gynae -
CEA125, teratoma - Alphafetaprotein, beta HcG)





Note if currently receiving radiotherapy
Note if currently receiving chemotherapy
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Appendix F: Patient Information and Consent Forms
PATIENT INFORMATION SHEET
EDINBURGH CANCER CENTRE SYMPTOM MANAGEMENT TRIAL
You are being invited to take part in a research trial. Before you decide, it is important
for you to understand why the research is being done and what it will involve. Please
take time to read the following information carefully and discuss it with others if you
wish. Ask us if there is anything that is not clear or if you would like more information,
take time to decide whether you wish to take part. Thank you for reading this.
What is the purpose of the Trial?
It is quite normal to suffer from some degree of stress symptoms in relation to the experience
of having and being treated for cancer. Sometimes these symptoms are severe and may be
called depression. We are testing a treatment for these symptoms and the best way to
evaluate how effective this treatment is, is by testing it in a randomised clinical trial.
Randomised Clinical Trial:
In order to find out whether a new treatment is better than an existing one, we have to
compare how much the patients improve with each treatment. In order for comparison to be
a fair one, we cannot choose which patients have which treatment, rather they have to be
randomly allocated (that is by chance) to one or other treatment.
In this trial, all patients will get the usual care for depression from their general practitioner
and the Edinburgh Cancer Service. The aim of this trial is to see whether patients get better
more quickly if they have the additional treatment as well.
What does the usual care for depression involve?
It is quite common for people who have cancer to suffer stress to some degree during their
illness. General practitioners and doctors at the Edinburgh Cancer Centre are familiar with
this. They may choose to let the stress take its course, to suggest that you try an
"antidepressant" drug or refer you for some form of counselling. This is the usual care.
What does the additional treatment involve?
The patients who are allocated to the additional treatment will, as well as receiving usual
care, also see a specially trained nurse. If you are allocated to this treatment, it will involve
visiting the Cancer Research UK Building on the Western General site once a week for visits
of 30-60 minutes for 6-8 weeks. In these sessions, you will talk with the nurse and discuss
how to cope with stress.
What else will I be asked to do?
All patients who take part in the trial regardless of which group they are in will be asked to
complete a number of questionnaires and to be briefly interviewed over the telephone by a
member of the research team on two occasions (3 and 6 months after you have entered the
study). These questionnaires will ask you questions about your physical and emotional
symptoms and about what other treatments you have received.
What are the possible benefits of taking part?
The benefit of taking part is that your depression will be carefully monitored and we will
review how you are at the end of the trial (6 months after you enter). If you are still
depressed at that time, we will advise you and your doctor about further treatment. We do
not know whether seeing the nurse for additional visits provides additional benefit; that is
why we are doing the trial. The information we get from this trial will, we hope, help us to
decide how best to treat patients in the future whose cancer is complicated by depression.
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Why have I been chosen?
All patients attending the Edinburgh Cancer Centre are routinely asked about how they are
feeling using a touch screen computerised questionnaire. The responses to these
questionnaires are reviewed and patients with high scores are telephoned and asked
additional questions. The answer to these questions tells us you have been severely
stressed. You may therefore eligible to enter the trial.
Do I have to take part?
It is entirely up to you to decide whether you want to take part or not. If you do decide to
take part, you will be asked to sign a consent form. Even if you decide to take part you are
still free to withdraw from the study at anytime and do not have to give a reason for doing so.
If you do decide not to take part or to withdraw this will not effect your future treatment from
the NHS in any way.
What if something goes wrong?
Whilst it is very unlikely that you would be harmed by taking part in this research if you are
there are no special compensation arrangements. If you are harmed due to someone's
negligence, then you may have grounds for a legal action but you may have to pay for it.
Regardless of this, if you wish to complain, or have any concerns about any aspect of the
way you have been approached or treated during the course of this trial, the normal National
Health Service complaints mechanisms should be available to you.
Is the information collected about me confidential?
All information collected about you during the course of this research will be kept strictly
confidential within the research team. We would only pass on information to your doctors.
Any information, which is presented elsewhere or published in medical journals, will be in a
form so that you are not individually recognisable. It may be necessary for research
regulatory authorities such as the Ethics Committee to have access to your medical notes
to verify that our research findings are accurate but in such cases, your confidentiality will
be preserved.
Who else would be involved?
Your own general practitioner and the cancer doctors at the Edinburgh Cancer Centre will be
notified that you are participating in the trial.
Will I be paid?
You will not be paid for your participation but we will reimburse all reasonable travel
expenses.
Who are the researchers?
If you have any further questions about the trial please contact Vanessa Strong the Trial
Research Nurse on 0131 777 3525. The doctor in charge of the study is Dr Michael Sharpe,
Consultant in Psychological Medicine at the Western General Hospital.
Can I get an independent opinion about this research?
If you wish to speak to a doctor who is knowledgeable about this sort of treatment but is
independent of the trial you can contact Dr George Masterton, Consultant in Psychological
Medicine at the Edinburgh Royal Infirmary on 0131 242 1398.
What do I do next?
Vanessa Strong will telephone you within the next few days to speak with you about this trial.
Thank you very much for your help.
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Study Number:
Patient identification Number for this trial:
CONSENT FORM
SMaRT -SYMPTOM MANAGEMENT RESEARCH TRIALS
Depression Trial
Researcher: Dr Michael Sharpe & Vanessa Strong
Please initial box
I confirm that I have read and understand the information sheet version
for the above study and have had the opportunity to ask questions.
1 understand that my participation is voluntary and that I am free to withdraw
at any time, without giving a reason, without my medical care or legal rights
being affected.
I understand my medical notes may be looked at by members of the research
team or by individuals from regulatory bodies where it is relevant to the
research.
I agree to my GP being informed of my participation in this trial
I agree to audio-recording of telephone interviews with researchers
I agree to take part in the above study.
Name of Patient Date Signature
Name of Person taking consent Date Signature




Professor Michael Sharpe (Supervisor); Dr Lucy Wall (second supervisor);
Paul Currie; Louis Currie; Jordan Currie; Aileen Morton and the SMaRT
Research Team.
Contribution to theWork in Each Chapter
Chapter 1: Background
I conducted the literature search and reviewed all the literature.
Chapter 2: A Nurse-Delivered Multiple Modality Approach to the Management
ofMajor Depressive Disorder in Cancer Patients
I designed a multi-component cancer nurse delivered intervention collaboratively with
Professor Michael Sharpe and tested it in a small non-randomised matched group
design pilot study to perform a preliminary evaluation of its feasibility and efficacy in
the treatment ofMDD in cancer patients. I also delivered the intervention to all the
patients in the pilot trial. I adapted the treatment manual from this pilot study and
wrote the treatment manual and treatment delivery protocol for the randomised trial.
Chapter 3: Aims and Hypotheses
I created the hypotheses under the supervision of Professor Sharpe from which the
trial methodology was developed.
Chapter 4: The Design of the Study
I developed the trial methodology collaboratively with Professor Sharpe and chose
(and adapted) the outcome measures used in the trial. I also developed and wrote the
trial protocol and submitted this for ethical approval. The depression screening system
was conceived by Professor Sharpe and Dr Ann Cull and I developed this to provide
the platform from which to identify patients with Major Depressive Disorder and set
up and supervised this screening system in NHS practice. I designed and wrote all the
staff training modules and training competency assessment protocols and delivered
training to all trial team staff. I provided supervision collaboratively with Professor
Sharpe for all trial staff in the screening of approximately 7,000 patients (for which
there were approximately 25,000 screening events) as part of the screening service
provided to the NHS and for the 200 patients within the trial. I supervised the conduct
of the trial procedures including the clinical assessment of patients for Major
Depressive Disorder and collaboratively with Professor Sharpe for Suicide Risk.
With regard to the actual treatment delivered, I developed and wrote a treatment
guideline algorithm and a quality control manual and a treatment delivery compliance
assessment tool and conducted all in-house treatment delivery adherence assessments.
I also delivered the treatment to 20% of the trial patients and provided management of
all 200 trial patients including liaison with the relevant health care professionals.
I was also responsible for and recorded and submitted all serious adverse events for
trial patients. I collected all the medical information for all trial patients and
conducted all the trial eligibility assessments and obtained trial consent.
With regard to the overall management of the trial, I organised all trial group
meetings and wrote all trial reports.
Chapter 5: Analysis of Data and Statistical Power
I contributed (and debated the issues) to the analysis plan in multidisciplinary
statistical plan meetings. The plan was finalised and written by the Trial Statistician,
Rachel Waters. I developed the treatment compliance definition for the analysis.
Chapter 6: Trial Results
All primary and secondary analyses were conducted by the Trial Statistician. I
interpreted the statistical data collaboratively with the Trial Statistician. I conducted
all the analysis of the screening data supervised by Dr Carina Hibberd, Screening
Data Manager.
Chapter 7: Exploration of Predictors of Outcome
Under the supervision of the Trial Statistician, I conducted the exploratory analyses. I
interpreted the statistical data collaboratively with the Trial Statistician.
Chapter 8 to end: I wrote these chapters independently of any help.
